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                                                                Abstract 
Chronic obstructive pulmonary disease (COPD) is a major health problem in the United 
States.  Acute exacerbations of COPD are primarily responsible for the physical, 
psychological and economic burden of this disease.  Early identification and treatment of 
exacerbations is important to improve patient and healthcare outcomes.  Little is known 
about how patients with COPD recognize an impending exacerbation and subsequently 
decide to seek treatment.  The purpose of this qualitative descriptive study was to explore 
and describe symptom recognition and treatment delay in individuals experiencing an 
acute exacerbation of chronic obstructive pulmonary disease (COPD).  Leventhal’s 
Common Sense Model of illness representation undergirded this study. 
Using semi-structured interviews, adults hospitalized with an acute exacerbation of 
COPD were asked to describe their symptom experience and self care behaviors, 
including treatment seeking, in the days to weeks prior to hospitalization.  Data analysis 
revealed one main theme: Recognizing, responding and reacting to change, and six 
subthemes: Something’s coming, Here we go again, Seeking urgent treatment, Riding it 
out, Not in charge anymore and My last day that richly described the COPD exacerbation 
experience.  The study revealed that patients experience an illness prodrome prior to 
exacerbation and have a recurrent exacerbation symptom pattern that was self-
recognized.  Treatment seeking was most influenced by the speed and acuity of 
exacerbation onset, severity of breathlessness, fears of death, nature of patient-provider 
relationship and the perception of stigmatization during prior healthcare encounters.  
These findings are important for the development of interventions to improve patient 
recognition and management of COPD exacerbations in the future 
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                                                              Introduction 
Chronic obstructive pulmonary disease (COPD) is a chronic, debilitating illness that has 
rapidly progressed into a major health problem.  It is currently the third leading cause of death in 
the United States (Murphy, Xu & Kochanek, 2010).  Despite declines in mortality from 
cardiovascular disease, stroke and cancer, morbidity and mortality related to COPD continue to 
rise (Mannino et al., 2000).  The prevalence of COPD in the US is 24 million, however it is 
estimated that the number is actually much higher (U.S Department of Health and Human 
Services [USDHHS], 2010).  This suggests that more than 13.9 % of the population has impaired 
lung function consistent with the diagnosis of COPD (Global Initiative for Chronic Obstructive 
Lung Disease [GOLD], 2004; Mannino, 2002), representing a two-fold increase in prevalence 
over the last two decades (Mannino et al., 2000).   In 2000, COPD was responsible for 119,000 
deaths, 726,000 hospital admissions, 1.5 million emergency room visits and 8 million outpatient 
and primary care visits.  This translates into 37 billion dollars a year in direct and indirect COPD 
related costs (Center for Disease Control and Prevention [CDC], 2002).  According to the 
American Thoracic Society (ATS), this figure is estimated to reach an unprecedented $832 
billion dollars by the year 2020 (Lee, Sullivan & Buist, 2006).  Acute exacerbations of COPD 
are a major cause of hospitalization and overall disease cost.  Many individuals experience four 
to five exacerbations a year (Goodridge, 2006; Izquierdo, Barcina, Jimenez, Munoz & Leal, 
2009) and the effects can have a devastating physical and emotional impact on their lives 
(Goodridge, 2006; Izquierdo et al., 2009; O’Neill, 2002; Seemungal et al., 1998).  Studies 
demonstrate that individuals who receive treatment at the onset of exacerbation recover sooner, 
and experience better health-related quality of life (HRQOL) and functional performance than 
individuals who delay treatment (Bourbeau & Nault, 2007; Wilkinson, Donaldson, Hurst, 
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Seemungal, & Wedzicha, 2004).  Early recognition, timely health practitioner consult and 
prompt treatment for an exacerbation would reduce the economic impact of COPD (Wilkinson et 
al., 2004). 
          There has been little research on an individual’s awareness of the early prodromal signs of 
acute exacerbation of COPD or recognition of individual symptom patterns representing acute 
worsening of baseline health (Caverley et al., 2005; Kessler et al., 2006; Wilkinson et al., 2004).  
Why patients with COPD delay seeking treatment when they experience symptoms indicative of 
an acute exacerbation is also unknown (Bourbeau & Nault, 2007; Langsetmo, Platt, Ernst, & 
Bourbeau, 2008; Wilkinson et al., 2004).  Therefore, the purpose of this qualitative descriptive 
dissertation study was to explore the COPD exacerbation experience with a primary focus on 
prodromal symptoms and symptom pattern recognition in addition to factors that delay 
treatment-seeking. 
This chapter describes COPD and the impact of acute exacerbation on the health status of 
individuals with COPD.  This chapter also reviews current research studies and expert reviews 
on symptom recognition and treatment delay in chronic illnesses with characteristics similar to 
COPD.   
COPD epidemiology  
Chronic Obstructive Pulmonary Disease (COPD) is a lung disease characterized by 
airflow obstruction that is not fully reversible.  The airflow limitation is progressive and 
associated with an abnormal inflammatory response in the lungs when exposed to noxious 
inhalants (Celli, MacNee et al., 2004).  In the US, the older terms chronic bronchitis and 
emphysema are included in the newer diagnostic term, COPD (WHO, 2011).  Patients typically 
have components of both these conditions in their disease presentation.  Emphysema 
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manifestations are the consequence of weakened alveolar walls with subsequent loss of elasticity 
and recoil, resulting in air trapping, and impaired gas exchange.  An estimated 3.1 million 
Americans have been diagnosed with emphysema, 58% of those are male.  The manifestations of 
chronic bronchitis are due to airway inflammation and scarring, resulting in excess mucus 
production that restricts airflow.  Chronic bronchitis affects an estimated 9.1 million Americans, 
and females are two times more likely than their male counterpart to experience chronic 
bronchitis as the predominant component of their COPD (American Lung Association, 2011).  
According to the 2007 National Health Interview Survey, Americans diagnosed with COPD are 
more likely to be White, less than 65 year old (70%), have a high school education or lower, 
classified in a lower socio-economic status, married or co-habitating (Pleis & Lucas, 2009).   
Although the predominant and most troublesome symptoms of COPD involve the 
respiratory system, COPD is a systemic disease with manifestations that also involve the 
cardiovascular, musculoskeletal, and immune systems (Celli, 2006; Punturieri, Croxton, 
Weinmann, & Kiley, 2007).  This multisystem involvement contributes to the significant 
morbidity and mortality associated with this disease (Celli, 2006; Yu-Isenberg, Vanderplas, 
Chang & Shah, 2005). 
The most important risk factor for COPD is smoking, although one out of every six 
individuals with COPD has never smoked (Mannino, Gagnon, Petty, & Lydick, 2000).  In non-
smokers, risk factors include occupational and environmental exposure, severe childhood 
respiratory infections and genetic factors (Rabe et al., 2007).  The pathophysiologic changes 
associated with COPD usually begin 10 years after an individual initiates smoking, although 
symptoms are seldom noticeable in these early stages.  Symptoms typically become more 
noticeable after the age of 40, with shortness of breath on exertion emerging first, which is often 
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interpreted as a sign of aging.  These factors contribute to the under diagnosis of COPD in the 
early mild stages and missed opportunities for early treatment (American Lung Association, 
2011; Rabe et al., 2007).  Gradual deterioration and increased symptom severity occur over time, 
ultimately leading to COPD diagnosis long after lung function has declined and HRQOL has 
been diminished (Donaldson & Wedzicha, 2006).  Most individuals are diagnosed in the fourth 
through sixth decades of life (American Lung Association, 2011; Anto, Vermeire, Vestbo, & 
Sunyer, 2001). 
COPD diagnosis, classification and manifestations 
 COPD has a heterogeneous clinical presentation, and each individual has a symptom 
pattern that is typical for them (Cicutto, Brooks & Henderson, 2004; McCarley, Hanneman, 
Padhye & Smolensky, 2007; Wedzicha, 2000), which is related to the predominant component 
(chronic bronchitis or emphysema) of their COPD pathology (Rennard et al., 2002; McCarley et 
al., 2007; Wedzicha, 2000).  Dyspnea is the hallmark symptom of COPD, although in some 
individuals cough may be present well before dyspnea emerges.  Dyspnea worsens as lung 
function deteriorates across the disease trajectory, and is the major cause of disability associated 
with COPD.  It is typically the emergence of persistent dyspnea that provides the impetus for 
health care consult, leading to a COPD diagnosis (Rabe et al., 2007). 
COPD is diagnosed based on spirometry and staged according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) criteria based on post-bronchodilator percent 
predicted forced expiratory volume in 1 second Forced Expiratory Volume (FEV1), and/or 
FEV1/FVC (forced vital capacity) ratio.  The spirometric cut-points and corresponding stages 
recommended by the GOLD committee for classification of COPD disease severity (Rabe et al., 
2007) are listed in Table 1. 
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Table 1 
 GOLD stages of COPD severity 
 
Stage                                        FEV1 Parameter                                                    FEV1/FVC % 
Stage I: Mild  FEV1 ≥  80% predicted FEV1/FVC < 0.70 
Stage II: Moderate FEV1 < 80% predicted FEV1/FVC < 0.70 
Stage III:  Severe FEV1 < 50% predicted FEV1/FVC < 0.70 
Stage IV: Very Severe FEV1 < 30% predicted or FEV1 < 50% 
predicted plus chronic respiratory failure 
FEV1/FVC < 0.70 
 
Additional daily symptoms (Table 2) experienced by individuals with COPD include 
cough, sputum production, wheeze and fatigue.  Cough and sputum production are more 
frequently observed in individuals with a predominant chronic bronchitis component in their 
COPD presentation. Chest tightness and sleep disturbance were also reported, but at a lower 
frequency (Barnett, 2005; Barr et al., 2005; Calverley et al., 2005; Chen,  Chen, Lee, Cho, & 
Weng, 2008; Donaldson, Wilkinson, Hurst, Perera, & Wedzicha, 2005; Gift & Shepard, 1999; 
Jablonski, Gift, & Cook, 2007; Miravitles, Anzueto, Legnani, Forstmeier, & Fargel, 2007; 
O’Neill, 2002; Reishtein, 2004; Seemungal, Donaldson, Bhowmik, Jeffries, & Wedzicha, 2000).   
Table 2 
 
 COPD Symptoms Experienced Daily  
               
Author                   Purpose                             Sample               Study Design             Usual Symptoms 
Barnett (2004) Pt experience of COPD N=10 Phenomenological Dyspnea 
fatigue 
cough 
 
Barr et al. 
(2005) 
Physician and patient 
perception of COPD 
N=1023 Survey dyspnea 90% 
cough 75% 
sputum 71% 
sleep disturbance 60%  
 
Calverley et al. 
(2005) 
Relationship between 
symptoms and 
treatment during 
exacerbation 
N=796 
mean age 64 
FEV1  36% 
 
Secondary analysis 
clinical trial data 
Rate 0-4 (min-max) 
SOB  1.9 
Cough  1.4 
chest tightness  1.2 
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Author                   Purpose                             Sample               Study Design             Usual Symptoms 
Chen et al. 
(2008) 
Self-management 
behaviors 
N= 18 
mean age 74 
 
Qualitative 
description 
Dyspnea 
cough  
sputum 
 
Donaldson et 
al. 
(2005) 
Exacerbations and time 
spent outdoors 
N=147 
mean age 68 
M101/F46 
FEV1 40.9% 
 
Prospective cohort dyspnea 55% 
wheeze 68% 
cough 54% 
sputum 47.6% 
Gift & Shepard 
(1999) 
Symptoms experience 
in COPD- determine 
differences between 
men and women 
N= 104 
mean age 60 
56M/48W  
FEV1  23% 
Correlational, 
predictive 
dyspnea 100 % 
fatigue 58 % 
cough 55 % 
dry mouth 50% 
 
Jablonski et al. 
(2007) 
Evaluate Memorial 
Symptom Scale for use 
with COPD 
N=72 
mean age 
FEV1  30% 
Secondary data 
analysis 
SOB 
fatigue 
cough 
difficulty sleeping 
 
Kinsman et al. 
(1983) 
Determine normative 
data for frequency of 
occurrence of each 
Bronchitis-Emphysema 
Symptom Checklist 
(BESC) symptom 
category 
 
N= 146 
mean age 63 
85M/61F 
Tool development dyspnea  88% 
fatigue  92% 
sleep disturbance 74% 
sputum 79% 
 
O’Neill (2002) Explore illness 
representation in 
women 
N= 21 
mean age 67 
F 21 
Qualitative 
description 
dyspnea 100% 
fatigue 47% 
sleep disturbance 
 
Reishtein 
(2004) 
Relationship between 
symptoms and 
functional performance 
N=100 
mean age 67 
M77/F23 
FEV1 41% 
Correlational Dyspnea 
fatigue 
sleep disturbance 
 
 
Seemungal et 
al. 
(2000) 
Time course and 
recovery of 
exacerbation 
N=101 
mean age 67.5 
FEV1 41.9% 
Prospective cohort dyspnea 40.6% 
wheeze 34.7% 
cough 54.5% 
sputum 58.4% 
 
COPD symptoms vary in intensity from hour to hour and day to day (Meek, Lareau, & 
Anderson, 2001; Rabe et al., 2007).  A unique pattern of symptoms characterize each patient’s 
clinical presentation, and include temporal variations of dyspnea and fatigue symptoms 
(McCarley, Hanneman, Padhye & Smolensky, 2007).  This day-to-day variation complicates 
symptom awareness (Adams, Chavannes, Jones, Ostergaard & Price, 2006).  The symptoms 
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experienced by individuals with COPD are not only physically distressing, but have 
psychological and social consequences that contribute to the overall burden of this disease (Dodd 
et al., 2001).  
Burden of COPD 
In a cross-sectional study (N=3619) on the burden of COPD, dyspnea was reported to 
constitute the greatest burden for individuals (Izquierdo et al., 2009).  This was supported by 
participants in Adams, Chavannes, Jones and Ostergaard’s (2006) grounded theory study (N= 
23), O’Neill’s (2002) qualitative descriptive study (N=21) and Fraser, Kee & Minick’s (2006) 
phenomenological study (N= 10).  Participants in these qualitative studies described how 
dyspnea invaded every aspect of their daily lives (Fraser et al., 2006) impacting even the 
simplest of daily living activities, such as moving between different levels in their homes 
(Adams et al., 2006).  They also described an illness that was unpredictable, especially with 
fluctuating levels of physical endurance and dyspnea, (Adams et al., 2006) and took up too much 
time related to symptom management and trying to get well (Cicutto et al., 2004).  
Fatigue, the perception of mental or physical exertion, is also common in COPD.  In a 
descriptive study of the prevalence, duration and severity of fatigue among patients with COPD, 
Theander and Unosson (2004) collected data using the Fatigue Impact Scale (FIS) (Fisk, Ritvo, 
Ross, Haase, Marrie, Schlech, 1994).  The questionnaire was completed by 36 patients and 37 
age- and sex-matched controls.  Daily fatigue was reported by 47.2% of patients with COPD, 
compared to 13.5% of the controls.   Fatigue duration was between 6 and 24 hours in 52.7% of 
patients, and 18.9% of control subjects.  Forty-four percent of the patients rated fatigue as the 
most bothersome, or one of the most bothersome symptoms.  The impact of fatigue on cognitive, 
physical and psychosocial functioning were also greater in the patient group than the control 
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group, as indicated by higher scores in the corresponding FIS dimensions (9.5, 19.2, 30.9 vs. 5.7, 
6.8, 10.2, respectively, t-test: p < .05) 
Significant correlations between fatigue and dyspnea have been reported in several 
studies of men and women with moderate to severe COPD (Baghai-Ravary et al. (2009) r = .34, 
p < .001, N=107); Gift & Shepard (1999) r = .63, p < .01, N=143; Kinsman et al. (1983) r = .76, 
p < .05, N= 146). Reishtein (2005) also reported a significant relationship between fatigue and 
functional performance (r = -.54, p < .001) in a sample of 77 men and 23 women with moderate 
to severe COPD.  Furthermore, Baghai-Ravary et al. (2009) reported that fatigue was not related 
to FEV1 (r = .1, p = .3) or GOLD stage (ANOVA p = .07), suggesting that the experience of 
fatigue was not associated with disease severity. 
Studies have also shown that fatigue in COPD is associated with depression and reduced 
health status (Al-shair et al., 2009; Baghai-Ravary et al., 2009; Nishimura et al., 2009; Webster, 
Cella & Yost, 2003).  Fatigue, measured on the chronic illness therapy-fatigue scale (FACIT-
fatigue) (Webster et al., 2003), was significantly associated with higher depression scores on the 
Center for Epidemiology Studies Depression scale (CES-D)  (Radloff, 1977).  Greater fatigue on 
the FACIT-fatigue (mean 27.7 vs. 40) was associated with clinical depression, defined as a CES-
D score ≥ 16  (r = -.59, p < .001) (Baghai-Ravary, 2009).  Fatigue was also associated with 
decreased time outdoors (r = -.43, p < .001) (Baghai-Ravary, 2009), which has been shown to 
also increase depression and HRQOL (Donaldson et al., 2005).  The association between fatigue 
and HRQOL was evident in the higher scores on the St Georges Respiratory Questionnaire 
(SGRQ) (Jones, Quirk, Baveystock, 1991), which were significant for total score (r = .61, p < 
.001) as well as the activity, impact and symptom subscales (r = -.44; r = -.65; r = -.36; all, p < 
.001) (Baghai-Ravary et al., 2009). 
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Al-shair et al. (2009) reported a significant relationship between depression and 
performance on a 6-minute walk distance test (6MWD) (rho = 0.33, 0.4, p < .001) even after 
controlling for severity based on FEV1.   Depression on the CES-D was a predictor of poor 
exercise tolerance (OR 1.11, 95% CI 1.05-1.18, p <.001) as well as depression on the BASDEC 
(Adshead, Day, Pitt, 1992) (OR 1.25, 1.08-1.42, p = .001).  A relationship between depression 
and poor health status was also demonstrated and was more pronounced than the impact of 
severe dyspnea on health status.    
Depression and anxiety are common features of COPD with higher rates of depression 
and anxiety reported in individuals with COPD compared to the general population (Putman-
Casdorph & McCrone, 2009).  Al-shair et al. (2009) identified depression in 17% of subjects 
(N=122) using the BASDEC, and 21% of patients using the CES-D assessment tool.  Funk et al. 
(2009) identified higher levels of depression (51%) in their subjects (N=122), as well as a high 
prevalence of anxiety (51% males, 57% females).  The presence of co-morbid anxiety was also 
noted in 78% of depressed individuals, and co-morbid depression in 78% of anxious individuals.  
According to de Voogd et al. (2009), depression impairs self care resulting in a lower body mass 
index (BMI), poor compliance with treatment plan and poor help-seeking behavior.  In a sample 
of 121 men and women, depression was also associated with continued smoking behavior (r = 
.27, p < .01) and mortality (OR 1.93, 95% CI 1.12-3.33), independent of other factors (de Voogd 
et al., 2009).  As COPD severity increases, social interaction and physical activity begin to 
decline, leading to increased dependence, social and emotional isolation, and poor HRQOL.  
These physical and emotional challenges often lead to feelings of frustration and depression 
(Cicutto et al., 2004; Fraser et al., 2006).  In a correlational study (N=92) Andenaes, Kalfoss and 
Wahl (2004) reported that longer disease duration was related to more physical symptoms and 
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additional psychosocial impact.  On regression analysis, psychological distress , measured by the 
Hopkins Symptom Checklist (HSCL) (Derogatis, Lipman, Rickels Uhlenhuth & Covi, 1974), 
significantly correlated with St. Georges Respiratory Questionnaire (SGRQ) impact scores (r = 
.41, p < .001), however not with the symptom (r = .01) or activity scores (r = .14), indicating that 
psychological distress was associated with the impact of the disease rather than with the 
symptoms themselves.   
The impact of COPD on social activity and work productivity was evident in the findings 
of a multinational survey study (N=3265) conducted in North America and six European 
countries (Rennard et al., 2002).  More than one-third (35.7%) of subjects reported they were 
unable, or had limited ability to work.  In subjects who did work, 45.3% reported work time loss 
related to their COPD symptoms.  All subjects reported some level of impact on ADLs, with 
middle age subjects reporting functional limitations similar to older adults in the area of 
recreation (65%), socialization (40%), household chores (50%), family activities (38%) and 
sexual relationships (35%).   Only normal physical activity remained a greater burden for 
individuals > 65 (67%) than those < 65 (56%) due to their COPD (Rennard et al., 2002).  This 
may have been related to the additive effect of aging; however the study design did not control 
for these confounding variables.  Regardless, the disease impact on normal daily living and 
important age-related developmental tasks is significant. 
COPD morbidity and mortality 
 The body-mass, airflow obstruction, dyspnea and exercise capacity (BODE) index (Celli, 
Cote et al., 2004) is a multidimensional grading system that assesses the respiratory and systemic 
expressions of COPD to categorize and predict outcomes in this population.  Individuals are 
scored on four criteria, receiving a score of 0-4 in each criteria area for a total score range of 0-
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10 (Table 3).  Individuals are then staged according to their BODE index score (Table 4).  
Higher BODE index stages are associated with greater morbidity and mortality.  In a prospective 
cohort study (N=625) designed to validate the BODE index, individuals with higher BODE 
scores were at higher risk for death; the hazard ratio for death from any cause per one-point 
increase in the BODE score was 1.34 (95 percent confidence interval, 1.26 to 1.42; p <.001), and 
the hazard ratio for death from respiratory causes was 1.62 (95 percent confidence interval, 1.48 
to 1.77; p <.001).  The BODE index is considered to be superior to the GOLD classification for 
assessing morbidity (Pauwels et al., 2001) and predicting in-hospital mortality following COPD 
exacerbation (Celli, Cote et al., 2004). 
Table 3  
 BODE Index  
                                                                       Points on BODE Index 
                                                0                                     1                              2                                 3 
FEV1 % predicted     ≥ 65          50-64    36-49         ≤ 35 
Distance walked in 6 
minutes  
    ≥ 350        250-349  150-249        ≤ 149 
MMRC dyspnea scale       0-1             2        3           4-5 
BMI     ≥ 21          ≤ 21 
 
 Table 4 
 BODE Stage 
Stage Index Score 
  I     0-2 
  II     3-4 
  III     5-7 
  IV     8-12 
 
A significant relationship between BODE scores and depression scores on the CES-D has 
been demonstrated (rho = 0.35, p < .001).  Patients with higher BODE scores are more likely to 
be depressed (OR 4.0, 1.5-10.6, p = .007).  Depression and GOLD stage were not correlated (OR 
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1.2, 0.5-2.7, p = .9).  In fact, both anxiety and depression correlated more closely with BODE 
stage (Kτ = 0.20, p = .001; Kτ = 0.41, p < .001) than FEV1/GOLD (Kτ = -0.13, p = .037; Kτ = -
0.28, p < .001).  The mean anxiety scores on the Hospital Anxiety and Depression scale (HAD-
A) (Zigmond & Snaith, 1983) for BODE Stage 1-IV were 6.3, 7.7, 9.5 and 8.5 respectively, p < 
.0001.  Mean depression scores in the HAD-D (Bjelland et al., 2002) for stages were 4.6, 7.2, 9.7 
and 10.9 respectively, p < .0001 (Funk, Kirchheiner, Burghuber, & Hart, 2009).  These findings 
indicate that overall disease impact constitutes a greater psychological burden than disease 
severity alone.    
There is currently no cure for this progressive, debilitating disease.  Treatment is aimed at 
slowing the rate of disease progression, slowing lung decline, improving overall functional 
ability, minimizing symptoms and maintaining HRQOL (Rabe et al., 2007).  This is 
accomplished through an overall disease management plan with a focus on prevention and early 
treatment of exacerbations (Bourbeau & van der Palen, 2009; Rabe et al., 2007), the major 
precipitator of overall decline (Donaldson & Wedzicha, 2006; Donaldson, Seemungal, 
Bhowmik, & Wedzicha, 2002; Seemungal et al., 1998) and mortality (Soler-Cataluna, Martinez-
Garcia, Sanchez, Salcedo, & Navarro, 2005) in patients with COPD.   
COPD exacerbation manifestations, diagnosis and classification  
Acute exacerbations are relevant events in COPD disease progression, and are related to 
morbidity, mortality (Donaldson et al., 2002; Donaldson et al., 2006; Seemungal et al., 2000) and 
poorer HRQL (Miravitles et al., 2004; Seemungal et al., 1998).  They are also a major cause of 
heath care utilization and cost (Yu-Isenberg et al., 2005).  
As COPD is heterogeneous in its pattern and presentation, so too is COPD exacerbation.  
Individuals experience a wide range of symptoms during their exacerbation, including increased 
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dyspnea, increased cough, increased sputum and/or purulence, wheeze, chest tightness and fever.  
Non-specific symptoms such as general malaise, fatigue, may also be present (Seemungal et al., 
1998).   The pattern of symptoms exhibited with each exacerbation is variable among 
individuals, but consistent within individuals (Kessler et al., 2006).  An individual’s unique 
exacerbation pattern is likely influenced by the characteristics of their underlying disease 
pathology as well as the infectious/inflammatory trigger.  Subjective symptoms are accompanied 
by an objectively measured increase in airway obstruction (reduced FEV1) (Seemungal et al., 
2000), however FEV1 change alone is not diagnostic of exacerbation. 
Bacteria and /or viral infections trigger 50-70% of exacerbations, but non-infectious 
factors have also been implicated.  Moreover, in 30% of exacerbations, no cause has been 
identified (Balcells et al., 2009).  Viral upper respiratory infections (URI) are a frequent 
exacerbation precipitant (50%) and are associated with more severe exacerbations, 
hospitalizations, and longer recoveries (Wedzicha, 2004).  Bacterial infection accounts for 30-
50% of COPD exacerbations, and are more frequently indicated in individuals with FEV1 % 
predicted < 50%, or severe disease (Sethi, Evans, Grant, & Murphy, 2002).  Increased air 
temperature, stress and air pollution play a minor role in COPD exacerbation, and often are a co-
contributor (Mallia & Johnston, 2005).   
Increased breathlessness is the primary symptom reported by individuals experiencing an 
acute exacerbation, and may or may not be accompanied by increased cough and sputum, change 
in sputum purulence, wheezing, chest tightness, and fever as well as non-pulmonary complaints 
such as fatigue, malaise, insomnia, depression (Rabe et al., 2007).  Although many describe one 
or more major Anthonisen criteria symptoms, many individuals reported minor symptoms such 
as fatigue, sore throat, cold symptoms and mood disturbance.  For example, in the Seemungal et 
                                                                              14 
al. (2000) study which identified 504 exacerbations in a population of 101 subjects, 8 % were 
associated with three major symptoms, 37% with two major symptoms and 55% of exacerbations 
were signaled by minor symptoms.  Patients and practitioners alike need to be more aware of the 
possibility of non-hallmark respiratory symptoms being an indicator of exacerbation onset in 
order to more effectively intervene in a timely fashion (Rabe et al., 2007).  Table 5 outlines 
exacerbation symptoms reported by subjects in the cited studies.  The symptoms represent a 
worsening of their daily symptoms, which are unique to their individual disease component, as 
well as characteristics of the exacerbation trigger, such as bacterial or viral infectious agents.    
A comparison of the symptoms listed on Table 2 and Table 5 will highlight the reason many 
individuals with COPD have difficulty recognizing exacerbations of their disease, as many of the 
listed symptoms are simply an increase in intensity of usual daily symptoms, or those of the 
common cold.   
Table 5 
 
COPD Exacerbation Symptoms 
 
Study Purpose Sample Study method Exacerbation symptoms 
increased or new onset 
Adams et al. 
(2006) 
 
Multinational 
Uncover patient 
perspective on 
COPD 
exacerbation 
23 subjects 
16M/7F 
Mod-severe  
mean age 67.7 
 
median yearly 
exacerbation rate 
3.0 (self-report) 
Grounded theory breathing difficulty 
sputum changes 
 cough (increased) 
coryzal symptoms 
wheezing 
anorexia 
pain 
dizziness  
fatigue, weakness, malaise, 
sweating 
 
Bourbeau et al. 
(2007) 
 
Canada 
Impact of early 
identification of 
AE on health status 
421 subjects 
M239/ 
FEV1/FVC 52% 
mean age 66 
 
mean  yearly rate 
exacerbation 1.6 
Prospective cohort- 
2 year 
increased cough (69%) 
dyspnea (65%) 
sputum color (41%) 
sputum amount (61%) 
wheeze 
chest tightness 
cold symptoms 
sore throat 
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Study Purpose Sample Study method Exacerbation symptoms 
increased or new onset 
All had worsening of 1 
Anthonisen symptom and 
minor symptom 
 
Costi et al. 
(2006) 
 
Canada 
Determine how 
COPD patients 
describe their 
exacerbation 
experience. 
 
32 subjects 
18M/14F 
FEV1 35% 
mean age 68 
 
Qualitative 
description 
difficulty breathing (84%),  
fatigue (81%) 
cold symptoms (59%) 
sputum color change (53%)  
increased sputum (47%) 
cough (44%)  
mood disturbance (44%) 
chest tightness 
 
Triggers: 
environment (47%) 
infection (31%) 
excess activity (25%) 
emotional factors (16%) 
change in medications (9%) 
 
Most patients ≥ 1 major 
Anthonisen symptom 
Many- fatigue, cold 
symptoms,  mood disturbance 
 
Donaldson et al. 
(2003) 
 
UK 
Changes in 
exacerbation 
severity/frequency 
132  subjects 
91M 
FEV 1  38.4% 
mean age 68.4 
 
(1111 
exacerbations) 
54% unreported 
 
median yearly 
exacerbation  rate 
2.53 
 
Longitudinal 
5 years 
dyspnea (60%) 
sputum purulence (17%) 
sputum volume (34%) 
cold symptoms (31%) 
wheeze (38%) 
sore throat (13%) 
cough (30%) 
Hurst et al.  
(2009) 
 
UK 
Temporal 
clustering of 
exacerbations 
297 subjects 
191M/106F 
FEV 1  45.4% 
 
(2189 
exacerbations) 
 
median yearly 
exacerbation  rate 
1.97 
 
Prospective cohort- 
12 years 
Symptoms for isolated, initial 
and recurrent events 
 
dyspnea (67- 73%) 
sputum purulence  (29-31%) 
sputum volume  (47-51%) 
wheeze  (37-33%) 
cold symptoms (37%, 31, 
27%) 
sore throat (17%, 13%, 11%) 
cough  (40%, 31%, 31%) 
 
Kessler et al. 
(2006) 
 
Europe 
Patient 
understanding, 
detection, 
experience of  
125 subjects 
82M/43F 
FEV1 50% 
mean age 66.6 
Qualitative 
description 
dyspnea (38.4%) 
fatigue (10.4%) 
URI (9.6%) 
cough (8.8%) 
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Study Purpose Sample Study method Exacerbation symptoms 
increased or new onset 
AECOPD   
mean yearly rate 
exacerbation:4.6 
 
pain (8%) 
Langsetmo et al. 
(2008) 
 
Canada 
Underreporting of 
exacerbations 
421 subjects 
59% M 
FEV1 46% 
mean age 66.5 
 
 
(486 
exacerbations) 
68% unreported 
 
mean yearly rate 
exacerbation 2.7 
 
Secondary analysis dyspnea (72%) 
sputum amount (42%) 
sputum color (21%) 
Miravitles et al. 
(2007) 
 
Europe 
Identify patient 
perceptions of AE 
and treatment 
expectations 
1107 subjects 
39% male 
51% > 51 yrs old 
 
80%  ≥ 1 
exacerbation/yr 
 
 
Telephone survey dyspnea (78%) 
cough (71%) 
mucus color (71%)  
SOBOE (49%) 
fatigue (48%) 
wheezing (47%) 
URI (45%) 
chest tightness (42%) 
 
O’Reilly et al. 
(2006) 
 
UK 
Incidence and  
burden of AE 
309 subjects 
56% M 
FEV1 50% 
 
mean yearly rate 
exacerbation:  
2.3 sx-based 
2.8 event-based 
33%  > 3/yr 
 
Prospective cohort-
1 year 
dyspnea (75%) 
sputum (49%)  Fev1 < 50% 
             (39%)  Fev1 > 50% 
minor symptoms: 
56%  Fev1 > 50% 
39%  Fev1 > 50% 
Parker et al. 
(2005) 
 
Canada 
Physiologic 
changes during AE 
symptom recovery 
20 subjects 
M7/F13 
FEV1 40% 
 
exacerbations 20 
 dyspnea (100%) 
cough (80%) 
sputum (70%) 
sputum color (65%) 
 
 
Russell et al. 
(1998) 
 
Europe 
Explanatory model 
of hospitalization 
 
 
30 subjects  
30M 
FEV1 < 41% 
mean age 67 
 
 
Qualitative 
description 
Dyspnea 
chest pain, 
sleep difficulties 
cough 
fatigue 
nausea 
malaise 
syncope 
 
Seemungal et al. 
(2000) 
 
Describe time 
course and 
characteristics of 
101subjects 
M73/F28 
FEV1 42% 
Prospective cohort- 
London  
1995-1998 
Dyspnea (64%),  
increased sputum (26%), 
sputum purulence (42%) 
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Study Purpose Sample Study method Exacerbation symptoms 
increased or new onset 
UK exacerbation 
 
mean age 67  
 
(504 
exacerbations) 
50% unreported 
 
mean  yearly rate 
exacerbation: 2.4 
 
 
cold symptoms (35%) 
wheeze (35%) 
sore throat (12%) 
cough (20%) 
 
37% associated with 2 major 
symptoms 
8% had 3 major symptoms 
 
Wilkinson et al. 
(2004) 
 
(UK) 
Determine effect 
of early treatment 
on exacerbation 
outcomes 
128 subjects   
128M 
FEV1/FVC 43% 
mean age 67.3 
 
(1099 
exacerbations) 
60% reported 
 
median 
exacerbation rate 
2.51/year 
 
Delay: median 
3.69 days 
Prospective cohort 
UK 
(1996-2002) 
 
 
Dyspnea (65.7%) 
sputum purulence (26.6%), 
sputum volume (41.3%) 
cold symptoms (29.1%) 
cough (30.7%) 
increased wheeze (31.7%) 
sore throat (13% 
 
Since there is no single diagnostic symptom or group of symptoms, no definitive sign   
(Celli, MacNee et al., 2004; Pauwels et al., 2004; Seemungal, 1998) and no serologic markers for 
COPD exacerbation (Donaldson & Wedzicha, 2006; Pauwels et al., 2004), diagnostic criteria are 
based on several working definitions developed by researchers for the purpose of their 
interventional studies, or by international panels of experts trying to develop a consistent 
definition (Pauwels et al., 2004).  Anthonisen et al. (1987) put forth the classic definition, based 
on patient symptomology, which is used by many practitioners and researchers today (Table 6) 
This definition has been modified (modified Anthonisen criteria) to include more discrete criteria 
and terms such as:  the patient experiences two or more of three major symptoms for two 
consecutive days (Seemungal et al., 1998).   
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Table 6 
Anthonisen Exacerbation Typology 
Type Definition 
Type 1 (major symptoms) The occurrence of increased dyspnea, sputum volume 
and increased sputum purulence 
Type 2 Two Type 1 (major) symptoms present 
Type 3 One Type 1 (major) symptom in addition to at least one 
of the following (minor) symptoms: upper respiratory 
infection in past 5 days, fever, increased wheezing or 
cough, 20% increase in respiratory or heart rate 
Modified Anthonisen Criteria For at least 2 consecutive days, either two or more of 
three major (Type I) symptoms or any one major 
symptom together with a minor (Type 3) symptom 
 
   More recently, an international work group of respiratory physicians developed the 
following consensus definition, which was presented at the Thomas L. Petty 42nd Annual Aspen 
Lung Conference:    
A sustained worsening of the patient’s condition, from the stable state and beyond normal 
day-day variations, that is acute in onset and necessitates a change in regular medication 
in a patient with underlying COPD (Rodriguez-Roisin, 2000, p 399S). 
The purpose of developing a standardized definition was to guide patient treatment seeking 
decisions and physician intervention decisions.  It would also standardize clinical trial 
definitions, allowing for results to be evaluated and compared.  This operational definition has 
proved problematic to some researchers due to measurement issues as well as the vagueness and 
subjectiveness of the terms:  sustained worsening and change from stable state (Pauwels et al., 
2004).  
 Researchers further categorized exacerbations in terms of clinical presentation (symptom-
based) (Anthonisen et al., 1987) and/or health care resource utilization (event-based) (Rodriguez-
Roisin, 2005).  Symptom-based definitions rely on worsening symptoms, primarily those 
described in the Anthonisen Type 1 definition.  However, not every individual with COPD 
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experiences these three specific symptoms in their exacerbation pattern, making it problematic 
(Pauwels et al., 2004).  A recent approach towards helping patients to identify exacerbations 
using daily diary card recording is based on the symptom-based definition.  Patients monitor 
changes in their unique daily symptoms and the presentation of any new onset symptoms that 
may indicate impending exacerbation (Donaldson et al., 2005; Hurst et al., 2009; Langsetmo et 
al., 2008; O’Reilly, Williams, Holt, & Rice, 2006; Seemungal et al., 1998; Seemungal et al., 
2000; Wilkinson et al., 2004).  
Event-based definitions of exacerbations are not concerned with symptom presentation, 
but a condition change that is significant enough to warrant a change in treatment and possibly 
hospitalization.  This definition is frequently used in clinical trials as it is treatment focused 
(Pauwels et al., 2004).  Unfortunately, for the purpose of research, event-based definitions do not 
capture unreported exacerbations (Seemungal et al., 2000).  This controversy is a concern when 
comparing studies, and/or outcomes related to treatment success (Pauwels et al., 2004).   
Annual exacerbation rates vary from as few as one (Caverley et al., 2005) to as many as 
five (Kessler et al. 2006).  Lower rates are typically associated with studies using an event-based 
definition of exacerbation. This was supported in the reviewed studies, with reported symptom-
based exacerbation rates of 2.3-2.7 (Donaldson et al., 2003; Langsetmo et al., 2008; O’Reilly, et 
al., 2006; Seemungal et al., 1998; Wilkinson et al., 2004) and 4.6- 5.0 (Haughney et al., 2005; 
Kessler et al., 2006; Miravitles et al., 2007). Calverley et al. (2005) reported an annual 
exacerbation rate of 1.3 events per year using an event-based definition, and a rate of 2.4 events 
per year using a symptom-based definition with diary card analysis.  The higher symptom-based 
rate includes unreported exacerbations identified upon reviewing daily symptom diary cards.  
These would have been missed using only an event-based definition.  Lower annual exacerbation 
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rates (1.95) were also reported by Hutchinson et al. (2007) and Marin et al. (2009) who used an 
event-based definition in their studies. 
Among these studies, upwards of 50% of unreported exacerbations were identified 
retrospectively from daily symptom diary cards (Calverley et al., 2005; Donaldson et al., 2003; 
Hutchinson et al., 2007; Seemungal et al., 1998; Seemungal et al., 2000).  This represents missed 
opportunities for early treatment. Failure to report exacerbations and/or seek timely health care 
consult is associated with an increased risk of hospitalization (rho = 0.21, p = .04) (Seemungal, 
2000).  Wilkinson et al. (2004) state that early treatment of acute exacerbation is associated with 
reduced mortality, reduced risk of hospitalization, faster recovery, preserved lung function and 
better HRQOL.  Individuals that did seek treatment earlier in the course of their exacerbation 
were noted to exhibit worsening dyspnea (- 0.42, 95% CI: -0.76 to - 0.08, p = .016), sputum 
purulence (- 1.30, 95% CI: - 1.60 to - 0.92, p = .001) wheeze (- 0.59, 95% CI -0.93 to - 0.25, p = 
.001) or sore throat (- 0.78, - 1.23 to – 0.33, p = .001).  
 The rate of hospitalization for reported exacerbation events ranged from 6% in three 
prospective cohort studies, (Donaldson et al., 2003; Hurst et al., 2009; Wilkinson et al., 2004) to 
21% in an international survey (Miravitles et al., 2007).  Of note is the smaller sample size (132, 
297, 128 respectively) in the former studies compared to the larger sample size (N=1100) in the 
Mirivitles et al. (2007) study.  Since Mirivitles and colleagues (2007) conducted a survey study, 
information regarding disease severity was unavailable, and age was reported broadly as percent 
of subjects’ age 51 or greater, making further comparison between studies difficult.   
Physiologic recovery from exacerbation occurs 5-14 days after onset of the exacerbation 
(Haughney et al., 2005; Hurst et al., 2009; Kessler et al., 2006; Langsetmo et al., 2008; 
Miravitles et al., 2007; O’Reilly et al., 2006; Seemungal et al., 2000; Wilkinson et al., 2004).  
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The time course of recovery may be influenced by many factors, including exacerbation severity 
and symptom presentation.  Wilkinson et al. (2004) reported that individuals with more severe 
symptoms had a longer exacerbation (2.68 days per symptom, 95% CI: 2.06-3.31, p < .001) 
period.  Seemungal et al. (2000) found that increased dyspnea and cold symptoms at 
exacerbation onset was significantly associated with longer recovery.  Recovery was also found 
to take longer with recurrent exacerbations over time, with recovery time for FEV1 and 
symptoms to return to baseline increasing by nearly one-half day every year over time.  Although 
Seemungal et al. (2000) demonstrated a median recovery rate of 6 and 7 days for pulmonary 
function and symptoms respectively, they also noted that only 75% of subjects had recovered to 
baseline at 5 weeks, and 7.1% of subjects were still not recovered at 91 days.  Donaldson et al. 
(2003) and Kessler et al. (2006) reported that some subjects believed they never returned to 
baseline after their exacerbation event.   
Hurst et al (2009) recently published findings that add new understanding of 
exacerbations, as events that cluster in time.  In their sample of 297 patients with COPD they 
noted that individuals who experienced a recent exacerbation were at increased risk for another 
in the following 8-week period.  A recurrent exacerbation, defined as an additional exacerbation 
event within 8 weeks of the previous, and after five symptom free days, occurred in 50% of 
subjects.  Recurrent exacerbations contributed significantly to overall exacerbation frequency 
(rho= 0.81; p < .0001), and occurred at a median yearly rate of 0.18 (IQR, 0.00-0.89) per 
individual.  There was no difference in individual symptom presentation between initial and 
recurrent exacerbations, or in recovery time.  
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Burden of COPD exacerbations 
COPD exacerbations significantly impact the health status and HRQL of individuals, and 
worsen depression (Quint, Baghai-Ravary, Donaldson & Wedzicha, 1998).  In a prospective 
cohort study with 169 subjects (Quint et al., 1998) the presence of clinical depression (CES-D 
score > 16) increased from 42% of the population at baseline to 60% of the population at the 
time of exacerbation.  SGRQ scores were also independently associated with CES-D, and 
significantly worsened as CES-D score increased (r = .47, p < .001).  Each 2.4 unit increase in 
CES-D corresponded to a 4 unit change in SGRQ total score (r2 = .03), which is the unit measure 
that constitutes a minimum clinically significant difference.  Individuals who spent less time 
outdoors following their exacerbation were also more significantly depressed (r = - .34,  
p <.001) and experienced a worsening in SGRQ score (r = -.22, p = .03) (Quint et al., 1998).   
Spencer, Calverley, Burge & Jones (2004) found that frequent exacerbations were 
independently associated with worsening of baseline SGRQ total score (P < .0001) and rapid 
deterioration of health status (p = .0003).   Health status, measured by SGRQ scores, deteriorated 
2 units.yr-1 (95% CI, 1.7-2.1, p=.004) in individuals with no exacerbations, and 2.6 units.yr-1 
(95% CI, 2.4-2.8, p= .004) in individuals who experienced exacerbations.  
Whereas, exacerbations increase depression, it has also been shown to increase 
exacerbation risk.  Jennings, DiGiovine, Obeid and Frank (2009) reported that depressed 
individuals were 2.8 times more likely to experience exacerbations than non-depressed 
individuals (95% CI, 1.1-7.3, p = .003).  In line with this association, the mental health (MH) 
score of the Medical Outcomes Study Health Survey- Short Form (SF-36) (Ware & Sherbourne, 
1992) has also been used as a valid predictor of exacerbation risk (Jennings et al., 2009; Parshall, 
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Mapel, Rice, Williams, & O’Reilly, 2008).  For every one-point change in MH score, 
exacerbation risk increases 12.6% (Jennings et al, 2009).  
 The BODE index (described earlier) is a sensitive measure used to assess the impact of 
exacerbations on individuals.  Cote, Dordley and Celli (2007) studied the impact of acute 
exacerbation on BODE outcomes.  A sample of 205 individuals with moderate-severe COPD 
was followed for 2 years.  As expected, individuals with a history of COPD exacerbations had 
worse baseline finding than those individuals with COPD who did not have an exacerbation 
event (4.2 +/- 2.1 vs. 3.57 +/- 2.3 respectively, p < .03).   Patients who experienced an 
exacerbation showed a significant worsening in BODE index of 1.38 points during the event, and 
remained above baseline up to 2 years (0.8 and 1.1 at 1 and 2 years respectively) compared to the 
control group that demonstrated no change from baseline.  
Deterioration in lung function is also associated with frequent exacerbations.  Donaldson 
et al. (2002) demonstrated that individuals who experience > 2.92 exacerbations a year (median 
4.2) have a significant decrease in FEV1 of 40 ml/yr compared to those 32 ml/yr in individuals 
with no, or infrequent exacerbation (median 1.9).  These individuals were also hospitalized more 
often, and for longer periods of time.  
If not treated early, acute exacerbations result in significant physical and psychosocial 
decline that persists from 2 weeks to several months. Early health care consult and treatment of 
an acute exacerbation of COPD reduces exacerbation severity and associated negative physical 
and psychosocial consequences.  However, as the studies have demonstrated, symptoms of 
exacerbation often go unrecognized contributing to a treatment delay and poorer outcomes.  
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Symptom recognition  
Symptom recognition and interpretation is complex in COPD, and involves an 
understanding of COPD, exacerbation, and relationship to disease severity (Wilkinson, 2004).  
There is a paucity of literature on symptom recognition in patients experiencing exacerbation of 
COPD.  Of three articles indexed in Pub Med for the terms symptom recognition and COPD 
exacerbation, only one specifically addressed patient symptom recognition.  The researchers in 
this study explored the influence of psychosocial factors on symptom recognition and disease 
self-management (Dowson, Town, Frampton & Mulder, 2004).   A further search of Pub Med 
identified 15 studies specific to symptom recognition studies in the myocardial infarction (MI) 
population. However, an MI is an acute event, and factors associated with symptom recognition 
may not be the same for individuals with chronic disease.  Symptom recognition in heart failure 
exacerbation is also scarce.  Five studies regarding symptom recognition in heart failure were 
indexed in Pub Med (Hedemalm, Schaufelberger, & Ekman, 2008; Horowitz, Rein, & Leventhal, 
2004; Jurgens, 2006; Jurgens, Hoke, Byrnes, & Riegel, 2009; Patel, Shafazand, Schaufelberger, 
& Ekman, 2007) and reviewed.  Heart failure and COPD are common in chronicity, symptom 
ambiguity and variability, presence of defining hallmark symptoms, and physical, emotional and 
economic burden of acute exacerbations (Jurgens, 2006).  Therefore, the heart failure literature, 
in addition to the COPD literature, was reviewed for insights into symptom recognition that 
might be extrapolated to the COPD population.   
Symptoms are sensations that signal a change in health status to the individual. 
Appropriate treatment-seeking behavior in response to symptoms is dependent upon symptom 
recognition, interpretation and evaluation of health status change (O’Neill & Morrow, 2001) 
making detection of subtle changes in symptom intensity challenging (Meek, Lareau, & 
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Anderson, 2001).  Symptom recognition encompasses perception and evaluation.  Symptom 
perception is the conscious cognitive interpretation of somatic information gathered through the 
senses that is subsequently interpreted through evaluation processes.  Although perception and 
evaluation are conceptually different, they are interdependent processes, where sensation is 
integrated with contextual meaning and interpretation (O’Neill, 2002).  If sensations are new to 
the patient, or ambiguous, recognition and subsequent action responses will be inadequate 
(Jurgens, 2006).  
Delay in seeking treatment for heart failure and COPD exacerbations may be related to 
poor symptom recognition of acute health status deterioration (Hedemalm et al., 2008; Horowitz 
et al., 2004; Insel, Meek & Leventhal, 2005; Jurgens, 2006).  Many individuals with COPD are 
always aware of their breathing, and may have less perceptual sensitivity to subtle changes (Insel 
et al., 2005).  This is particularly implicated in individuals with higher PaCO2 levels (Dowson et 
al., 2004).  Poor symptom recognition is also related to the chronicity of the conditions, daily 
presence of multiple symptoms and variability in intensity and frequency of symptoms that can 
sometimes be insidious (Carlson, Riegel, & Moser, 2001; Evangelista, Dracup & Doering, 2000; 
Insel et al., 2005; Jablonski, Gift & Cook, 2007; Main, 1983; Meek et al., 2001; Patel, 
Shafazand, Schaufelberger, & Ekman, 2007).  In Hedemalm et al. (2007), a qualitative study 
(N=42) of symptom recognition in heart failure, 52% of subjects failed to recognize early 
warning signs of decompensation (exacerbation).  Horowitz et al. (2004) reported that heart 
failure subjects (N=19) detected a change from baseline status, but failed to interpret them as a 
severe threat necessitating urgent health care consult.  Patient’s with COPD also need to 
understand there is a range of symptom intensity at baseline that constitute ‘good days’ and ‘bad 
days’.  It is also important for patients to recognize changes in symptom patterns that 
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distinguishes a ‘bad day’ from one that requires health care consult (Adams et al., 2006; 
Bourbeau & Nault, 2007).  This includes associating non-respiratory symptoms with acute 
exacerbation (Costi, Brooks, & Goldstein, 2006).  
  In both COPD and heart failure, dyspnea and fatigue are prominent symptoms at 
baseline and during exacerbation (Barnett, 2005; Gift & Shepard, 1999; Jablonski et al., 2007; 
Jurgens, 2006), and interpreting a change that is significant is challenging due to the high level of 
daily variability (Carlson et al., 2001).  Additionally, patients tend to normalize symptoms to 
contextual factors such as environment and fatigue, contributing to minimization of symptom 
threat (Posey, 2006).  This is especially evident in COPD, where environmental factors and 
physical activity play heavily into the symptom experience.  Dyspnea is especially ambiguous in 
COPD, as it is not specific to airway obstruction, but involves interplay of physiological and 
psychological factors (Reishtein, 2005).  However, even in heart failure, perception of dyspnea 
change is difficult, with perception improving significantly as the duration of change becomes 
longer (r= .30, p = .013) (Jurgens, 2006).  Wilkinson et al. (2004) call for further studies into 
mechanisms of symptom recognition in individuals with COPD to better inform how to improve 
reporting behavior during exacerbation and improve outcomes. 
Prodromal symptom recognition 
   Prodromal symptoms are subtle symptoms that present before the onset of an illness, 
and are often ignored (Seemungal et al., 2000).   To date, no studies were found in which patient 
awareness of prodromal symptoms that precede COPD exacerbation was the specific research 
topic.  However, the importance of prodromal symptom recognition in facilitating early 
treatment of COPD has been discussed (Langsetmo et al., 2008; Seemungal et al., 2000).  The 
authors acknowledge the presence of a prodromal period of from one to seven days prior to 
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exacerbation onset.  Seemungal et al. (2000) reported that during this period subjects 
experienced subtle changes in dyspnea, cold symptoms, sore throat and cough, without a 
significant decline in lung function measurement.  However, on the day of exacerbation onset, 
subjects experienced a sharp increase in dyspnea (65%), sputum purulence (42%), cold 
symptoms (35%), wheeze (35%), sputum amount (26%), cough (20%) and sore throat (12%). 
Peak expiratory flow (PEF) measurements also declined by 8.6L/min at onset of exacerbation. 
Since intervention prior to this sharp decline can significantly alter outcomes, prodromal 
symptoms (dyspnea, cold symptoms, sore throat and cough) are particularly important to 
recognize and respond to in an attempt to avert exacerbation (Langsetmo et al., 2008). 
Treatment Delay 
It has been well documented that 50% or more COPD exacerbations go unreported 
(Calverley et al., 2005; Donaldson et al., 2003; Hutchinson et al., 2007; Seemungal et al., 1998; 
Seemungal et al., 2000) and therefore are untreated, or treated late in the course of exacerbation, 
(Calverley et al., 2005).  Individuals delayed seeking treatment from a median of 3.69 days 
(Wilkinson et al., 2004) to 7 days (Gruffyd-Jones et al. (2007), often waiting until symptoms 
were unbearable (Chandra, Tsai, Camargo, 2009; Russell et al., 1998).  The reason for this delay 
is not clear. Individuals may not understand the disease course and importance of prompt health 
care consult and treatment (Rennard 2002, Wilkinson, 2004).  Depression has also been 
implicated in treatment delay, as depressed individuals often lack the motivation to seek care 
during a change in health status (Donaldson & Wedzicha, 2006; Dowson et al., 2004).  It is also 
not certain if unreported exacerbations are so mild as to be dismissed by patients as a normal 
day-to-day variation in their disease state (Donaldson & Wedzicha, 2006).  It is known that 
patients who do not report exacerbations consequently have a poorer HRQOL.  This is associated 
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with the prolonged recovery and physiologic impact of delaying treatment (Wilkinson et al, 
2004).  It is therefore imperative to understand the reason individuals delay seeking treatment, 
and intervene appropriately. 
Although treatment delay was not the primary research question in the following COPD 
studies, many factors associated with delay were extrapolated.  Situations and behaviors 
associated with delay included: poor provider relationship and/or communication (Adams et al., 
2006; Schofield, Knussen & Tolson, 2006), lack of specific knowledge about COPD (Adams et 
al., 2006; Dowson et al., 2004), unawareness of symptoms of worsening state (Adams et al., 
2006; Dowson et al., 2004; Schofield et al., 2006; Wilson et al., 2007), concern over family 
responsibilities (O’Neill, 2002), not wanting to bother health care providers (Gruffyd-Jones et 
al., 2007), fear of hospitalization (Gruffyd-Jones et al., 2007), lack of knowledge regarding when 
and where access to care (Gruffyd-Jones et al., 2007; O’Neill, 2002; Wilson et al., 2007), denial 
(Schofield, Knussen & Tolson, 2006), wait and see behavior (Schofield et al. 2006; Wilson et al., 
2007) and co-morbid depression (deVoogd et al., 2009; Putnam-Casdorph & McCrone, 2009; 
Wilson et al., 2007).  
The Asthma population shares some commonalities with the COPD population in 
symptomology and medication treatment, although asthma is more episodic in nature than 
COPD.  Research findings regarding treatment-seeking delay in this population may have 
implications for the COPD population as well.  Janson and Becker (1998) described treatment-
seeking delay in a sample of 82 patients with asthma.   Eighty-six percent of patients exhibited 
treatment-seeking delay, that was attributed to uncertainty (74%), not wanting to disrupt family 
(86.5%), minimization of symptoms (90%), having a previous bad experience with health care 
system (42%), fear of systemic corticosteroids (31%), a need to tough it out (46%), and 
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economic reasons (6%).  In this sample, 74% of patients had three or more reasons for delay, and 
16% experienced a “crisis” before seeking treatment.  Thirteen patients, who did not delay in this 
study, reported delaying treatment in the past but now feared they would die if they did not seek 
timely health care consult.  This was a result of the frightening near death experience they had 
during a previous exacerbation episode.   Similar to Jason and Becker’s (1998) findings, fear of 
death has been expressed by individuals with COPD (Andenaes, Kalfoss, & Wahl, 2006).  
Again, because of similarities between COPD and heart failure, the heart failure literature 
was examined to glean insight into delay in treatment seeking.  In the heart failure studies the 
inability to recognize and address worsening symptoms, inappropriate perception of illness threat 
(Horowitz et al., 2004), taking a wait and see approach, and barriers to care were cited as reasons 
for delay in seeking treatment (Horowitz et al., 2004; Patel et al., 2007).  Failure to recognize 
insidious symptoms of heart failure, and assess the seriousness of hallmark symptoms were also 
cited as causes of delay by the authors, stating 57% of subjects were uncertain as to the cause of 
their symptoms. Even experienced heart failure patients have difficulty recognizing subtle 
changes heralding worsening heart failure (Freidman & Quinn, 2008) and distinguishing between 
acute and chronic symptoms (Jurgens, 2006).  
Treatment-seeking delay is a problem that impairs health status, and is prevalent in acute 
and chronic illnesses.  In acute illness, unawareness of symptoms is a commonly reported feature 
of delay.  However, in chronic diseases, treatment delay involves multiple, complicated factors, 
as noted above.  Factors contributing to treatment delay in COPD need to be articulated so that 
prompt identification and treatment can be promoted, and health outcomes improved. 
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                                                   Summary   
A clear pattern of COPD symptoms, dominated by dyspnea and fatigue that varies in 
intensity from day to day has emerged from this review.  The presence of fatigue is also 
associated with a decline in physical function (Adams et al. 2006), worsening dyspnea (Baghai-
Ravary, 2009; Kinsman, 1983), depression and anxiety (Al-shair et al., 2009; Putnam-Casdorph, 
2009) that lead to social isolation and poorer HRQOL (Cicutto, Brooks & Henderson, 2004).  A 
constellation of exacerbations symptoms that present in a recurring, individualized pattern has 
also been highlighted.  In one study, more than one-half of exacerbations manifested with 
‘minor’ Anthonisen criteria symptoms (Seemungal et al., 2000).  Although these symptoms can 
be subtle, and often ambiguous, some subjects were able to identify and quantify them using a 
daily symptom diary cards in many of the studies (Caverley et al., 2005; Donaldson et al., 2003; 
Seemungal et al., 2000). However, this recognition did not translate effectively into meaningful 
action.  Fifty percent or more exacerbations, identified retrospectively from diary cards, went 
unreported and untreated, representing missed opportunities for timely treatment and improved 
disease outcomes (Caverley et al., 2005; Donaldson et al., 2003; Seemungal et al., 2000).  This is 
especially critical in light of new understanding of exacerbations as events that cluster in time, 
with recurrent exacerbation occurring within 8 weeks of the initial event, with multiplicative 
negative consequences (Hurst et al., 2009).  
 Across studies, subjects consistently delayed treatment seeking, often resulting in costly 
hospitalizations.  It is not understood why this delay occurs.  It is possible that patients are not 
appropriately judging the seriousness of their symptoms, are not recognizing symptoms (or 
symptom patterns) as signs of exacerbation, or that psychological mechanisms are affecting 
judgments and impeding action.  Since most of the physiologic, psychosocial and economic 
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burden of COPD is associated with acute exacerbation events, early recognition and treatment of 
acute exacerbations of COPD is an important management goal, and meeting this goal is 
predicated upon understanding how individuals with COPD recognize and respond to symptoms 
of exacerbation. 
                                    Purpose and specific aims 
The purpose of this qualitative descriptive study was to explore the COPD exacerbation 
experience. The specific aims are to:   
        1. Explore awareness of prodromal symptoms in the days preceding an acute exacerbation  
            of COPD. 
       2.  Describe recognition of symptom patterns associated with acute exacerbations. 
       3.  Identify dimensions of illness representation (identity, time-line, cause, consequence,        
           controllability) in individual descriptions of treatment-seeking delay during exacerbation 
           of COPD. 
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                                                                      Chapter 2 
                                               Theoretical Framework 
This chapter describes the Common Sense Model (CSM) of illness representation 
(Leventhal, Meyer & Nerenz, 1980) that undergirded this study (Figure 1) The CSM is based on 
the parallel response (process) model (Leventhal, 1970) and self-regulatory information 
processing theory (Leventhal, 1971) and is the result of an extended program of research by 
Leventhal and colleagues (Johnson & Leventhal, 1974; Leventhal, 1970; Leventhal, 1971; 
Leventhal, Meyer & Nerenz, 1980; Nerenz & Leventhal, 1983).  The Common-Sense Model is 
sometimes referred to as the Illness Perception Model, Illness Representation Model, Self-
regulatory Model and the Parallel Process Model (Hale, Treharne & Kitas, 2007).  The name 
changes reflect new evidence and insights into the mechanisms that underlie responses to health 
threats (Leventhal, 2011). 
Although there are other general self-regulation models that are similar in their use of a 
systematic process to modulate behavior, such as the Social Learning Model (Bandura, 1969), 
Health Belief Model (Rosenstock, 1966), Theory of Reasoned Action, (Fishbein & Ajzen, 1975), 
Self-Efficacy (Bandura, 1982), and The Self Regulation Model, (Carver & Scheier, 1981), the 
unique properties and assumptions of the CSM sets it apart from the others.  In this model, 
cognitive representations, or patient beliefs and expectations about a health threat or illness, are 
the central component of the theory.  Illness representations have five distinct attributes: identity, 
timeline, consequences, cause and control.  As an illness representation is formulated and   
processed through parallel cognitive and emotional processes, a subsequent health behavior is 
engaged (Brownlee, Leventhal & Leventhal, 2000, Diefenbach & Leventhal, 1996).  Because of 
the CSM's core construct of an illness representation with five distinct attributes, its parallel 
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processing of cognitive and emotional aspects of the illness threat, and focus on illness behavior, 
it is a good fit to guide this study.   Individuals experiencing acute exacerbation of COPD are 
challenged with distinguishing new or worsened symptoms from their day-to-day symptom 
experience, accurately representing the health threat as an exacerbation and taking appropriate 
action.  This is complicated by emotional processing of symptoms using prior experience 
memories, which may interfere with accurate illness representation and/or coping (action).  
The CSM is an information-processing model that describes the processes individuals use 
to represent their illness threat and take action, in the form of self-regulating behaviors.  Within 
the context of the common-sense model, self-regulation refers to the regulation of the physical 
self and available resources in order to achieve identified goals.  Actions taken in the process of 
regulation depend on each specific threat to health, resources available to the individual and the 
social context in which the individual is situated (Leventhal, Brissette & Leventhal, 2003).  The 
central assumption of the CSM is that information processing involves three stages: 
representation, coping and appraisal.  In the representation stage, individuals organize, analyze 
and interpret information and provide meaning.  Based on the specific representation that is 
formulated, a response is initiated during the coping stage.  In the final appraisal stage, coping 
responses are evaluated for effectiveness (Keller, Ward, & Baumann, 1989).  Individuals may 
process the same illness differently with subsequent occurrences, cope accordingly and appraise 
the event using different criteria each time (Leventhal & Cameron, 1987).  This dynamic 
processing and appraisal also distinguishes the CSM from the other self-regulatory models. 
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Figure 1.  The commonsense model of illness representation (Diefenbach & Leventhal, 1996) as 
applied to acute exacerbation of COPD.  Model was adapted and used with permission from Dr. 
Howard Leventhal.  The non-shaded boxes define the attributes of cognitive illness 
representation, and the stimulus for cognitive and emotional processing in this study. The light 
shaded concepts will be explored in this study. 
The CSM model also proposes that individuals use parallel cognitive (objective, 
controlled) and emotional (subjective, automatic) processes to generate “commonsense” 
perceptions of health threats that lead to the formation of an illness representation (Leventhal, 
Meyer & Nerenz, 1980, Leventhal, Meyer & Steele, 1984).  These processes are independent, 
but interact and may facilitate or interfere with treatment seeking (Leventhal, Meyer & Steele, 
1984).  As an exemplar, consistent with the proposed study, an individual with COPD might 
experience an increase in cough and sputum production and remember having similar symptom 
with a previous “exacerbation”, and thus form a cognitive illness representation of acute COPD 
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exacerbation.  Additionally, a parallel emotional reaction to the illness threat, one that involves 
the physician prescribing “those terrible steroid medications” may be formed.   
Illness representations provide the impetus for subsequent coping actions (adaptive or 
maladaptive) including treatment-seeking behaviors (Leventhal, Meyer & Nerenz, 1980).  If the 
illness threat is perceived as low, or involves undesirable treatment, then the representation may 
not lead to appropriate coping or action.  However if the symptom is perceived as serious, 
socially isolating or difficult to manage, then the individual is more likely to seek medical 
attention (Cameron & Leventhal, 1993).  Continuing with the prior exemplar, the individual may 
be directed by the cognitive representation to seek health care provider consult, or be influenced 
by the emotional process and take a wait and see approach in an attempt to avoid steroids.    
During the final stage of the process, outcomes are appraised (reappraised) and may 
initiate a revision of the initial representation, coping strategy, or emotional response (Leventhal, 
Benyamini, Brownlee et al., 1997; Leventhal, Meyer & Nerenz, 1980; Leventhal, Nerenz & 
Steele, 1984).  In the ongoing exemplar, this might include worsening of symptoms to an 
uncomfortable level, a revision of the cognitive and emotional representation to “serious” 
exacerbation, and possibility of death, and a new coping strategy that includes treatment seeking.   
As illustrated above, the illness representation stage of information processing involves 
cognitive and emotional processes.  There are five domains (attributes of an illness 
representation) associated with the cognitive process: identity, consequences, causes, timeline 
(Leventhal, Meyer & Nerenz, 1980) and controllability (Lau & Hartman, 1983). 
Identity 
Identity, the identification of disease/illness threat, is the core domain.  It involves 
abstract cognition (vulnerability) and concrete experiences (symptoms) to produce an illness 
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label (Leventhal, Meyer & Nerenz, 1980, Meyer, Leventhal & Guttmann, 1985).  Individual 
differences in the extent to which individuals are sensitive and aware of bodily sensations will 
also have a strong impact on this domain (Keller et al., 1989).  Appropriate identification and 
labeling of a symptom or illness is contingent on having knowledge (education or experience), 
intact symptom awareness, and the ability to perceive the seriousness of the event.  In the 
proposed study of individuals with COPD who experience multiple symptoms of varying 
intensity on a daily basis, it may be more difficult for them to differentiate acute illness-related 
symptoms from fluctuations in chronic symptoms.  Additionally, biochemical alterations related 
to chronic hypoxemia and hypercarbia may decrease perceptual abilities in these individuals.   
These deficits may contribute to failure to identify acute illness and/or inaccurate representation, 
and subsequent treatment delay. 
Consequences  
Consequences refer to the perceived physical, emotional, social and economic impact of 
the disease/illness threat.  It is influenced by the severity of the specific illness event and beliefs 
about the impact the illness will have on daily life and functioning (Leventhal, Meyer & Nerenz, 
1980).   For the COPD patient experiencing an acute exacerbation, undesired medication side 
effects, hospitalization and fear of death are a few common consequences that influence illness 
representation. 
Cause 
The perceived cause of a disease/illness can be multifactorial, and includes infection, 
stress, environment, emotions and heredity.  Causes are further categorized into internal and 
external factors.  Internal factors include personal behaviors that the individual believes caused 
their health threat. External factors include environmental factors, as well as the individual’s 
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belief system, such as fate (Leventhal, Meyer & Nerenz, 1980).  For a patient with COPD, 
continued smoking and overexertion are factors that may inhibit treatment seeking as a coping 
behavior due to self-incrimination over their “forbidden” lifestyle behaviors. 
Timeline 
The perceived timeframe for the onset and duration of the disease/illness constitutes the 
timeline.  It is often based on experience and abstract knowledge (Leventhal et al., 2003).  For 
the individual with a chronic disease like COPD, the timeline is naturally long, and these 
individuals often employ a “tough it out” strategy even during acute illness episodes. 
Controllability/Cure 
Lau and Hartman (1983) added this fifth attribute.  The individual’s perceived ability to 
prevent, control or cure an illness or disease influences their perception of disease controllability 
and how one goes about recovery (Lau & Hartman, 1983).  Again, the chronic, debilitating 
nature of COPD can negatively impact the individual’s perception of control over their disease 
and/or acute flare ups.  
Emotional Processes 
Emotional processes also affect illness representation, and can directly affect the 
representation as well as coping behaviors.  Emotional responses can alter perception of 
symptom severity as well as produce additional symptoms not otherwise included in an illness 
presentation.  Emotional responses may also negatively affect cognitive processing of the illness 
representation, resulting in ineffective coping responses (Leventhal, Brissette & Leventhal, 
2003).  Illness representations are also influenced by the individual’s existing knowledge base 
and information sources.  These knowledge and information sources include prior experiences 
with illness, media sources, health provider resources, social contacts and cultural beliefs 
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(Leventhal & Nerenz, 1985).  If an individual with COPD typically has moderate to severe 
exacerbations that require undesirable hospitalizations, then he might inaccurately represent a 
mild episode as a cold and self treat rather than seek health care consult.  This represents a 
missed opportunity for early treatment of exacerbation and preservation of vital lung function.  
Three patterns of illness representations, with interrelated attributes, have been proposed 
by Leventhal, Nerenz and Steele (1984) based on the identity, consequence, timeline and cause 
attributes: a short term acute episode model that culminates with cure, a cyclic model of illness 
exacerbation and remission, and a chronic model involving long-term symptom monitoring and 
care.  For the individual with COPD, the chronic model best fits their disease trajectory as their 
disease never goes into remission, but fluctuates from an individualized baseline level of stability 
to acute instability associated with each acute exacerbation. 
Use of the Common Sense Model in Research  
The common-sense model has been used in many qualitative and quantitative research 
studies to describe how individuals derive illness representations from symptoms, and how 
illness representations affect care seeking and management.  Findings in these studies have 
supported its usefulness in understanding health behaviors and predicting health outcomes.  The 
CSM also undergirded the development of the Illness Perception Questionnaire (IPQ), a 
psychometrically sound scale that provides a quantitative assessment of the cognitive and 
emotional components of the CSM of illness representation (Weinman, Petrie, Moss-Morris & 
Horne, 1996).  The following is a literature review of research (see Table 7) conducted in the last 
2 decades in which the CSM was used to better understand symptom recognition, coping actions, 
treatment adherence and/or care seeking.  Because of the paucity of literature available in which 
the CSM was used with the COPD population, research on non-COPD pulmonary (asthma) and 
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cardiac (heart failure) populations was included.  These chronic illnesses are similar to COPD in 
that they have a chronic illness trajectory that is often punctuated with cyclic episodes of acute 
illness (exacerbations).  Additionally, individuals with these illnesses often experience similar 
daily symptoms (dyspnea, fatigue) that fluctuate in intensity making exacerbation symptom 
recognition challenging. 
Table 7 
 
Studies that used CSM  
 
Author, Date Title Sample 
Method 
Assessment Tool 
Based on CSM 
Results 
Quantitative Studies 
Albert & 
Zeller (2009) 
Depressed 
patients 
understand heart 
failure (HF) 
prognosis but not 
how to control it 
N=219 Survey of illness 
beliefs in HF 
(Albert & Zeller, 
2007) 
 
Mean score ≥ 3 
indicates 
accurate illness 
beliefs 
Mean illness belief score = 2.99 
(slightly inaccurate beliefs) 
 
Consequence attributes 
significantly more accurate in 
individuals with higher levels of 
depression (mean 3.31, p = .001) 
 
Consequences, timeline, identity, 
control illness beliefs predictive 
of depression r =.22, p  .001; 
r=.17, p < .01; r=.13, p< .05; 
r=.12, p< .05 respectively. 
 
Howard, 
Hallas, Wray 
& Carby  
(2009) 
Relationship 
between illness 
perceptions and 
panic in COPD 
N=59 
Cross- 
sectional 
 
Illness 
Perception 
Questionnaire-
Revised (IPQ-R) 
(Moss-Morris et 
al, 2002) 
Beliefs relating to illness 
identity, timeline, consequences, 
emotional representation 
differed in panic (maladaptive) 
vs. non-panic (adaptive) 
emotional responses to COPD 
symptoms 
 
Panickers had stronger identity 
beliefs ( t = 2.734, p = .01), 
longer time-line expectation  ( t 
= 2.026, p < .05), perceived 
more severe consequences ( t = -
2.373, p < .05, and had greater 
emotional representation ( t= -
2.093, p < .05)  than non-
panickers 
 
Correlation between panic 
severity and consequences  
(.768, p=.000); emotional 
representation (.750, p=.000). 
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Author, Date Title Sample 
Method 
Assessment Tool 
Based on CSM 
Results 
Jurgens, Hoke, 
Byrnes & 
Riegel (2009) 
Why do elders 
delay responding 
to heart failure 
symptoms? 
N= 77 
Mixed-
methods) 
 
IPQ Poor symptom recognition due 
to subtlety/ambiguity of early 
warning signs to contribute to 
treatment delay > 3 days in 50% 
subjects 
 
56% did not know symptoms of 
HF (identity) or perceive 
seriousness (consequences) 
80% waited for symptoms to go 
away 
 54% believed had no control 
over symptoms (controllability) 
50% reluctant to trouble anyone 
 
Lack of emotional response to 
early symptoms (anxiety or fear) 
surprising, compromised action 
Scharloo, 
Kaptein, 
Schlosser, 
Pouwels, Bel, 
Rabe & 
Wouters 
(2007) 
Illness 
perceptions and 
QOL in patients 
with COPD  
N=171 
Correlational 
IPQ-R 
 
 
Illness perceptions related to 
QOL 
Identity (-.45, p <.001) 
Consequences (-.40, p< .001) 
emotional representation (-.60, 
p< .001) inversely correlated 
with QOL (QoLRIQ)* 
 
Less belief in chronic timeline 
associated with improved QOL 
(-.44, p< .001)(SF-36)** 
Cherrington, 
Lawson & 
Clark (2006)  
Illness re-
presentations of 
patients with 
systolic heart 
failure 
 
N=22 
Descriptive 
IPQ-R 
Subscale means 
measured (+/-) 
from neutral 
point (3) 
Subjects perceived HF as cyclic 
(3.5), chronic (4.1), with serious 
consequences (3.9) and some 
controllability (4.2) 
Jessop & 
Rutter (2003) 
Adherence to 
asthma 
medication: the 
role of illness 
representations 
N=737 
Exploratory  
 
Beliefs About 
Asthma 
Questionnaire 
(Jessop & Rutter 
1999)  
(based on IPQ) 
Illness representations that 
predicted adherence in multiple 
regression analysis included 
illness label t (227) = 2.53, p < 
.05), external cause t (227) = 
2.04, p < 0.05, and cure-control t 
(227) = 2.01, p < .05).   
 
Horne & 
Weinman 
(2002) 
Self-regulation 
and self-
management in 
asthma: exploring 
the role of illness 
perceptions and 
treatment beliefs 
in non-adherence 
to preventer 
medication 
N=100 
Cross-
sectional 
IPQ  
Beliefs about 
Medicine 
Questionnaire 
(BMQ) (Horne et 
al., 1999) 
Non-adherence associated with 
doubts about medication 
necessity (r = .32, p < .01), 
concerns about side effects 
 
Positive inter-correlations 
between medication necessity 
beliefs and timeline (r= .30, p < 
.01), consequences (r= .30,  p< 
.01) and adherence 
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Author, Date Title Sample 
Method 
Assessment Tool 
Based on CSM 
Results 
Byer & Myers 
(2000) 
Psychological 
correlates of 
adherence to 
medication in 
asthma (2000) 
N=64 
Correlational 
IPQ, BMQ Increased self-reported 
adherence correlated with illness 
perception domains of identity & 
timeline (long, chronic) (r = .40, 
p < .01; r= .30, p < .05   
  
Scharloo, 
Kapstein, 
Weinman, 
Hazes, 
Willems, 
Bergman, 
Rooijmans  98) 
Illness 
perceptions, 
coping and 
functioning in 
patients with RA, 
COPD and 
psoriasis 
N= 244 
COPD n=80 
Cross-
sectional 
IPQ 
 
 
COPD- in stepwise regression, 
passive coping explained 8% 
variance on physical function, 
(MOS)** small but significant 
finding.  Identity  explained 13% 
variance on role functioning, 
18% variance on social 
functioning  
 
Strong illness identity, passive 
coping, long illness duration, 
strong consequences belief and 
low FEV1 correlated with worse 
outcomes 
Qualitative studies 
Horowitz, Rein 
& Leventhal 
(2004) 
A story of 
maladies, mis-
conceptions and 
mishaps: 
effective 
management of 
heart failure 
N=19 
GT 
Interview and 
analysis guided 
by CSM 
Patient's low perception of HF 
symptoms and poor 
understanding of illness affect 
behavior. 
Patients understood HF as acute 
event > chronic event- so poor 
routine management, and 
preventative +/or minimizing 
behaviors during exacerbation. 
Themes:  
1. Inadequate information about 
CHF (impacts all domains of 
representation) 
2. Insufficient tools to prevent, 
recognize, act on exacerbations 
in early stages 
3. Barriers to care 
 
O’Neill (2002)                       Illness
representation and 
coping of women 
with COPD: a 
pilot study 
N=21 
Qualitative 
description 
Interview and 
analysis guided 
by CSM 
Causes and consequences 
attributes most fully elucidated 
in illness representations. 
Subjects has correct label for 
identity (n=20) and a vague 
timeline representation. Coping 
strategies were triggered by 
beliefs about their symptoms, 
prior experiences with symptoms 
and techniques learned in rehab  
*Quality of Life for Respiratory Illness Questionnaire (Maille, Konig, Zwinderman, Willems, Dijkman& Kaptein, 
1997) 
**Medical Outcome Survey (MOS) SF-36 (Ware & Sherbourne, 1992) 
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The cited qualitative studies (Horowitz et al., 2004; O’Neill, 2002) used the CSM to 
inform interview guide development as well as data analysis.   O’Neill (2002) tailored interview 
questions to specifically address each of the five cognitive domains to describe how individuals 
represent and cope with COPD.  Inductive content analysis revealed a rich description of 
patient’s understanding and living with COPD.  Findings included a clear identification (label) of 
COPD, a rich representation of the cause (smoking, occupational exposure), well elucidated 
consequences, and coping strategies that were clearly linked to patient beliefs and experiences.  
Horowitz et al. (2004) compared themes generated from interview data to the CSM framework to 
better understand how perceptions and knowledge of heart failure guided action and coping.  
Clearly the cognitive domains of identity, consequences and timeline influenced self-
management and treatment seeking behavior.  Inaccurate or incomplete illness identity was 
linked to decreased knowledge and understanding of heart failure with subsequent poor 
recognition and management of their chronic illness and/or acute exacerbations. This was 
compounded by an inaccurate representation of heart failure as an acute illness rather than a 
chronic illness punctuated by episodes of acute exacerbations.  In these studies, the CSM was 
beneficial in describing factors that can impede self-management of chronic illness (Horowitz et 
al., 2004; O’Neill, 2002) and symptom recognition and treatment seeking during acute 
exacerbations (Horowitz et al., 2004). 
 The reviewed quantitative studies (Albert & Zeller, 2009; Byer & Myers, 2000; 
Cherrington, Lawson & Clark, 2006; Horne & Weinman, 2002; Howard et al., 2009; Jessop & 
Rutter, 2003; Jurgens et al. , 2009; Scharloo et al., 2007; Scharloo et al., 1998) used a variety of 
scales (developed based on the CSM framework) to measure cognitive and emotional 
components of the CSM and/or to explore relationships between the domains of illness 
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representation and QOL, depression, medication adherence, coping and functioning, and 
treatment delay.  Studies in COPD will be reviewed first, followed by asthma and then heart 
failure. 
Scharloo et al. (1998) investigated the association of illness perceptions and coping with 
daily functioning (1998) in individuals with COPD, rheumatoid arthritis and psoriasis.  Illness 
perceptions were assessed using the Illness Perception Questionnaire (IPQ) (Weinman, Petrie, 
Moss-Morris, Horne, 1996).  Coping and daily activities of living were also quantified utilizing 
disease appropriate scales.  In COPD patients, FEV1 was also measured to determine disease 
severity.  Multiple regression analysis was conducted to examine the influence of illness 
perception domains and coping on daily functioning.  Findings revealed that coping did not 
contribute to variance on any outcome measure in COPD.  However the illness representation 
domain identity (more symptoms) explained 13% of variance in role functioning (R2= .30, 
F=8.82, p =.001) and 18% of variance in social functioning (R2= .18, F=6.21, p < .01).  Nearly a 
decade later a revised version of the IPQ (Moss-Morris et al, 2002) was used to examine the 
relationship between illness perception and QOL (Scharloo et al., 2007).  This study revealed 
that the cognitive domains of identity (r = - .45, p < .001) as well as consequences (r =-.40, p < 
.001) and emotional representations (r =-.60, p < .001) of illness were inversely related to QOL 
on the QoLRIQ (Maille et al., 1997).  
Similarly, Howard et al. (2009) noted a correlation between panic severity and illness 
representations of consequences (r = .768, p = .000) and emotion (r - .750, p  = .000).  
Individuals with maladaptive (panic) emotional responses had stronger identity beliefs (t = 2.734, 
p = .01), longer time-line expectation (t = 2.026, p < .05), perceived more severe consequences (t 
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= -2.373, p < .05, and had greater emotional representation (t = -2.093, p < .05) than individuals 
with adaptive (non-panic) emotional responses.   
 Jessop and Rutter (2003), Horne and Weinman (2002) and Byer and Myers (2000) used 
CSM informed questionnaires to investigate adherence to asthma medications.  Utilizing the 
Beliefs about Asthma Questionnaire (Jessop & Rutter, 1999) Jessop and Rutter (2003) found that 
identity (t = 2.53, p < .05), external cause (t = 2.04, p < .05, and cure-contol (t = 2.01, p < .05) 
domains of illness representation predicted adherence to asthma medications in multiple 
regression analysis.  Using the IPQ and BMQ, Byers and Myers also found that adherence was 
significantly correlated with identity (r = .40, p > .05) in addition to (chronic) timeline (r = .30, P 
< .01) domains.  Horne & Weinman (2002), also using the IPQ and Brief Medication 
Questionnaire (BMQ) (Svarstad, Chewning, Sleath & Claesson, 1999), observed a relationship 
between medication non-adherence and doubts about medication necessity (r = .32, p < .01). 
 This review concludes with the cited heart failure studies.   Albert and Zeller (2009) 
examined the relationship between the accuracy of illness beliefs and depression.   Using the 
Survey of Illness beliefs in HF tool to assess illness beliefs, a mean score of 2.99 was obtained, 
indicating subjects had slightly inaccurate beliefs about HF (mean score ≥ 3 indicates accuracy).  
Accuracy of illness beliefs was related to level of depression (r = .224, p < .049) due in the most 
part because of an increased accuracy in beliefs about consequences as depression severity 
increased.  In contrast, Cherrington, Lawson and Clark (2006) reported that knowledge and 
illness belief in the controllability domain resulted in a positive illness representation, improved 
compliance and improved outcomes.  In a mixed methods study describing why elders delay 
seeking treatment for acute HF symptoms, Jurgens et al. (2009) employed the IPQ and semi-
structured interviews to explore illness perception domains.  The most significant contributors to 
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delay were poor symptom recognition (50%), poor identity (56%), and poor understanding of 
consequences (56%).  The most common coping action was to wait for symptoms to go away.  
Lack of an emotional response to early symptoms was also surprising, and further compromised 
early treatment seeking behavior actions.   These findings are similar to those of Horowitz, Rein 
and Leventhal’s grounded theory study described above. 
 In the previous studies, measurement scales informed by the CSM were instrumental in 
achieving study aims.  The specific domains of illness representation were independently 
measured with these scales and then entered into regression models or correlation matrices with 
other variables to predict or examine relationships (or mediating factors) between illness 
cognitions, coping and outcomes.  
 In summary, the CSM has been useful in describing attribution and treatment delay, 
explaining coping behaviors and predicting treatment adherence.  This framework has great 
utility for examining factors that influence health behaviors and illness responses.  In COPD, 
patients experience multiple symptoms that fluctuate in severity day-to-day.   Internal and 
external (stress, weather, activity level) factors contribute to this variability.  Additionally, their 
disease course is marked by frequent hospital visits, the use of multiple medications and an 
undulating emotional state.  All of these factors will impact illness representation, coping and 
appraisal.     
Little is known about prodromal (early) symptom awareness and pattern recognition in 
individuals with COPD who are experiencing a disease exacerbation, despite the frequency of 
these episodes.  Factors that contribute to treatment-seeking delay are also unknown.  The CSM 
offered a framework in which to explore and describe these phenomena.  The framework was 
used to develop interview questions, with attention to targeting each cognitive domain of the 
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illness representation. The framework also undergirded data analysis, with particular attention to 
understanding treatment delay. 
Operational Definitions 
Treatment seeking delay (number of days). 
The day from when prodromal or acute exacerbation symptoms were first noticed by the 
individual, until the time when the individual presented to a health care provider or emergency 
department for consult. 
Prodromal symptoms- The symptoms or group of symptoms that appear before the acute 
exacerbation onset.  Typically include: subtle changes in dyspnea, cold symptoms, sore throat 
and cough. 
Prodromal symptom awareness. 
The perceptual awareness of the early onset of prodromal symptoms and/or subtle 
changes in baseline COPD symptoms indicating a change in health status. 
Acute exacerbation of COPD. 
An acute, sustained worsening of the patient’s condition, from the stable state and beyond 
normal day-day variations.  Includes, but not limited to, the occurrence of increased dyspnea, 
sputum volume and sputum purulence, increased wheezing, fever, or cold symptoms.  
Symptom patterns. 
A constellation of symptoms that are unique to the individual and are present with each 
acute exacerbation experience. 
Pattern recognition. 
The perceptual awareness of a cluster of symptoms that is consistently present with each 
acute exacerbation experience. 
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Illness representation.  The concrete (symptoms- dyspnea) and abstract (label- COPD 
processing of somatic stimuli or functional change that results in the formulation of an illness 
label (COPD exacerbation) and guides subsequent self-regulating health behaviors.  Illness 
representations contain five cognitive attributes (domains): identity, time-line, cause, 
consequences and controllability. 
 Identity. The name (label) that is given to symptoms or functional changes based on the 
individual’s ideas about the illness of health threat.  In this study the assigned label may be acute 
exacerbation of COPD, or another labels based their perception of the symptom presentation.  
Time-line. The perceptions and beliefs about how long the physical, psychological and 
social impact of an acute exacerbation of COPD will last.  Also beliefs about whether their 
illness is a chronic, acute or cyclic condition. 
Cause. The external (bacteria, virus, environment conditions), internal (genetics, stress 
response), and behavioral (smoking) factors believed to precipitate an acute exacerbation of 
COPD.  
Consequences. The individual’s beliefs about the physical, psychological, social and 
economic impact of acute exacerbation of COPD. 
Controllability. The beliefs about whether an acute exacerbation of COPD is amenable to 
interventions by the individual or health care provider. 
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   Chapter 3 
    Methods 
This chapter outlines the methods used in this qualitative descriptive study that explored 
patients’ prodromal symptom awareness, symptom pattern recognition, and reasons for treatment 
delay during an acute exacerbation of COPD.  Recruitment, data collection, data management 
and analysis are discussed in addition to strategies used to establish trustworthiness and 
protection of human subjects.   
 Design 
 Qualitative description was used to describe the acute exacerbation symptom experience 
and elicit reasons for delay in seeking treatment from the patient’s perspective.  According to 
Sandelowski (2000, 2010), qualitative description is the method of choice when trying to 
uncover the particulars (who, what, where, why) of poorly understood phenomena.  The 
researcher conducting a qualitative descriptive study gathers in-depth, contextual descriptions of 
a phenomenon of interest, and reciprocally gains insight into complex human experiences 
(Sandelowski, 2000, 2010; Sullivan-Bolyai, Bova & Harper, 2005).  Unlike positivist informed 
quantitative research, which searches for measurable truths, the post-positivist naturalistic 
underpinnings (epistemology) of qualitative description seeks holistic (ontology) understanding 
of complex human phenomenon.  In this study, the multifaceted experience of COPD 
exacerbation was illuminated.  These findings may assist healthcare professionals to better 
understand COPD exacerbation from the individual’s perspective, and to collaborate with them 
in improving illness self-management. 
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Setting 
Study participants were recruited from Charlton Memorial Hospital and Tobey Hospital, 
affiliates of Southcoast Hospital Group located in Bristol and Plymouth Counties, MA.  A 
pulmonologist and a primary care physician, both members of Southcoast Physicians Group, also 
agreed to participate in study recruitment.  However, recruitment from the physician sites was 
abandoned in February 2012, as recruitment efforts were unsuccessful to that date.  The 
physicians reported that fall and winter 2011-2012 was atypical with few managed in the 
outpatient setting.  Patients in the practices who experienced acute exacerbations presented 
directly to the emergency room, or were admitted directly from the office.  The hospital sites 
were the recruitment source for patients with moderate to severe acute exacerbation of COPD.  
The office settings were intended to be the recruitment sites for a sample of participants with 
mild exacerbation of COPD.   
Charlton and Tobey Hospitals are not-for-profit institutions with 362 and 80 beds 
respectively.  Results of a medical record search revealed that between January 1, 2009 and 
December 31, 2009 there were 1,070 patients admitted with the diagnostic code 491.21, 
obstructive bronchitis with acute exacerbation, to these facilities.  The distribution of admissions 
month to month totaled between 70 and 103 patients, with the higher rates of admission 
occurring between January and May. The number of patients treated for acute exacerbation at the 
physician sites was not available, but was reported to be significant by the participating 
physicians.  Collectively, the inpatient and outpatient recruitment sites were determined to be 
adequate to provide the necessary number of subjects required by this study.  
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Sample 
Male and female patients admitted to the local hospitals with acute exacerbation of 
COPD were recruited.  Recruitment was initially aimed at enrolling 50% of subjects from the 
outpatient setting, and 50% from the inpatient setting to better describe any similarities and 
difference between groups.  However, as previously described, recruitment from the physician 
sites was subsequently abandoned.   Purposive sampling was used to uncover rich, detailed 
information regarding the acute exacerbation experience and treatment-delay behavior.  
Purposive sampling is the purposeful selection of subjects known to have experience, or 
expertise, with the phenomenon to include in the study (Kemper, Stringfield & Teddlie, 2003).   
This was guided by the following inclusion and exclusion criteria. 
The study inclusion criteria were: 
1. Diagnosis of COPD made prior to the current hospitalization or office appointment 
with the pulmonologist/primary care MD.  This was confirmed by pulmonary 
function test or spirometry results, performed on a date at least one month prior to 
current health care encounter.  When test results are not available, a documented 
history of COPD in the medical record was used as verification of pre-existing 
COPD.  
2. Recent diagnosis (within 7 days) of acute exacerbation of COPD, defined by  
hospitalization with an admitting diagnoses of acute exacerbation of chronic 
bronchitis, acute exacerbation of COPD or pneumonia with acute exacerbation of 
COPD. Outpatient participants, had recruitment been successful, were to have a 
diagnosis of acute exacerbation of COPD confirmed by documentation in the patient's 
office medical record. 
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3. Ability to read and speak English 
4. Age 18 years or older 
5. Ability and willingness to provide written consent. 
6. Score of 24 or greater on the mini-mental status exam 
The study exclusion criteria were: 
1. Initial diagnosis of COPD 
2. Non-English speaking 
3. Co-morbidity of acute heart failure (determined by elevated plasma B-type natriuretic 
peptide [PBNP] laboratory results) in hospitalized patients.  
4. Severe cognitive impairment (MMSE score < 23) 
5. Unwilling or unable to provide informed consent 
6. Hospitalized patients on critical care units 
7. Hospitalized patients on mechanical ventilation 
The rationale for exclusions was that the researcher is fluent only in English, a co-
morbidity of acute heart failure complicates symptom recognition and illness representation, 
cognitive impairment impairs the informant’s ability to meaningfully engage in the research 
procedures and patients in critical areas and/or mechanical ventilation are assumed to be too ill to 
participate in research procedures. 
A sample size of 14 participants was recruited.  Sampling was discontinued when data 
saturation/redundancy was achieved (Sandelowski, 1995a). Data redundancy was determined to 
be achieved when well established themes evolved and there was no new information uncovered 
(Lincoln & Guba, 1985). 
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Recruitment  
The PI met with the hospitals’ unit managers and resource nurses as well as office 
physicians and their office managers to describe the study, explain recruitment procedures and 
provide contact information.  Study flyers, study information sheets, and contact consent forms 
were provided to the office practice managers at that meeting.  A copy of the study proposal and 
IRB approvals from Southcoast Hospital and UMass Worcester were provided.  Additionally, a 
written script was provided for unit nurses to use when approaching patients to gain permission 
for the PI to discuss the study with them.   
 Eligible office patients were to be identified by the office practice managers and 
informed of the study.  Interested individuals were to be given the information sheet that outlined 
the study title, study purpose, investigator’s name and investigator’s contact number.  Potential 
study participants would be given the option to either call the PI directly or provide written 
consent (HIPAA Authorization) to be contacted by the PI by telephone. Once consent was 
confirmed, the PI would contact potential participants by phone to arrange a time to meet in their 
home.  As no participant’s were recruited from the office settings, these procedures were never  
initiated. 
In the hospital setting, potential study participants were identified by the unit resource 
nurse.  Permission for the PI to visit with each potential participant was obtained either by the 
resource nurse or primary care nurse using the standard written script provided by the PI.  Before 
making contact with any potential participant, eligibility based on diagnosis and ability to speak 
English was confirmed with the RN.  
During the initial face-to-face contact with potential participants, the PI explained the 
purpose of the research study, provided an opportunity for questions to be answered, and 
                                                                              53 
obtained written consent.  HIPAA authorization was also obtained as part of the consent process 
to access the participant’s health record for the purpose of documenting COPD severity and/or 
confirming the absence of an acute heart failure diagnosis.  The informed consent document also 
included permission for the PI to re-contact the participant for the purpose of clarifying or 
verifying data at a later date as needed.  Participants were informed that they could withdraw 
from the study at any time.  All participants were given a copy of the consent, with the original 
copy retained by the researcher and secured in a locked file.  A numeric code was assigned to 
each participant, and recorded in a recruitment log that was also be maintained in a locked 
drawer separate from other study documents.  A $25.00 American Express gift card was given to 
all participants who participated in the study. 
Procedures  
After ensuring patient comfort, safety and privacy the study measures and interviews 
were conducted (Figure 2).  Participants were interviewed in their hospital room or a private 
conference room on the unit.   
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Figure 2.  Data collection procedures 
The Mini Mental State Exam (MMSE) (Folstein, Folstein & McHugh, 1975) was 
administered to assess mental status. This was important as disease related factors such as 
hypoxemia, hypercarbia and steroid use can alter cognition and impair recall and decision 
making (Meek et al., 2001).  The MMSE is a valid and reliable instrument (test-retest r = .89, 
interrater reliability r = .82) that has been used extensively in clinical practice and research since 
1979.  It is an 11-item measure that tests five areas of cognitive function: memory, attention, 
recall, orientation and calculation ability.  A score of 23 or lower (maximum 30) is indicative of 
cognitive impairment. Administration time was 5-10 minutes, as estimated by Folstein et al. 
(1975).  If a participant had failed to obtain a score of 24 or greater on the initial assessment, no 
further procedures were to be administered, and the participant was to be reassessed within 1-3 
days.  If a participant failed the MMSE on the second assessment, then he/she would be 
                                                                           Procedures 
 
   In-patients identified by unit staff                       Out-patients identified by office manager 
                      ↓                                                                                    ↓                                                                                                                                                       
         Confirm eligibility                                                        Confirm eligibility 
                      ⎮                                                            Verify consent to contact signed 
                      ↓                                                                                   ↓ 
    Obtain permission to visit                                              Call potential participant  
        potential participant                                                        Arrange home visit 
                      ⎮_________________________________________ ⎮         
                                                                   ↓ 
                             Describe study, answer questions, obtain consent 
                                                                   ↓ 
                                                     Administer MMSE 
Data Collection    ←⎯  YES ⎯⎯⎯   Score ≥ 24 ⎯⎯⎯ NO ⎯→ Repeat in 24-72 hours 
  Demographics           ↓ 
  Interview                                                                                       YES ← Score ≥ 24 → NO 
  MHI-5                                                                                               ↓                                ↓        
    Data Collection              Withdraw 
                    from study 
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withdrawn from the study and no additional study procedures to be conducted.  No participants 
attained a score less than 24 in this study.  
            Demographic and clinical data were collected from the participant and/or patient health 
record and recorded on the data extraction sheet (Appendix A) for the purpose of describing the 
sample.  Data collected included age, gender, ethnicity, education, marital status, smoking 
history, exposure to second hand smoke in the home, years with COPD diagnosis, number of 
prior hospitalizations with COPD exacerbation, date of last exacerbation (approximate) and 
COPD medication use.  Pulmonary function tests were also obtained from the medical record for 
the purpose of assigning a COPD stage according to GOLD criteria.    
The qualitative interview followed.  They were semi-structured, following an interview 
guide (Appendix B) informed by dimensions of Leventhal’s ‘common-sense’ model (Leventhal, 
Meyer & Nerenz, 1980).  Face-to-face interviews were conducted by the PI with the aim of 
deriving rich descriptions of prodromal symptom awareness and pattern recognition associated 
with participants’ current exacerbation experience.  Contextual factors that impacted treatment-
seeking behaviors, in particular treatment delay were also elicited.  A calendar was utilized to 
provide a visual, contextual cue that may assist participants in more accurately determining when 
their symptom(s) occurred.  After administering to the first participant, data collection 
procedures were assessed by the PI and dissertation advisor to determine effectiveness of 
procedures, calculate time required for procedures and evaluate patient comfort.  Interviews were 
audio recorded using one pretested digital recording device and a traditional tape recorder.  Field 
notes were maintained to record non-verbal observations and personal reflections that enriched 
and augmented the audio transcription (Creswell, 2003).  Data collection continued until data 
saturation occurred (Sandelowski, 1995a). 
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The five-item Mental Health Inventory (MHI-5) subscale of the SF-36 (Ware & 
Sherbourne, 1992) was administered at the conclusion of the interview.  This brief scale 
measures anxiety, depression, loss of control and psychological well-being of individuals 
(Berwick et al, 1991).  Internal consistency of the MHI-5 was demonstrated with a Cronbach 
alpha of 0.74. The MHI-5 performs best in screening for mood disorders (AUC: sensitivity 0.83; 
specificity 0.78) and anxiety disorders (AUC: sensitivity 0.73; specificity 0.60) (Rumpf, Meyer, 
Hapke & John, 2001).   For the assessment of depression, a calculated score ≥ 52 on the MHI-5 
indicates absence of symptoms and a score < 52 indicates presence of symptoms (Arroyo et al., 
2004).  This data was important for describing the study sample. 
Data Management 
All forms, measurement tools and audio files for each participant were de-identified and 
assigned a code number.  They were maintained in individual folders labeled with the assigned 
participant code.  Folders were stored in a locked file cabinet within the PI’s private locked 
office.  A record of each participant and their unique code was maintained in a recruitment log 
that was secured separately in a locked draw within the same office. The researcher’s reflective 
journal, field notes, audit trail and data analysis coding sheet were also secured in the same 
locked file cabinet. 
After each participant session, the digitally recorded interview was forwarded to a 
professional transcriptionist and transcribed verbatim into a word-processed document.  
Transcripts were forwarded and returned electronically through Files Direct, a secure password 
protected, HIPPA approved service. Upon electronic return of each transcript, the PI proofed it 
against the audiotape for any inaccuracies.  Field notes collected during the interview were 
transferred onto the transcript.  These provided background and insight into verbal and non-
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verbal communication that occurred during the interview.  Electronic copies of the transcript 
were stored in a file on the PI’s password protected computer and backed up in the PI’s file on 
the UMass Dartmouth server.   A hard copy of the transcript and corresponding back up audio 
taped recording was placed in each participant’s study folder.    
All electronic files were backed up on the server at the University of Massachusetts 
Dartmouth, where the PI maintains her office.  Only the researcher had access to the 
computer on which data was stored, and to the locked data. 
Data Analysis  
Consistent with the tenets of qualitative description, data collection and data analysis 
occurred simultaneously, and subsequent sampling and interview probes modified accordingly to 
achieve maximum exploration of themes to the point of redundancy.  In the following paragraphs 
the data analysis procedures used to address each specific aim are described, followed by a 
description of the content analysis process. 
Aim 1: Explore awareness of prodromal symptoms in the days preceding an acute 
exacerbation of COPD.   
To address this aim, interview transcripts were analyzed for prodromal symptoms 
reported in response to guided interview probes.  These symptoms were entered on the symptom 
data collection sheet.  The number of subjects who report awareness of prodromal symptoms 
were calculated.  Additionally, the frequency of individual prodromal symptom experienced 
across all subjects, were calculated. 
Aim 2: Describe symptom patterns associated with acute exacerbations.  
Interview transcripts were examined for the presence of a unique acute exacerbation 
symptom pattern, evidenced by participant description of a prior presentation of the same cluster 
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of symptoms on at least one occasion.   This data was transferred to the symptom data collection 
sheet.  The incidence of each cluster of symptoms was calculated and classified by the 
Anthonisen typology of acute exacerbation. 
Aim 3: Identify dimensions of illness representation (identity, time-line, cause, 
consequence, controllability) in individual descriptions of treatment-seeking delay during 
exacerbation of COPD. 
The median time of treatment delay was calculated.  Delay time was calculated from the 
day the patient reported exhibiting a symptom change, determined using modified Anthonisen 
Criteria, and the day on which the health care encounter occurred.  Variables (age, gender, 
ethnicity, marital status, education level, disease severity, disease length, smoking status, and 
insurance status) and treatment delay were also examined to identify any trends.  Non-parametric 
statistical measurements were used to detect associations and differences between variable, 
however the small sample size render the results statistically non-significant.  
                       Qualitative content analysis.  
 Data was analyzed using qualitative content analysis.  Content analysis institutes a 
systematic method for developing codes, and themes from transcribed interview data.  Pertinent 
data chunks from each transcript were pulled out of the text, coded and categorized, then 
reorganizing into focused descriptive themes that explained the phenomenon of interest (Hseih & 
Shannon, 2002; Knafl & Webster, 1988; Miles & Huberman, 1994; Sandelowski, 1994).  Coded 
data was compared and contrasted within and across subjects (Knafl & Webster, 1988) as well as 
compared to the dimensions of the guiding framework (Sandelowski, 1995).  Content analysis 
proceeded as follows: 
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1. The PI read transcript in entirety several times to appreciate the overall gestalt and to 
develop initial insights.    
2. A preliminary summary reflecting first impressions and general analysis of each 
transcript was word-processed. 
3. Transcribed interviews were reviewed against audio-recordingd and each line of the 
transcript individually numbered.  Key passages were highlighted and notated. 
Associated field notes were transcribed into each document. 
4. Transcripts were deconstructed and key segments sorted and coded in chunks that 
represented the key concepts specified in research aims.  These were cut and pasted 
into individual word document files. 
5. A codebook was maintained clearly defining each code and category, and explicating 
the category inclusion criteria for consistency within and across transcripts.  As new 
codes and/or categories emerge from the data, the definitions and categories were 
modified as needed.  
6. Once the general categories were established from all the data, they were analyzed 
and collapsed into more abstract themes.   
7.  Using constant comparison techniques, patterns of similarities and differences in 
categories and themes within and across participants were examined. Interview 
probes were modified to facilitate this exploration.  
8. Themes were compared and contrasted in relationship to the framework.   
Trustworthiness 
The analysis and findings of qualitative research findings must be shown to be 
“systematic, objective and worthy” (Wolf, 2003, p. 175).  Lincoln and Guba (1985) refer to this 
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illumination of rigor in research procedures as trustworthiness.  Trustworthiness in the 
naturalistic paradigm parallels the positivist concepts of reliability and validity.  The components 
of trustworthiness include transferability, dependability, confirmability and credibility (Lincoln 
& Guba, 1985) 
 Transferability is loosely comparable to the concept of internal validity (generalizability) 
in quantitative research.  It refers to the extent in which findings can be applied to other contexts 
or populations.  In qualitative methods this is accomplished through the use of appropriate 
sampling techniques and by obtaining thick, rich descriptions of the phenomenon under 
investigation.  In this study, the PI used purposive sampling to obtain rich descriptions of the 
acute exacerbation experience (Lincoln & Guba, 1985).   Vivid descriptions of participants 
experiences, supported by quotes, and a clear representation of established themes was included 
in the report of findings to support transferability.   
 Dependability mirrors the quantitative concept of reliability and confirmability the 
concept to objectivity.  Evidence if rigor in these components is demonstrated through 
maintenance of an audit trail, or documentation of the research process (Lincoln & Guba, 1985). 
An audit trail is written documentation of data analysis decisions and inferences that start with 
the transformation of raw data into codes and themes, and culminates in the report of study 
findings.   An audit trail file was maintained by the PI and contains personal reflections, 
bracketed biases and preconceptions and methodological decisions.  Decisions and rationales 
made regarding sampling, changes in interview questions or probes, coding decisions, category 
and theme development and data analysis were documented.  
Credibility is compared to internal validity in quantitative methods.  In qualitative 
methods it represents confidence in the interpretation of data (Lincoln & Guba, 1985). 
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Credibility infers that the findings are authentic and represents the emic perspective of 
participants (Sandelowski, 1994; Whittemore, Chase, Mandle, 2001).  Credibility was 
established in this study by prolonged engagement with subjects and data.  This was 
accomplished by providing adequate time for patient interviews, avoiding premature closure of 
data collection, and collecting data until saturation was accomplished.  Participating in peer 
debriefings with the dissertation advisor via email and phone conferences meetings to review 
procedures, coding decisions and analysis also strengthened credibility of findings.  An audit 
trail folder containing documentation of the PIs reflections, and process decisions was 
maintained.  Lastly, as recommended by Lincoln and Guba (1985) member checks were 
conducted with participants to verify themes, and the author’s interpretation of the data.  
Member Checks 
  After the main theme and subthemes were delineated, three participants were contacted 
by phone for the purpose of verifying that the themes accurately described the acute exacerbation 
experience.  After defining and providing content exemplars of the main theme and subthemes, 
participants agreed that the themes semantically and descriptively represented their experiences.  
One participant vehemently acknowledged the analysis stating, “That’s exactly how it goes.”   
Another stated, “That’s a good description of the process I go through.”  The three member 
check participants reiterated their experiences as discussed during the interviews and one 
participant elaborated on her feelings of being stigmatized by healthcare workers. 
Reflexivity 
In qualitative studies using a naturalist paradigm, the researcher serves as the instrument, 
remaining very close to the data during collection and analysis phases (Lincoln & Guba, 1985).   
Additionally, the relationship between the researcher and the participant is an important tool in 
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extracting rich, detailed data (Milne & Oberle, 2005).  The intimacy of this relationship requires 
that the researcher remain cognizant of any personal or professional biases and preconceptions 
that may be inadvertently imbued during data collection or analysis (Lincoln & Guba, 1985;  
Malterud, 2001). Reflexivity, or purposeful analysis of any researcher influence on the research 
process, is a necessary component of qualitative research because of this relationship (Koch & 
Harrington, 1998).  Koch and Harrington (1998) recommend the use of a journal to bracket 
biases and demonstrate reflexivity.  Documentation of the researcher’s self-reflection on the 
challenges inherent in separating their nurse role and experiences from their researcher role also 
enhances credibility of research findings (Dowling, 2006).  
  The PI has 30 years experience in acute and critical care nursing, working closely with 
individuals who have experienced exacerbation of COPD.   This experience was beneficial in 
developing rapport with subjects and inserting appropriate probes into the interview, however the 
researcher needed to consciously refrain from leading the respondents and making assumptions 
about the meaning of vague responses during the data collection and data analysis processes 
(Milne & Oberle, 2005).  Preconceptions formulated from prior professional experiences were 
acknowledged and recorded in a journal to ensure that individual experiences were interpreted 
without bias.   
Ethical considerations 
The health and well being of each participant remained the utmost concern.  When a 
participant exhibited dyspnea (n =1) and emotional distress (n=1) during the procedure, data 
collection was halted until the participant recovered physically and emotionally.  Interviews 
continued when the participant verbalized willingness and readiness to continue.  As an 
experienced clinician with over 25 years of experience with individuals with COPD, the 
researcher was competent to recognize the signs and symptoms of distress in this population.  
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Health care consult was not required, however, the patient’s primary care nurse would have 
been summoned if necessary.  In the interest of patient safety, one participant’s self-report of 
suicidal ideation was reported to the resource nurse and subsequently her primary care 
physician.  
Human Subjects Consideration 
Approval was obtained from the Internal Review Board of Southcoast Hospital Group, 
which oversees research conducted at Charlton Memorial Hospital and Tobey Hospital, the 
inpatient sites from which patients were recruited.  Approval was also obtained from the IRB at 
the University of Massachusetts Medical School, Worcester, MA where the researcher is 
enrolled in doctoral studies.   
Written informed consent was obtained from participants at the initial researcher-
participant encounter.  Subjects were informed that participation was voluntary, that care would 
not be influenced by a decision not to participate, and that they had the right to withdraw from 
the study at any time. Individuals were informed that their participation in the study was 
confidential, and that study data was not part of their medical record.  Methods for ensuring 
safety of data and how information would be used were detailed. The consent included access to 
medical records, permission to notify health care provider if participant experienced physical or 
emotional distress, and for phone follow-up if necessary.  Risk-benefits were discussed, and 
patients were given ample opportunity to ask questions.  Two copies of the informed consent 
were obtained.  Each participant received one copy, and the researcher retained one copy.   
Risks-Benefits 
There were no direct benefits to individual study participants.  However, the knowledge  
gained from this study may help COPD patients in the future by increasing knowledge and 
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understanding of symptom recognition during acute exacerbation of COPD, and the reasons 
patients delay seeking treatment.  This information may guide future intervention development, 
such as action plans, and patient education.   
Potential risks to the patient-participant included emotional discomfort in reviewing the 
symptoms and decision-making they enacted during their acute exacerbation.  Physical 
discomfort during the interview, related to the additional physiologic demand conversation 
places on the respiratory system was also a potential risk.  Had significant emotional or physical 
discomfort occured during the interview, the interview would have been discontinued and 
appropriate assessment and interventions delivered by the appropriate medical staff member.   
Summary  
 This study, employing a qualitative descriptive design, describes the little-known 
phenomena of prodromal symptom awareness, pattern recognition and the reasons individuals 
delay seeking treatment during acute exacerbation of COPD.  Leventhal’s “common-sense” 
Model (Leventhal, Meyer & Nerenz, 1980) guided the development of the interview guide, data 
analysis and discussion of findings.  The goal of this study was to obtain knowledge and 
understanding that can guide the development of patient interventions so that acute exacerbations 
of COPD will be identified and treated earlier. Early treatment reduces the negative 
consequences of exacerbation and improves health outcomes for patients with COPD. 
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                                                                Chapter IV 
                                                                    Results 
Introduction 
Qualitative description was used to explore the acute COPD exacerbation experience. 
The primary focus of this study was to explore participant awareness of prodromal symptoms 
and exacerbation symptom patterns as well as factors that delay treatment-seeking during an 
acute exacerbation.  Face to face semi-structured interviews were conducted with fourteen 
individuals during their hospitalizations for acute exacerbation of COPD.  Qualitative analysis 
revealed a main theme of Recognizing, Responding and Reacting to Change.  This theme 
represents participant recognition of impending acute exacerbation, and subsequent illness 
management responses and emotional reactions.  Six subthemes were linked to the main theme: 
something’s coming, here we go again, seeking urgent treatment, riding it out, not in charge 
anymore and my last day.  The subtheme something’s coming reflects the participant’s awareness 
of symptoms that are a change from their typical day-to-day COPD symptom variation.  Here we 
go again represents the participant’s recognition of their acute exacerbation symptom pattern and 
what is to follow.  Participants reacted to their baseline symptom change by seeking urgent 
treatment or by riding it out and engaging in self-management behaviors in the hope that 
symptoms would resolve spontaneously.  As a result of their exacerbation event and its impact, 
participants described feeling as if they are not in charge anymore of their life and many felt as if 
it were their last day when their symptoms reached peak acuity. 
Participants 
Twenty-one individuals hospitalized in two community hospitals in Southeastern Massachusetts 
were identified as potential study participants by the unit resource nurses, and agreed to discuss  
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the study with the Principal Investigator (PI).  After discussing the study requirements one 
individual declined to participation due to fatigue, another declined due to feeling "short of 
breath and panicky" and a third individual stated that he was not appropriate because he had 
"lung cancer not COPD.  "Four additional individuals who consented to participate had to be 
excluded upon chart review because their laboratory results (pBNP) indicated the presence of 
concomitant heart failure (exclusion criteria).  The remaining fourteen individuals met inclusion 
criteria and were enrolled.  Data collection took place between October 2011 and February 2012.   
The sample included five male and nine female participants with a mean age of 66.21  
years (median 65, range 49-87).  All participants had medical insurance.  The ethnic distribution  
of participants included 11 non-Hispanic whites, one Cape Verdean, one West Indian and one  
individual of Portuguese decent.  Six participants were married, four were divorced, three were  
widowed and one was single.  The majority of participants were high school educated, with 50%  
(n = 7) of the sample having post-secondary education.  Participants had moderate (n =6) to  
severe (n =8) COPD based on GOLD classification (see Table 1). The mean number of years  
since diagnosis of COPD was 7.75 (SD = 5.0) during which time participants experienced an  
average of 3.29 (SD = 3.75) exacerbations a year, resulting in an average of 4.14 (SD 4.04, range  
1-17) hospitalizations yearly.  All of the participants had a history of cigarette smoking and  
28.6% (n = 4) were current smokers. A summary of this data is included in Tables 8 and 9. 
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Table 8 
 
Sample characteristics for categorical variables 
 
Variable                                                      n                                      % 
Gender 
   Male 
   Female 
 
5 
9 
 
35.7 
64.3 
Marital status 
   Single 
   Married 
   Widowed 
   Divorced 
 
1 
6 
3 
4 
 
7.1 
42.8 
21.5 
28.6 
Education 
    Some HS 
    HS Degree 
    Some College 
    AD 
    BS 
MS 
 
2 
5 
1 
3 
1 
2 
 
14.3 
35.8 
7.1 
21.4 
7.1 
14.3 
Ethnicity 
   White 
   Portuguese 
   Cape Verdean 
   West Indies 
 
11 
1 
1 
1 
 
78.6 
7.1 
7.1 
7.1 
Smoking status 
   Current Smoker 
   Previous Smoker 
 
4 
10 
 
28.6 
71.4 
COPD severity  (GOLD staging) 
   Stage I     Mild 
   Stage II    Moderate 
   Stage III   Severe 
   Stage IV   Very Severe 
 
0 
6 
8 
0 
 
 
42.8 
57.2 
Insurance 
   Medicare 
   Mass Health 
   Private 
 
8 
2 
4 
 
57.1 
14.3 
28.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                              68 
Table 9 
 
Sample characteristics for continuous variables    
    
Variable N=14  
Age Mean 
Median 
SD 
Range 
66.21 
65 
(12.09) 
49-87 
Years since COPD diagnosis Mean 
Median 
SD 
Range 
7.75 
5.0 
(9.93) 
1-40 
Exacerbation rate (# per year) 
 
 
Mean 
Median 
SD 
Range 
3.29 
2.0 
(3.75) 
1-15 
Hospitalizations per year 
 
Mean 
Median 
SD 
Range 
4.14 
3.0 
(4.04) 
1-17 
Years smoked Mean 
Median 
SD 
Range 
34.21 
34 
(18.27) 
5-60 
Calculated pack years Mean 
Median 
SD 
Range 
42.71 
30 
(32.19) 
5-100 
Treatment delay (# days) Mean 
Median 
SD 
Range 
7 
7 
(4.96) 
0-14 
MHI-5  (N=11) 
  Score range 0-100 
  < 52 = depression symptoms 
 
Mean 
SD 
Range 
Alpha 
67.27 
(23.9) 
32-100 
.913 
MMSE Scores   
  Possible range 0-30 
  ≤ 23 = cognitive impairment 
 
Mean 
Median 
SD 
Range 
27.71 
28 
(2.05) 
25-33 
 
Gender differences 
         Of the five male and nine female participants in this sample, more male participants  
were married (60%) and had Stage III COPD (80%).  Participants in this study did report 
being encouraged by their spouses to seek treatment, although there was no significant difference  
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in treatment delay between married and unmarried participants, or between male and female  
participants (6.8 vs. 7.0 days) in this study.  
Smokers vs. nonsmokers 
Two of the four current smokers continued to smoke despite directly associating their  
current, and prior, acute COPD exacerbations to smoking.  One participant stated that after 53  
years she had reduced the amount she smoked, however “ just can’t seem to quit completely.”  
The other participant described full awareness of the impact of smoking on her exacerbation rate,  
disease progression and mortality, resolving to finally quit.  She stated, "This is a last chance for  
me."  
The remaining two participants who smoked linked their COPD to smoking, but did 
notidentify smoking as a cause of their exacerbations (or current exacerbation).  One participant 
who smoked 2 packs of cigarettes per a day for over 40 years reported quitting on a prior 
occasion “until he snapped.”  After a “bad day” he resumed smoking despite understanding the 
health consequences.  On the day of the interview the patient stated he had decided to quit 
smoking. “I have a choice to smoke or breathe and if I keep [smoking] I won’t be doing either 
one for long.”The fourth participant, who had recently been diagnosed with COPD, was 
gradually reducing her cigarette consumption at the time of her exacerbation.  She does not 
intend to resume smoking upon discharge.   
All four participants were counseled regarding the importance of smoking abstinence by  
their healthcare providers.  Southcoast Hospitals offered participation in the Quit Works smoking  
cessation program to each participant who currently smoked. 
Depression 
Three female participants scored less than 52 on the MHI-5, indicating the presence of  
                                                                              70 
depressive symptoms.  At the conclusion of participant interviews, this subscale was  
administered to individuals who were not too fatigued(n = 11) to complete an additional  
measure. The scale was administered for the purpose of describing the sample.  Other than  
gender (female) and ethnicity (Caucasian) there were no commonalities in the characteristics of  
individuals with depressive symptoms. 
Although two participants were among the younger (49, 52) aged participants, two other  
participants in the same age group were not noted to have depressive symptoms on the MHI-5.  
Of the participants (n =11) who completed the MHI-5, the individual with the greatest number of  
years since COPD diagnosis (12) did score in the depressive symptom range.  However, the  
remaining two participants were more recently (1, 4.5) diagnosed with COPD.  In contrast, the  
participant with the greatest number of yearly acute COPD exacerbations (15) and 
hospitalizations (17) was not found to have depressive symptoms on the MHI-5.  Participants  
who had a score indicating the presence of  depressive symptoms (n =3) experienced between  
one and three COPD exacerbations and hospitalizations yearly, as did participants (n =7) who  
were not found to be have depressive symptoms on the MHI-5. 
During the interview, one participant (MHI-5 =40) described being very depressed when 
she could not breathe during this exacerbation episode. “I even had thoughts of that really bad 
‘S’ (suicide) word.”  A second participant (MHI-5 =36) did not specifically describe being 
depressed, but did discuss being frightened by the severity of her dyspnea on the day of her 
hospital admission.  Interestingly, she had resisted recommendation by friends to seek healthcare 
sooner.  Both of these individuals delayed seeking treatment for 14 days.  The third participant 
with an MHI-5 score indicative of depressive symptoms (MHI-5 =32) also did not directly 
address feeling depressed, nevertheless she did discuss her disappointment in not being eligible 
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for lung transplant.  Furthermore, she discussed preparing a “bucket list” and other end-of-life 
activities.  Each of the participants who scored < 52 on the MHI-5 were currently being treated 
by their primary care physician for depression. 
Treatment delay 
           The variable of treatment delay was also analyzed for commonalities among participants 
who delayed seeking treatment for seven days or more, as well as differences between those who 
delayed more than seven days and those who sought treatment sooner.  One finding of note was 
that two of three participants who delayed seeking treatment the longest (14 days) had depressive 
symptoms according to the MHI-5.  Their treatment seeking behavior is discussed above.  An 
additional finding was that the participants (n =2) with the highest yearly frequency of acute 
COPD (7, 14) exacerbations only delayed treatment seeking for two days.  These individuals 
reported recognizing the signs of their exacerbation and its consequences.  No other 
commonalities or differences were noted across characteristics within the treatment delay group 
or between treatment delay and non-treatment delay groups.   No relationship between any 
variable and treatment delay was found.  
Themes and Subthemes 
 The main theme and six subthemes represent the physical, cognitive, and emotional 
experiences of individuals hospitalized for acute exacerbation of COPD.  A rich description of 
the themes and subthemes, supported by participant quotes, follows. 
 Recognizing, responding and reacting to change 
The main theme of recognizing, responding and reacting to change is threaded  
throughout all participant descriptions of their acute exacerbation of COPD experience.  This  
theme represents the participant’s recognition of a change in their baseline COPD status, their  
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response to change in the form of self-care or treatment seeking, and their emotional reaction to  
the exacerbation event.   
COPD exacerbations can present insidiously over days, or abruptly over minutes.  A pre- 
exacerbation prodrome of vague symptoms such as headache, fatigue, and upper respiratory  
symptoms preceded exacerbation onset by one to four days in individuals who had a crescendo-  
type exacerbation onset.  However, the majority of these participants did not understand these  
vague symptoms to be a precursor of exacerbation.  Prodromal symptoms are typically different  
than exacerbation symptoms, but serve as a warning sign and trigger for exacerbation.  Of the  
individuals who experienced an abrupt exacerbation onset, most were unaware of having any  
prodromal symptoms in the preceding days. 
In the course of the interviews, participants came to recognize that they had a recurring 
pattern of exacerbation symptoms that was a qualitative or quantitative change in their typical 
daily symptoms such as worsening dyspnea, change in sputum character or quantity, or the 
development of wheezing.  In most individuals, this pattern was the same with each exacerbation 
but the patterns varied across individuals, based on the underlying component of their COPD 
(emphysema vs. bronchitis) and the etiology of their exacerbation (infectious vs. environmental).  
Most participants intuitively recognized their symptom worsening as a “flare-up” of their COPD, 
or acute exacerbation, based on a prior experience with a similar pattern of symptoms occurring 
with a prior diagnosed exacerbation(s).  However participants only became consciously aware of 
their repeating symptom pattern during the study interview discussion. 
The participants responses to exacerbation onset was most influenced by the abruptness  
and severity of exacerbation symptom presentation.  Participants who experienced a precipitous 
onset of symptoms presented to the emergency room immediately for treatment because of the  
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life-threatening severity of their dyspnea.  Participants who experienced an insidious onset more  
often delayed seeking treatment until it became evident that their self-management behaviors of  
activity reduction, medication adjustments and breathing techniques were unsuccessful or they 
became incapacitated by their symptoms.  At this point participants either contacted their health  
care provider or presented to the emergency room.  Participants who had their exacerbation  
successfully managed on an outpatient basis by their pulmonologist or primary care physician in  
the past were more likely to initially contact their physician for treatment.  Participants who had  
little success with prior outpatient management, or who have been directed by office staff to the  
emergency room on prior occasions, more often chose the emergency room as their initial  
healthcare contact for exacerbation management. 
Emotional reactions to the exacerbation experience were as divergent as the individual  
symptom presentation themselves.  Participants described feelings ranging from simple  
frustration over being ill again to an overwhelming fear of impending death due to the severity of  
their breathlessness.  Furthermore, psychosocial factors played a role in treatment seeking delay.   
Participants reported financial concerns, social obligations, attempting to maintain control over  
life and illness, avoiding healthcare interactions and stubbornness as reasons that contributed to  
delayed treatment seeking.  Six subthemes (Figure 3) were linked to the main theme of  
recognizing, responding and reacting to change and more fully describe each of the main  
theme’s components.  These subthemes are further described with exemplars below. 
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                                  Recognizing, Responding  & Reacting to Change 
 
 
 
 
 
 
 
Figure 3: Themes and subthemes 
Something’s Coming 
Something’s coming, a subtheme of recognizing, responding and reacting to change, 
refers to the initial recognition of a health status change. All participants (N = 14) described an 
awareness of a change in their baseline COPD symptom status that occurred from a few hours to 
two weeks prior to seeking healthcare. Participants compared their new or worsening symptoms 
to the way they usually felt as the primary way of sensing a significant change in their baseline 
disease status.  They also compared their current activity tolerance for typical activities to their 
usual tolerance as a gauge for assessing changes. For example, "I noticed that my activities have 
dropped, you know to eat, prepare a meal took a great deal out of me "and" the stairs were a little 
heavier...for me to climb, harder." Although all participants recognized the onset of new 
symptoms or a change in symptoms or functional status, not all of them evaluated these changes 
as a prodrome to impending acute COPD exacerbation.  They sometimes believed they were 
“just tired” from doing too much or simply coming down with a simple cold.  The vagueness in 
Something’s Coming 
 
Here We Go Again 
 
 
 
     Seeks Urgent    
        Treatment 
 
     Riding it Out 
      My Last Day 
 
Not in Charge Anymore 
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the statement "I knew something was coming" by two participants illustrates the ambiguity 
participants were confronted with when trying to differentiate their symptoms.  They knew they 
were “coming down with something ” but were not certain if it was COPD related.  Two 
participants did admit to having difficulty distinguishing between “a bad day” on their dyspnea 
symptom continuum from a severity point that could signal impending exacerbation. The 
participant who experienced sputum changes with his exacerbation onset found it much easier to 
discern between baseline and exacerbation state, as there was a marked qualitative and 
quantitative change in usual sputum production.  The sputum character change also marked the 
crossover point from illness prodrome to exacerbation for this individual. 
In total, eleven participants described an illness prodrome that preceded the onset of their 
acute exacerbation of COPD.  The symptoms experienced during this time period were not 
"classic" exacerbation symptoms, differed from the individual's day-to-day symptom variance 
and made them aware that "something was coming on."  The prodromal symptoms reported by 
study participants included:  palpitations (n =1), sinusitis (n =2), headache (n =2), fatigue (n =8) 
and cold symptoms (n =8).  Although more than 50% of individuals (n =8) experienced a variety 
of cold symptoms, fatigue seemed to be the most bothersome symptom.  Participants gave 
detailed descriptions of how fatigue impacted their daily functioning.  One participant stated “[I 
was] tired all the time…I’d sleep, wake up in an hour, sleep again.”Other participants describe 
fatigue and decreased functional ability, explaining “I felt more tired; I couldn't do as much 
walking as I usually could” and "I had absolutely no energy. I was so worn out I didn't want to 
go out, visit with friends or even eat my meals." 
Although eleven participants were aware of the presence of prodromal symptoms 
retrospectively, only four participants specifically identified their symptoms as being a prodrome 
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of their COPD exacerbation.  This is exemplified in the participant comment "[I thought] the 
same thing is happening", which was echoed by two additional participant statements of "I knew 
what was happening because I've been down that road so many times." and "I just knew it was 
coming on[again]."The fourth participant, who has frequent exacerbations, recognized his signs 
of impending exacerbation and self-initiated his physician prescribed action plan.  Another 
participant discussed never knowing that cold symptoms can present as a prodrome to an acute 
exacerbation episode and shared having a newly learned understanding of this relationship after 
researching symptoms on the internet during this current exacerbation episode.  As she reported, 
I came down with a cold, a head cold, and I didn’t [know] that chronic bronchitis can... 
start with a cold and a headache...and I googled it and it said a COPD exacerbation starts  
[as a] cold and then it goes to your lungs.   
Three participants denied having a prodromal illness period, reporting instead sudden 
onset of severe (or worsening) dyspnea, without any precipitating or accompanying symptoms. 
These individuals immediately sensed something was wrong associated with COPD, and knew 
they needed prompt medical attention.  One participant reported awaking in the early morning 
hours and "not being able to breathe" further stating that "it felt like somebody just shut my lungs 
down."  In retrospect, he admitted that he had felt a little more tired than usual on the prior day 
and maybe a little short of breath during the evening.  Upon reflection, the remaining two 
participants also admitted to being a little more fatigued in the days prior to hospital admission. 
However, these individuals experienced fatigue simultaneously with an increase in perceived 
dyspnea, so it is not clear if the fatigue was a prodromal symptom or a consequence of the 
individual's dyspnea and subsequent increased work of breathing.  Nevertheless, fatigue was 
                                                                              77 
described by all three participants as being a significant indicator of a change in their COPD 
baseline status just prior to exacerbation onset. 
Here We Go Again     
Here we go again is the second subtheme related to the recognizing change component of 
the overarching main theme.  It relates to the transition from prodromal symptom awareness to 
exacerbation symptom recognition.  Although not all participants experienced, or were aware of 
experiencing prodromal symptoms, exacerbation symptom patterns were more readily described 
during the interviews.  Through questions and probes, a pattern of exacerbation symptoms that 
recurred with more than one exacerbation event was illuminated.  The presence of a recurring 
pattern of exacerbation symptoms was confirmed by 13 of 14 participants in the study.  This was 
the first COPD exacerbation for the remaining participant; therefore she had no prior experience 
upon which to draw on for pattern recognition. Four study participants were cognizant of their 
own specific exacerbation pattern without needing to be guided to this realization.  This was 
evident in statements such as “that’s how it always is…it’s the same pattern it doesn’t change” 
and “it's the same symptoms that I’ve been getting for the last five to six years, every three to 
four months” and “here we go again.”  Another participant not only recognized her personal 
symptom pattern, but a recurring hospitalization pattern when stating, "it's the same each time, it 
builds then I have to go [to the hospital]".Although the individual symptom that comprised the 
pattern for each individual differed amongst individuals, the pattern remained consistent across 
exacerbations within each individual.  
The remaining participants came to recognize they had a consistent exacerbation 
symptom pattern during the course of the interviews.  As a result of directed probes, an epiphanal 
moment of recognition occurred.  This is evident in one participants response:“Could be, could 
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be coming one [a pattern].”  Data analysis revealed that the majority of participants in this study 
(n =8) experienced Anthonisen Type 3 (Table 6) exacerbations. Table 10 describes the symptom 
patterns of participants in this study. 
Table 10 
Exacerbation Symptoms with Anthonisen Typology Classification 
Symptoms n Anthonisen Classification 
Increased dyspnea, sputum amount and purulence 1 Type 1 
Dyspnea, sputum 1  Type 2 
Increased dyspnea, cough, sputum amount 4 Type 2 
Dyspnea, wheezing, anxiety, sleeplessness 1  Type 3 
Sudden onset SOB 4   Type 3 
Dyspnea, wheeze 1  Type 3 
Dyspnea, cough 1  Type 3 
Dyspnea, cough, wheeze 1   Type 3 
 
Seeking Urgent Treatment  
          Responding to change, the second component of the main theme, is represented by two 
subthemes. The first subtheme, seeking urgent treatment, represents the immediate recognition  
of a life-threatening change in health by participants, and subsequent seeking of treatment early  
in the course of their event.  Three participants in this study experienced a sudden onset of severe  
dyspnea, and responded by seeking urgent treatment within 2 to 48 hours of symptom onset.   
This early treatment seeking was influenced by the severity of their dyspnea during the event, as  
well as having a prior similar exacerbation experience. The rapid onset and acuity of their 
symptoms caused them to be frightened, leading to a greater sense of urgency in seeking care.   
One participant stated: 
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              I woke up twice during the night a little [short of breath], I sat up, calmed myself down, 
took a couple deep breaths, [used] my inhaler, went back to sleep.  I woke up again 
being unable to breathe. I took my inhaler, I said its 3AM I might as well get up and get 
ready for work anyway and take a shower. I went in, got in the shower. I was in the 
shower long enough to get wet and soapy and that was it, it felt like somebody shut my 
lungs down, it felt like I couldn’t expel any air. I banged on the door for [my wife] to 
call 911.  I don’t think I finished rinsing the soap off.  I put my jeans on...and went out 
on the porch to get some cold air in me.  I almost went to the floor twice.  I was real 
lightheaded, like I was going to pass out.  Being a guy, we don’t like to do that; we’re 
supposed to be tough.  I was out [on the porch] for a few minutes and then I came in 
and sat in the chair.  I was going to wait out front for the ambulance and she [wife] 
talked me into sitting down in the dining room and wait[ing] for them (911) to come.  
When the ambulance got there they put the mask on me.  I kept fighting the mask.  But 
it was real, real panic. 
This participant reported that a similar episode had occurred one year prior, and he 
remembered from that experience that time was of the essence.  Another participant who  
presented early for treatment shared a similar experience: 
            I know [when] I'm in full exacerbation...everything shuts down.  I know I'm in trouble 
when none of my rescue inhalers or nebulizers work.  Nothing (air) was getting in.  [My 
husband] thought I was on my way out.   
This participant contacted her healthcare provider and was directed to present to the emergency  
room promptly. This patient also had prior experience with a significant exacerbation, and  
understood the consequences associated with treatment delay.  The third participant who sought  
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treatment within 48 hours of dyspnea onset also had prior severe exacerbation experience, and  
was able to get an appointment with her pulmonologist within hours of calling for an  
appointment.  She was seen and immediately referred to the emergency room.  In all these  
examples a combination of symptom severity, prior exacerbation experience, early recognition 
and/or healthcareprovider advice contributed to early presentation for treatment. 
Riding it out  
       The second subtheme related to responding to change is riding it out.  Riding it out refers  
to a wait and see approach to illness management.  This decision making process contributed to  
treatment delay (time from exacerbation symptom onset to engaging healthcare) that ranged from  
two days to two weeks.  The decision to ride it out was described as being influenced by many  
factors including personality traits such as stubbornness (n =2) and psychosocial factors such as  
prioritizing social commitments over health concerns (n = 3), stigmatization (n=2) and avoiding  
hospitalization (n =6).  Many participants used this approach despite assessing their illness as an  
exacerbation (n =1), COPD worsening (n =4) or infection (n=4), all of which should have served  
as an indicator that healthcare intervention was necessary. 
       As previously noted, all participants were able to identify a change in their baseline COPD 
status, but not all participants sought healthcare in a timely manner.  The average treatment delay 
time was seven days from the onset of symptoms. In contrast to the urgent treatment seeking 
behaviors described previously, a “ride it out” or waiting to see if the illness resolves on its own 
approach was utilized by most (n =11) participants.  Nine participants delayed treatment for 
seven days or more because they did not have a sense of urgency regarding their symptoms.  
This is in spite of, and in some cases due to, prior exacerbation experience.  For example, one 
participant reported consistently delaying treatment seeking despite early recognition of 
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exacerbation symptoms and having a good relationship with her physician because she wanted to 
“give it a few days to see where it goes.”  She was hospitalized 15 times in 2011 as a result of 
delaying care, and never quite recovered to baseline between exacerbations.  Her decision to 
present to the emergency room is predicated on the severity of her dyspnea, and not her illness 
knowledge or prior experience.  Another participant reported she just does not like being in the 
hospital so ignores her symptoms hoping they will go away and she can avoid hospitalization.  
Calling their primary care physician to initiate early home treatment did not occur to either 
participant in the above examples.  Two other participants shared that the don’t call their primary 
care physicians when they recognize that they are having an acute exacerbation because “he 
can’t do anything to change it.” 
       One participant waited for symptoms to resolve for two weeks.  She was admitted on the day  
she was interviewed.  She explained: 
 I was going to wait until today to call my doctor.  Usually he would put me on prednisone  
            and antibiotics [and my symptoms would improve].  All of a sudden I got really bad last  
            night, and scared.   Going to bed, using oxygen, nothing was helping me. 
Despite recognizing an impending exacerbation, and knowing that she typically needs  
medications to improve her symptom, this participant delayed calling her physician because she  
was waiting for her regularly scheduled appointment.  When further probed about this, she  
explained that she did not “want to be a bother.”    
 Two participants described finally seeking treatment after having an especially difficult  
sleepless night, thinking they may not even survive the night.  “It was hard to breathe.  I was  
lying in bed waiting to check out.  I couldn’t even make it to the bathroom, I was coughing and 
 so short of breath.  It was a horrible feeling.”    
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     In a unique situation, one participant reported riding it out because his only child  
was getting married, and he wanted to walk her down the aisle.  However, he also admitted to  
riding it out on prior occasions due to pure stubbornness.  When he does seek healthcare it is  
always at his daughter's insistence.    
       Another aspect of this subtheme includes wanting to continue with life as usual.  One  
participant who runs her own business describes wanting to manage her treatment on her own,  
despite her husband's urging to call her physician.  She insisted on continuing to run her own  
errands, keep her appointments, and entertain relatives despite her symptom progression.  She  
continued like this until her dyspnea was beyond control despite self-treatment, upon which she  
saw her physician who immediately admitted her. 
          I wasn't getting any air but I paid no attention to it.  My husband suggested I better go    
           to the doctor because something [was] wrong.  He told me to call on Monday, I called  
           on Wednesday and got an appointment for Thursday.  When I saw...my primary  
           doctor...he said you are going straight to the [hospital]. 
One participant with severe COPD described delaying calling her healthcare practitioner despite 
significant symptoms and distress because she wanted to cook thanksgiving dinner "as stupid as  
that sounds."  Even her family’s concern was not enough to change her mind.  
A particularly independent participant discussed trying the “riding it out” strategy before seeking 
healthcare advice stating, "I just hoped I could ride it out, but it reaches a point where it 
progresses and…it's beyond me to stop [it]."  She describes herself as being a very active person 
and not wanting to give in to illness, stating: 
I’m apt to ignore it (symptoms) until it gets to a point where I can’t walk from the kitchen  
to the dining room without having trouble breathing. I don’t like being sick, I don’t like  
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being inactive, not producing, not seeing people, not doing things.  I’m not happy here  
(hospital), which is normal.  I don’t want to give into to it because it’s something then I  
don’t have control over. 
When she reaches the point where she can’t control her symptoms with self-help strategies,  
she goes to her pulmonologist’s office to get “medication samples” but not necessarily for an  
office visit.  She proceeds to the emergency room for treatment when her dyspnea becomes  
“unbearable.”  
       Resistance to friend and family encouragement to seek healthcare in spite of significant 
symptoms was noted in a single woman's description of events.  As she describes: 
Sunday I went out with my friends.  I was so cold [and not feeling well].  I shouldn't 
have gone. They (friends) wanted to call the medics.  I went into the ladies room and 
the woman there wanted to call the medics.  I said no. I wanted to go home.  I was 
going to call my doctor today, but I had to call the ambulance last night.   
During the interview it was revealed that she prefers to see her physician and be treated at home  
with steroids and antibiotics.  She tends to wait until scheduled appointments rather than calling  
when she has a change in her COPD symptoms, not wanting to bother healthcare personnel  
on holidays and weekends.  One other participant reported not wanting to seek healthcare on the 
weekend, but it was because she did not want to see the physician on call. She prefers to see her  
own physician who understands her complex medical history and the treatment protocol that  
works for her.  In all, seven participants resisted recommendations from family and friends to  
seek treatment earlier.  Resistance was also evident in three participants refusal to call an  
ambulance for transport to the hospital despite the severity of their respiratory distress.  
            One participant, a current smoker, suggested that her embarrassment over her continued  
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smoking may have contributed to her riding it out. She discussed feeling that as a smoker  
she was stigmatized, and wished she could overcome her “addiction.”She felt that as a smoker  
she was treated differently. 
         Participants who chose to ride it out used a variety of self-management measures as they 
attempted to manage symptoms, resolve their illness and avoid emergency room visits,  
hospitalizations and health care expenses.  The participants who expressed trying to avoid  
engaging with the healthcare system (n =5) did not describe having a prior negative experiences  
with emergency room utilization or hospital admission.  They “just didn’t like being there.”   
However, the cost of hospitalization was a concern for a single participant.  During a previous  
non-COPD related hospital admissions she was uninsured and incurred rather large out of  
pocket expenses that drained her financial resources.  Although she has subsequently acquired  
health insurance, she has ongoing concerns regarding co-payments and other non-insured  
expenses potential taxing her family resources.  
            Participants described employing the following self-management measures: activity  
modification (n=14), rest (n=12), rescue inhaler use (n=9), cold medications (n=8), breathing  
exercises (n=4), special positioning (n=4), nebulizer use (n=2), oxygen use (n=2), relaxation  
techniques (n=2), initiation a physician prescribed action plan of antibiotics and steroids (n=1)  
warm showers (n=1) and hope(n =4).  Although these actions did provide some subjective  
relief of symptoms, they were not successful in averting the onset of exacerbation or subsequent  
need for hospitalization. Many participants reported repeatedly responding to COPD baseline  
changes with a "ride it out" approach despite lack of success in avoiding exacerbations and its  
consequences with this behavior on prior occasions. 
Not in charge anymore     
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           The subtheme not in charge anymore is a subtheme related of the reacting to change  
component of the main theme.  It represents the participant’s personal experiences regarding the  
impact of COPD on their lives, and how acute exacerbations compound this negative impact on  
their physical health and emotional well-being.  What they described in essence was an  
overwhelming loss of control, especially when they were feeling breathless due to an  
exacerbation event.  Study participants used strong descriptors such as frustrating, frightening,  
limiting, discouraging and powerless in describing this phenomena. 
       The perceived loss of control over their illness and the effect that these participants 
experienced during an acute COPD exacerbation is clearly articulated in the following excerpt  
from one participant interview: "Most fears come with losing control, feeling like you are not in  
charge anymore."All participants expressed distress over losing control of their symptoms, and  
the impact it had on their life activities.  Of course this distress is common in COPD, however it  
is potentiated during an acute exacerbation when symptoms are less easily controlled and  
physical activity is quite impacted.  One participant described the burden of symptoms on her  
sense of control stating, "When I can't breathe, needless to say I can't do anything.  You know it  
makes you down." She went on to say, "I have no control over it, you know, it's (exacerbations)  
part of my life now and it's no fun.” This is true not only during the exacerbation, but for an  
extended length of time following exacerbation. As one participant explained “after an  
[exacerbation]you are down for three weeks really sick, and then several more weeks trying to  
get back to where you were before.”  The lingering effects of exacerbation is again described by  
another participant who has been suffering frequent, repeateexacerbations, stating his recovery  
“timeline is different”.  It (baseline) doesn’t seem to come back.  I haven’t come back from last  
summer.”  This has resulted in a significant alteration in his lifestyle, inhibiting social activities  
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and modifying his role function within his family.  
             Not being able to manage symptoms, especially shortness of breath, was most  
distressing for participants.  As one individual stated, “I had no control, I used my inhaler  
[several] times and it didn’t work.”  Further adding, “when you can’t breathe there’s nothing you  
can do about it and it’s scary.” Another participant compared her escalating, uncontrollable  
symptoms to “a train running down the tracks out of control.”  Lack of control over symptom  
management during an exacerbation is richly described in the following quote: 
         I was getting short of breath…I went and laid down.  I switched body positions to get a  
         good breath.  I fell asleep and woke up and it was worse.  I put on a fan and let it hit me in  
         the face.  If I had to use the bathroom it was like taking a chance of [passing out].  I was  
         afraid to use any energy.  It’s scary when you can’t control something. 
The burden of not being able to control symptoms during an exacerbation is reiterated by another  
participant in the following: 
          If I like was laying in bed and I had to get up to go to the bathroom it would literally take  
          me.  I would get up and I would go into a coughing fit if I moved too much or walked from  
          here to there…it was out of control.  I would have to stop and try to breathe and get all the  
          junk that’s in there out and do that until I finally make it where I have to go.  That was the  
          process of one place to another. 
           Many participants also had concerns about becoming a burden to their family as they  
began to recover less completely, or suffered frequent exacerbations.  One participant was  
particularly remorseful about having smoked and that now her children were going to have to  
watch her die, as she had watched her father succumb to the complications of COPD as a result  
of smoking.“I do want to live, I don’t want my children to go through what I went through with  
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my father, to see that.”  This topic was painful for her, and she began to cry as she discussed her  
father’s death, her smoking habit, and fear of her own mortality as a consequence of smoking.  
        A male participant spoke about his lungs and health slowly deteriorating from recurrent  
exacerbations and as a result never fully recovering from exacerbations anymore.  He spoke of  
beginning to put his affairs in order, preparing a will, solidifying finances and transferring his  
role as head of household and caregiver to his wife.  This transfer of caregiving role has been  
especially difficult for him, as he felt strongly it was his duty to take care of his family. A female  
participant also discussed getting things in order and being distressed over giving up her  
caregiver role: "I'm trying to get everybody in order just in case. It's frustrating because I was  
always the one people went to." Again, this role change was difficult: 
          I had to get off my high horse.  I’m a general.  I hate getting helped; I like to [be the one  
          giving help], I would ignore my symptoms [and proceed with life as usual].  Getting use to  
          change is the hardest part.  I almost died [because of it]. 
        The impact of physical performance during, and for a period of time after, an exacerbation  
was discussed by male (n=3) and female (n=3) participants equally,  but was more elaborately  
described by male participants.  One male participant’s description details this decline:  
         I’ve been unable to do much physical work at all without my heart racing and breathing  
         hard.  How pathetic…I can’t go out and cut brush on a piece of land. I can barely get down  
         the stairs and bring up a load of laundry. It’s very restrictive… 
Another male participant highlighted the impact of physical decline on his job performance 
stating, “I noticed my coworkers starting to pick up the slack.”  And finally, the impact of  
physical decline on his role in the family, and his ability to keep them safe is prominent in this  
male participant’s quote: 
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            The kids can’t say to me watch the little ones while I run in the store, watch them with  
            the pool, watch them when their swimming.  I can’t do that alone.   I have the fear that [I 
            can’t go and catch them before they fall].  I can make the initial try by won’t finish so  
            that really, really bothers me.  
Female participants also described their decline in physical function, but also described a  
willingness to modify their physical intensity to manage symptoms similar to the following  
example by one participant: 
         Toward the end I may slow down and do more deskwork…rather than bounce around  
          outside.  I’m a very active person but when this (exacerbation) hits me… 
My last day    
       The final subtheme, also related to reacting to change is my last day. The fear of dying  
during the peak acuity of their acute exacerbation episode was described by 64% of the 
participants.  They described the panic, distress and feeling of suffocation that they experienced  
at the pivotal point when they finally decided it was time to seek treatment. A few participants 
expressed that they had waited too long, and were afraid they were not going to get professional  
help in time.  
           Nine participants described feeling as if it was their "last day" because their symptoms  
were so severe at the moment they sought healthcare.  As one participant shared: "I honestly  
thought it was going to be my last day.  Nobody wants it to be their last day.” This subtheme was  
especially evident in descriptions by patients who had a sudden onset of dyspnea requiring  
immediate healthcare assistance. The following recollection illuminates the panic and distress  
experienced as a result of breathlessness: “trying to gasp for air and I don’t have it there, you see  
that’s the worse, trying to get air and you can’t.”       
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         Other participants (n = 2) discussed a fear of death and dying that has climaxed over the  
years as their disease has worsened, and their exacerbations become more frequent.  As one  
participant who has experienced frequent, prolonged exacerbations in the last year explains: 
 I got a little more frightened this time than in the last 10 years.  I didn't seem to be able to  
control it as quickly and thought it was going to get the best of me.  Of course then you are  
concerned about your family coming in and [finding you dead].  You have to worry about  
them.  
Another participant who has experienced several exacerbations over several years stated  
       I’m going to have a cardiac arrest and die, that’s the first thing that crosses my mind.  You          
       know you’re gasping for air and it’s so frightening and that’s why I…think that this is one      
       that’s going to take me one day-cardiac arrest. 
Other participants (n =4) described their fear more vaguely stating “I thought I wasn’t going to 
make it through the night” and “I thought it was going to end, it’s always bad when you can’t 
breathe.” 
          For many, a conscious delay in treatment seeking preceded (n =7) the escalation of their  
symptoms.  Participants recognized that by delaying treatment seeking, the acuity of their illness  
built to a severity level that became uncontrollable and frightening.  One participant shared that  
if his daughter had not insisted he get care when he did that he “might have passed out or  
something.”  Recognition of personal responsibility for the severity of their current health crisis  
is embodied in the following exemplar:  
I was {afraid] that it was going to end.  I thought I was gonna not breathe at all.  You 
 know it got worse and worse and even when they were bringing me in, in my mind I was  
saying it, I’m going to die and they (medical personnel) don’t even have enough time to  
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change this. I thought it was too late 
One participant, who insisted on seeing her primary care physician instead of going to, 
emergency services for her severe symptoms “because he’s my doctor and that’s his job”,  
explained: 
        While I was waiting I thought I was not going to make it, like 99 check out time, and 
        he saw me coming down the hall and he came over and said ‘you need to be in the  
        hospital, you’re bad’.  I agreed and went to the hospital.  
The participant further shared that she had a similar “bad episode” several years prior.  However, 
despite her prior experience, severity of symptoms, and fear that death was imminent, she 
insisted on seeing her primary care physician for treatment instead on engaging emergency 
medical services.  
     For two participants who did not express a fear of dying, it was a fear of requiring  
endotracheal intubation and ventilation that was articulated.  This fear was based on prior  
experience with severe exacerbation that necessitated this treatment.   
                                                   Summary 
       Five males and nine females, age 49-87, with moderate to severe COPD participated in this  
qualitative descriptive study exploring awareness of prodromal symptoms, recognition of  
symptom patterns and treatment delay during acute exacerbation of COPD.  All participants  
were hospitalized in community hospitals in Southeastern Massachusetts. 
       In summary, participant awareness of prodromal symptoms included noticing new 
symptoms such as palpitations, sinusitis, headache, fatigue and cold symptoms.  These symptoms 
were different from their usual day-to-day COPD symptoms.  Common cold symptoms were the 
most prevalent (n=8), however participants described fatigue as being the most bothersome 
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because of the impact it had on modifying their activities.  Seventy-eight percent (n =11)of 
participants recalled having prodromal symptoms in the days preceeding their exacerbation, but 
most did not identify their symptoms as a prodrome of COPD exacerbation. 
      Thirteen participants (93%) recognized their unique exacerbation pattern that recurred with  
exacerbation event.  For some, conscious awareness of their symptoms as a pattern evolved only  
during the course of the study interview. The most prevalent (57%) exacerbation pattern in this  
sample was Anthonisen Type 3, the combination of dyspnea with a minor symptom such as  
cough or wheeze.  Anthonisen Type 2 exacerbation, increased dyspnea and sputum, was  
experienced by 36%  of participants, and only one participant experience a Type 1 exacerbation,  
increase in dyspnea, sputum production and sputum purulence. For many participants, the  
recognition of their exacerbation symptoms, or pattern of symptoms, alerted them to an  
impending exacerbation, and precipitated the initiation of self-management behaviors.  For  
others, the symptom onset was so abrupt, or so severe that healthcare was sought immediately. 
      Finally, treatment delay(a delay in seeking care from the time of exacerbation symptom  
onset until initial contact with healthcare) was experienced by most (n =11) participant.  Three 
participants presented for healthcare within 2-48 hours of their initial symptom onset  
because of abruptness of the onset of their symptoms (dyspnea), or the sudden worsening of their  
dyspnea.  However 79% of participants delayed seeking treatment between three days and two  
weeks.  Mean delay was seven days (SD 4.96).  During this time, participants initiated self- 
management behaviors that included activity modification, rest, inhaler use, cold medications,  
breathing exercise, positioning, nebulizer use, oxygen use, relaxation techniques, action plans,  
warm showers and hope.  The primary reason for delay was reported to be waiting to see if the  
illness resolved on its own.  Many psychosocial factors contributed to participants engaging this  
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management approach. The physical, social and emotional consequences of COPD exacerbations  
are also richly described as well as feelings of loss of control over one’s life, and fear of death 
during an exacerbation event.     
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                                                                  Chapter V 
                                                                  Discussion  
Introduction   
       The purpose of this qualitative descriptive dissertation study was to explore the COPD 
exacerbation experience. A primary focus was to investigate prodromal symptom awareness, 
describe symptom pattern recognition, and identify factors that delayed treatment seeking.  This 
topic is important because the incidence of COPD is steadily increasing, and COPD 
exacerbations represent a significant physical, psychological and economic burden for patients 
and the healthcare system.  Early recognition and treatment of exacerbation is important to 
decrease this burden.  Little is known about how individuals recognize and respond to early signs 
of impending exacerbation. The study’s major findings will be discussed in relationship to 
Leventhal’s common sense model and the empirical literature reviewed for this study.  The 
major findings include: participant awareness of an illness prodrome that precedes exacerbation 
onset, identification of a recurring exacerbation pattern, descriptions of psychosocial factors that 
contributed to treatment seeking delay and details of fears and concerns that arise during the 
exacerbation event.  This information will add to the currently growing body of knowledge 
regarding the COPD exacerbation experience.  This chapter will also discuss the study 
limitations and recommendations for future research, practice and health policy.    
Theoretical Framework 
 
       The commonsense model (Leventhal, Meyer & Nerenz, 1980) undergirded this study, which 
focused on exploring symptom recognition and treatment delay during an acute exacerbation of 
COPD.  This model was useful in developing the interview guide, directing probes and analyzing 
the data.  In chronic illnesses such as COPD, patients experience occasional changes in their 
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health status illness, or exacerbations, that require patients to immediately process and respond to 
their health change.  The symptoms of COPD exacerbations engage perceptual, cognitive and 
emotional processes.  Leventhal’s model provided insight for understanding how individuals 
experiencing acute exacerbation of COPD integrate these processes to recognize, respond and 
react to symptoms within the context of their individual experience.  Through use of the model, it 
became clear how prior experience and psychosocial factors influenced each participants coping 
behaviors, self-management of treatment seeking actions and emotional appraisal of their illness 
situation.  
Prodrome 
       This study’s findings suggest that patients with COPD experience, and are aware of, an 
illness prodrome prior to the onset of acute exacerbation.  These symptoms are different from 
typical day-to-day symptom variations and more subtle than usual exacerbation symptoms.  The 
phenomenon of a prodromal period was identified in two longitudinal cohort studies conducted 
by Aaron et al. (2012) and Seemungal et al. (2000).  The importance of understanding this phase 
in relationship to exacerbation onset is seen as an important opportunity for initiating early 
treatment (Wilkinson et al., 2004).  Prodrome characteristics are also helpful in determining the 
etiology (viral vs. bacterial) of exacerbation triggers, and guiding appropriate therapy (Aaron et 
al. 2012).  In both cohort studies, subjects experienced worsening dyspnea, cold symptoms, sore 
throat and cough in the days prior to exacerbation onset.  These symptoms were identified 
through examination of the subjects’ daily symptom diary recordings.  It is not clear if the 
subjects who completed the symptom diary cards were aware that their symptoms were worse or 
different from their baseline, or if they associated the symptoms with an exacerbation prodrome.  
All participants in the current study self-reported the presence of the same prodromal symptoms 
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described by Aaron et al. (2012) and Seemungal et al, (2000).  Additionally, in the current study 
fatigue was reported as a significant prodromal symptom.   
       The data analyzed in this study agrees with Aaron’s et al. findings (2012) that prodromal 
symptoms are experienced regardless of whether the exacerbation has a sudden or gradual onset.  
In contrast, Kessler et al. (2006) reported that 32.8% of the participants in a similar study had no 
recognizable warning sign prior to exacerbation. Most participants in the current study were 
unfamiliar with the phenomenon of an exacerbation prodrome, and therefore did not link the 
symptoms to imminent exacerbation.  This represents a missed opportunity for early treatment to 
avert exacerbation and its negative consequences.   However, the finding that all participants in 
the present study were aware of their prodromal symptoms, even if retrospectively, holds 
promise for developing early recognition skills and initiating early treatment.    
       Fatigue 
       Fatigue has been reported as a common symptom in COPD (Baghai-Ravary et al., 2009, Gift 
& Shepard, 1999, Theander & Unosson, 2004) as well as a consequence of exacerbation 
(Baghai-Ravary et al., 2009; Rabe et al. 2007), however the finding of fatigue as a significant 
indicator in the prodromal period has not been previously reported.   Kessler et al. (2006) 
discussed fatigue as a warning sign that occurred in 10% (n =13) of participants at exacerbation 
onset, but this report did not discuss a prodromal period.  In the present study, bothersome 
fatigue was reported by 57% of participants.  The experience of fatigue in COPD has been 
related to increased dyspnea (Baghai-Ravary et al., 2009, Gift & Shepard, 1999.  During COPD 
exacerbation, Baghai-Ravary et al. (2008) also found that fatigue increased considerably, 
peaking three to fours days after exacerbation onset.  This increase in fatigue was also associated 
with increased depression. 
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       COPD is an inflammatory disease, and recently Al-shair et al. (2011) reported a possible 
association between systemic inflammation and symptoms of fatigue in stable patients with 
moderate COPD.  One might hypothesize that the presentation of fatigue in the prodromal period 
may also be linked to an increase in circulating inflammatory factors prior to exacerbation onset. 
Exacerbation Symptom Patterns  
        The current study findings demonstrated that patients experiencing exacerbation of COPD 
have an individual pattern of exacerbation symptoms that recurs with each exacerbation event  
(Kessler et al., 2006).  Similar to novel findings from a prospective cohort study by Aaron et al. 
(2012), two distinct exacerbation presentations were reported by participants in the this study: 
sudden onset and gradual onset.   Sudden onset exacerbations were marked by a brief (hours) 
period of fatigue and increased dyspnea followed by a sharp onset of intractable dyspnea that 
was frightening and precipitated urgent care-seeking.  Three participants (21%) experienced a 
sudden onset type exacerbation as compared to 55% of subjects as reported by Aaron et al. 
(2012).  Gradual onset exacerbation was preceded by a two to seven day prodrome of symptoms.  
In the current study 79% of participants experienced a gradual-onset exacerbation compared to 
45% of subjects in the cohort study.  The difference in sample size between this study (N = 14) 
and the Aaron et al. (2012) study (N = 1995) may account for some of the findings. 
Treatment delay 
       To date, there is paucity of research literature specific to treatment delay in COPD. 
Participants in thid study sought treatment for their exacerbation based on the severity of their 
symptoms, with participants experiencing sudden, severe dyspnea presenting earliest for 
treatment.  The severity of symptoms in these individuals precipitated a sense of urgency 
regarding their situation.  Participants who experienced a more insidious exacerbation onset 
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waited to see how their illness progressed before seeking treatment, and presented only when 
symptoms were no longer tolerable.  Other qualitative studies have reported the same 
relationship between illness severity and treatment seeking behavior (Adams et al., 2006; Russell 
et al., 1998).  Adams et al. (2006) cited poor symptom recognition and attribution as the reason 
for delay by participants in their study.   In the present study, symptom recognition was not a 
factor, however unawareness of the relationship between prodromal symptoms and exacerbation 
onset was a factor for many participants.  Psychosocial factors such as social commitments, not 
wanting to bother providers, patient-provider relationships, avoidance of hospitalization and 
stigmatization also contributed to delay.  The most significant of these factors were patient-
provider relationship and stigma. 
       Patient-Provider relationship 
       According to Fox and Chesia (2008) patient-provider relationships that includes good 
communication, continuity among providers and recognition of patient individuality and self-
management abilities were the most satisfying for participants.  Conversely, participants who did 
not feel understood or respected by their provider(s) became insecure and untrusting of them.  
This is consistent with the current study’s findings, which demonstrated that participants delayed 
care because they (a) did not want to bother their provider, (b) believed that their provider could 
not help them or (c) did not want to see the physician on call.   Instead these participants delayed 
care and presented to the emergency room for care only when they could no longer tolerate their 
symptoms.  In contrast, several participants who reported having a good relationship with their 
provider believed their provider understood their individual treatment needs during exacerbation 
and were supportive.  These participants called, or presented to their provider for advice prior to 
presenting to the emergency room. 
                                                                              98 
       Stigma 
       According to Earnshaw and Quinn (2011) patients with chronic illness may experience 
internalized, experienced or anticipated stigma within the context of healthcare interactions.  
Reduced healthcare access and quality of life are potential consequences of stigmatization.  
Individuals who smoke are stigmatized by societies attitudes towards smoking and may feel 
shame and guilt about their smoking behavior (Earnshaw & Quinn, 2011; Halding, Heggdal & 
Wahl, 2010).  These patients internalize those negative beliefs and subsequently may anticipate 
stigmatization in healthcare interactions (Earnshaw & Quinn, 2011).  Three participants in the 
present study who delayed treatment continued to smoke, however only one of these participants 
expressed concerns over stigmatization related to their smoking behavior.  This topic was not 
addressed with the other participants, as they had been interviewed prior to this topic emerging.    
     Stigmatization occurs when a patient perceives that healthcare workers blame him/her for 
his/her illness, or that health care workers are frustrated with him/her (Earnshaw & Quinn, 
2011).  Patients with chronic illness who require frequent hospitalizations to manage their illness 
are often labeled as “frequent-fliers” in healthcare settings. One participant did share that her 
decision to delay treatment was related to feelings of being stigmatized by the emergency room 
staff related to her frequent visits.  She shared this during a member check interview.  One may 
postulate that she felt comfortable discussing this out of the physical context of the healthcare 
environment.  It is possible other participants may have had similar experiences, but this was not 
explored in the interviews.  Although only two participants explicitly discussed stigma, this is a 
major finding as it influences quality healthcare interactions.  In general, research focusing on 
the stigma experienced by individuals with COPD during healthcare interactions is sparse. 
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Emotional reactions  
       Participants discussed the overwhelming loss of control they experience during an acute 
exacerbation, as well as their fear of dying at the moment that their exacerbation peaked and 
dyspnea became intolerable.   Participants described feeling frightened, frustrated, discouraged 
and powerless as they lost control over their symptoms, their illness and their life during these 
illness events.  Two major findings in this domain were fear of death, and discussion of suicide. 
      Depression and suicide risk 
      Findings that 21% (n =3) of participants had symptoms suggestive of depression are 
consistent with a large observational study (Schneider, Jick, Bothner and Meier, 2010) where the 
prevalence of depression was 23.1% among individuals with COPD.   The three participants with 
depressive symptoms were women, which is consistent with other findings that women are twice 
as likely as men to experience depression (Laurin et al., 2007).  In a smaller prospective cohort 
study by Regvat, Vegnuti, Kosnik and Suskovic (2011), the prevalence of depression during 
hospitalization for exacerbation of COPD was 42%.  According to Jennings, DiGiovine, Obeid 
and Frank (2009), depressed individuals are 2.8 times more likely to experience exacerbation 
than non-depressed individuals.  It is also important to note that depression scores worsen during 
exacerbation, with the greatest increase in those with lower levels of depression at baseline 
(Quint et al, 1998).  Depression is also associated with alteration in motivation and cognition and 
feelings of hopelessness and powerlessness (Dowson et al., 2004).  Consequently, illness self-
management and treatment-seeking behaviors may be impaired in depressed individuals. 
       The three participants who demonstrated depressive symptoms in the present study were 
being treated for depression prior to admission.   It is not known if there was a change in these 
participants baseline depression level as a result of the current exacerbation, however one 
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participant did discuss having thoughts of suicide after the current exacerbation onset and 
another participant was initially placed on suicide precautions on admission.  These findings 
suggest a rise in depression acuity during exacerbation as noted by Regvat et al. (2011) and 
Quint et al., (1998).   A search of the literature did not uncover any studies specific to suicide 
risk and COPD.  
       All participants in this study were screened for depression and suicide risk on admission 
according to the institutional policy, however screening practices in the larger population of 
patients experiencing exacerbation of COPD is not known.  The current and past research 
findings suggests that depression screening for all individuals experiencing exacerbation of 
COPD needs to be a routine practice across all settings.  
        Fear of death 
        Fear of death during the current exacerbation was discussed by 64% of participants in this 
study.  The panic they experienced as they felt they were suffocating and taking their last breath 
was vividly described.  Six participants had delayed seeking treatment until this pivotal point, 
and many of them took responsibility for reaching this frightening climax before calling for help.   
In an observational study of COPD exacerbations, Kessler et al. (2006) found that 12% of 
participants feared dying and 9.6% of participants feared suffocating during exacerbation.  Only 
one study regarding death fears during acute exacerbation of COPD was found for comparison.  
Bailey’s (2001) narrative analysis of 10 patient-family-nurse dyads describes two distinct death 
fear experiences: near-death, which involves patient resuscitation, and shadow of death, where 
the patient fears death as a consequence of the perceived seriousness of their dyspnea.   The 
death fears reported by participants in the current study are consistent with the near-death 
narrative described by Bailey (2001), however whether treatment delay was a factor in the Bailey 
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(2001 study is not known.  How much the emotional overlay of regret related to treatment delay 
contributed to distress in this study is also not known. 
Research Implications 
         Findings from the current study suggest that research is needed to address: cognitive 
dysfunction in COPD, fatigue as a prodromal symptom, stigmatization during health care 
interactions and efficacy of nurse-led self-management programs for COPD. This research is 
important to add to the knowledge base of COPD and to guide practice and policy development. 
        Current research suggests that deficits in cognitive function are associated with chronic 
illnesses in which hypoxemia is a feature such as COPD (Dodd et al., 2010; Kapstein et al., 
2009). The cognitive dysfunction in COPD is manifested as impaired decision-making, memory, 
recognition and executive functioning, which may contribute to poor symptom recognition 
(Dodd et al., 2010).  Depression also impacts cognition (Dawson et al., 2006).  As chronic illness 
self-management is increasingly recommended, the effect of COPD on learning and self-
management behavior needs to be investigated to ensure patients have the requisite skills to 
effective self-management their disease and make the necessary judgment to seek treatment 
when appropriate.  Additional research is needed to establish the prevalence of cognitive 
impairment in COPD, identify correlating factors, and determine the impact of deficits on 
symptom recognition and treatment decision-making. 
 Despite earlier evidence to the contrary (Monninkhof et al., 2003), a recent Cochrane 
Review (Effing et al., 2007) and study (Schofield et al, 2006) indicated that nurse-led self-
management education, interventions and programs may be beneficial in improving outcomes for 
individuals with COPD.  Successful management of COPD requires a chronic care model 
approach to care that is patient-centered, empowering, provides competency-based self-
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management education and decision-making support.  The success of this model is predicated on 
the successful development of the nurse-patient relationship, shared knowledge of the patient’s 
illness experience and collaboration between all health team members (Corsello & Tinkelman, 
2008).  In other chronic diseases, such as heart failure, nurse-led self-management programs 
have been successful in supporting patient self-management, reducing hospitalizations and 
improving patient and healthcare outcomes.  Success has been demonstrated in clinic delivered 
(Smeulders et al., 2010), telephone delivered (Brandon, Schuessler, Ellison & Lazenby, 2009) 
and home monitoring support (Manning, 2011).  The implementation of a nurse-led self-
management program for the management of COPD has implications for improving the care of 
individuals with COPD, however the research supporting implementation of this intervention is 
limited.  Additional research is needed to identify essential program components, determine the 
most appropriate delivery model and assess the long-term effectiveness of a nurse-led self-
management program for COPD. 
       Stigma was identified as a potential barrier for healthcare access and quality care.   Research 
is needed to understand more about how stigma affects access to prompt care for persons with 
COPD.  Additionally we need to understand how health care provider attitudes affect self-
management and prompt treatment of COPD exacerbations.   
      As a result of the current study’s findings, it appears that strategies to improve prodromal and 
exacerbation symptom recognition is a priority to improve early detection and treatment.  
Symptom diaries have been used in large longitudinal cohort studies investigating exacerbation 
prevalence and typologies.  In the cohort studies, the diaries were used as a data collection tool 
rather than a self-management tool.  Symptom diaries have improved symptom recognition and 
self-care in individuals with heart failure (White, Howie-Esquivel & Caldwell, 2010) when 
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participants adhered to daily symptom recording and sought prompt healthcare attention in 
response to symptom change.  The efficacy of a daily symptom diary to improve exacerbation 
recognition and treatment seeking in individuals with COPD needs to be investigated.  
Adherence to diary use, accuracy of data interpretation and appropriateness of care seeking in 
response to symptom change in this population needs to be determined.  
 Findings in this study implicate fatigue as a prodromal symptom of acute exacerbation.  
Fatigue as a co-morbid condition in COPD, and fatigue changes related to dyspnea intensity 
during baseline COPD and exacerbation have been well documented.  However, further research 
is needed to specifically measure changes in fatigue intensity in the time period just prior to 
exacerbation onset, and to establish a clear association between fatigue and impending 
exacerbation.   
Practice Implications    
        Practice implications from this study include: developing patient-provider partnerships and 
improving patient teaching for patients with COPD.  Data analysis revealed that participants who 
had confidence in their healthcare provider, and who felt comfortable contacting them during 
illness were more likely to call the office for advice than to utilize emergency services.  Given 
the physical and emotional complexity of this chronic illness, as well as the economic burden, it 
is important for healthcare professionals to develop collaborative partnerships with patients to 
improve health outcomes on all levels.  Healthcare workers need to be sensitive to each 
individual’s perspective and goals regarding their illness management.  Healthcare personnel 
also need to engage in self-reflection and examine their own biases regarding individuals with 
COPD to avoid inadvertently stigmatizing patients.   
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Nurses caring for patients with COPD need to provide patient education that will support 
and improve patient self-management.  In 2008, the Institute for Healthcare Improvement (IHI) 
(Nielsen et al., 2008) instituted a campaign to improve the care of patients with heart failure.  
Important components of this program are strategies to improve the impact of patient education.  
Guidelines to improve nursing knowledge of heart failure management and core measures to be 
addressed during patient teaching are outlined.  A similar strategy, based on research evidence as 
outlined in the prior section, should be considered to improve COPD patient education and self-
management.  The Joint Commission’s (JCAHO) Management of the Patient with COPD 
Certification Program states that the most successful elements of a COPD management program 
includes competency-based COPD education for nurses as well as patients.  Although these 
recommendations are targeted toward outpatient and ambulatory care settings, they have 
important implications for acute care nurses who manage patients during acute exacerbations of 
COPD.  
Findings from this study suggest that regardless of setting, COPD exacerbation teaching 
should include assisting patients to recognize their individual prodromal symptoms and to 
understand there importance as a warning sign of impending exacerbation.  The onset, or 
worsening, of fatigue in the prodromal period in more than 50% of our participants is also 
important finding for patient teaching.  Patients should be instructed to interpret this onset or 
change as a prodromal symptom.  Since it is possible that patients may not experience (Kessler et 
al., 2006) or recognize early signs of impending exacerbation, patients also need to be assisted to 
recognize their individual exacerbation symptom pattern and be encouraged to seek treatment 
immediately upon presentation of these symptoms.   
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Policy 
 
        The main policy recommendation is support for the development of COPD management 
programs to improve the quality of care for patients and reduce the economic burden of COPD 
related hospitalizations on the health care system.   The Institute of Medicine Committee on the 
Quality of Health Care in America has recommended disease management programs, based on 
evidence based-guideline, for patient-centered, coordinated management of chronic diseases 
such as COPD.  Educational programs for patients and providers, and supported self-
management are the cornerstones of disease management programs.   
        COPD exacerbation is one of the leading causes of hospitalization for older adults (Wier, 
2008).  The high rate of hospitalization in this population suggests that patients with COPD are 
not adequately managing and responding to their symptoms.  This is confirmed by the substantial 
treatment-delay by the majority of participants experiencing an exacerbation in this study.   In a 
national survey, only 25% of respondents believed they had the information they needed to 
successfully manage their disease (Barr et al., 2005).  The present study uncovered knowledge 
gaps regarding the importance of prodromal symptom and the presence of recurring exacerbation 
symptom patterns.  This is a missed opportunity for early treatment, avoidance of hospitalization, 
and reduced physical and economic consequences of exacerbation. 
        The literature suggests that empowering patients with the knowledge, skills and support to 
manage their disease is the best approach to improving the quality of care and quality of life of 
these individuals (Bourbeau et al., 2003; Cicutto, Brooks & Henderson, 2004).  Self-
management with supported decision-making is a health care intervention that empowers 
patients to partner with their providers in managing their health and ensuring appropriate health-
care actions are taken (Embrey, 2006). The goals of COPD self-management programs are to 
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address physical and emotional symptoms and improve patient and financial outcomes.  
Recommended program components include an emphasis on patient education and self-
management skills, workshops to enhance symptom recognition and self-management, 
population specific literature, internet support and a detailed action plan for exacerbation 
management (NCQA, 2009).  Similar programs in Australia and the United Kingdom have been 
successful in decreasing hospitalization rates and emergency room visits (Adams, 2007).   
       The American Lung Association is currently working with state agencies to develop and 
designate funds for COPD programs. All stakeholders involved in the care of individuals with 
COPD across the continuum to advocate and support the development of quality COPD 
management programs that includes a pulmonary nurse specialist case-manager to support 
patient self-management and decision-making.  
Limitations 
 
       There are several limitations in this study.  The small purposive sample was predominantly 
white (79%), female (64%) and educated (mean 13.4 years) with moderate to severe (Stage 2-3) 
COPD.  All participants had medical insurance and lived in Southeastern Massachusetts.  
Therefore, results can only be interpreted in this context.   These findings may not reflect the 
experiences of individuals in other geographic areas, or populations that are more culturally 
diverse, less educated and uninsured.  These findings also may not represent the experience of 
individuals with mild (Stage 1) or very severe (Stage 4) COPD.  The small sample also limited 
the use of statistical methods to analyze data for any associations.  
       Despite using a calendar to facilitate symptom recall, patients had difficulty remembering 
the exact day and time their prodromal and exacerbation symptoms appeared.  Therefore the 
number of days reported for prodrome and treatment-delay length must be evaluated with 
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caution.  The use of daily symptom diary card might have been useful for capturing these data, 
although studies by Bennett, Amtmann, Diehr and Patrick (2012) and Meek et al. (2001) 
revealed no differences when comparing memory recall of COPD symptoms to daily diary 
reports. Nonetheless, a symptom diary should be considered in future COPD studies to 
authenticate prodromal symptom duration and treatment delay time. 
       Participant burden was a limiting factor for at least two participants.  The total  
 
procedure collection time was 40-60 minutes, depending on patient  rest and hygiene  
 
needs (using bathroom).  In one case, the participant became tearful when discussing her  
 
illness, requiring periods of rest and support.  A second participant experienced dyspnea   
 
during the interview period necessitating that the participant rest at two separate time points.   
 
This may have precipitated premature closure of the interview by the PI, as she became  
 
concerned for the participant’s well-being. 
 
     In this study the MHI-5 was administered following the participant interview.  This was 
placed at the end to decrease participant burden prior to the interview, as demographic data and 
the MMSE preceded the interview procedurally.  Three participants declined completing the 
MHI-5 when asked if they felt up to completing and additional measure. Although they reported 
fatigue as the reason for the decline, in all three cases visitors were arriving, or pending and that 
may have influenced participant participations.  For participants who did complete the subscale, 
it is possible that illness details discussed during the interview could affect the scoring of the 
MHI-5, and would recommend administering before the interview in subsequent studies.   
Conclusion 
 
        This is the first comprehensive qualitative study on prodromal symptom awareness, 
symptom recognition and treatment delay in patients experiencing an acute exacerbation of 
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COPD.   Analysis revealed that patients are aware of the presence of prodromal symptoms in the 
pre-exacerbation period.  The onset, or worsening of fatigue was also a found to be a significant 
prodromal indicator.  Participants also recognized that they had an individual exacerbation 
symptom pattern.  However, participants needed to be guided to awareness of their prodromal 
symptoms and exacerbation symptom pattern experiences.  Patients also did not understand the 
importance of prodromal symptoms, or their relationship to exacerbation onset.  These findings 
are important for developing patient education and support tools that facilitate early recognition 
and treatment of exacerbation to improve patient outcomes.  
      When self-management behaviors are unsuccessful, patients need to engage with healthcare 
providers.  Factors that facilitate successful engagement must be promoted, and factors that 
impede engagement removed.   Good patient-provider relationships are integral to empower 
patients, develop collaborative relationships and promote effective COPD self-management.  
Barriers to seeking healthcare treatment such as perceptions or experiences of stigma and co-
morbid depression need to be addressed and the appropriate intervention applied.   
  
  
 
 
 
 
 
 
 
 
                                                                              109 
                                                                References 
Aaron, S. D., Donaldson, D. G., Whitmore, G. A., Hurst, J. R., Ramsay, T., Wedzicha, J. A.  
            (2012).  Time course and pattern COPD exacerbation pattern.  Thorax, 67, 238-243.     
            doi:10.1136/thoraxjnl-2011-200768 
Adams, R., Chavannes, N., Jones, K., Ostergaard, M. S., & Price, D. (2006). Exacerbations of 
chronic obstructive pulmonary disease- A patients’ perspective. Primary Care 
Respiratory Journal, 15, 102-109.  doi:10.1016/j.pcrj.2006.01.003 
Albert, N. M., & Zeller, R. (2007). Development and testing of the Survey of Illness Beliefs in 
Heart Failure Tool.  Progress in Cardiovascular Nursing, 22, 63-71. doi:10.1111/j.0889-
7204.2007.06539.x 
Albert, N. M., & Zeller, R. (2009). Depressed patients understand heart failure prognosis but not 
how to control it.  Heart & Lung, 38, 382-391. doi:10.1016/j.hrtlng.2008.10.007 
Al-shair, K., Dockry, R., Mallia-Milanes, B., Kolsum, U., Singh, D., & Vestbo, J. (2009). 
Depression and its relationship with poor exercise capacity, BODE index and muscle 
wasting in COPD.  Respiratory Medicine, 103, 1572-1579. 
            doi:10.1016/j.rmed.2008.11.021 
American Lung Association. (2011, August). Trends in COPD: Morbidity and Mortality 2011 
(American Lung Association). Available at: http://www.lung.org/finding-cures/our-
research/trend-reports/copd-trend-report.pdf 
 Andenaes, R., Kalfoss, M. H., & Wahl, A. K. (2006). Coping and psychological distress in 
hospitalized patients with chronic obstructive pulmonary disease. Heart & Lung, 35, 46-
57.  doi:10.1016/j.hrtlng.2005.09.009 
                                                                              110 
Anthonisen, N. R., Manfreda, J., Warren, C. P., Hershfield, E. S., Harding, G. K., & Nelson, N. 
A. (1987). Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. 
Annals of Internal Medicine, 106, 196-204. 
Anto, J. M., Vermeire, P., Vestbo, J., & Sunyer, J. (2001). Epidemiology of chronic obstructive 
pulmonary disease. European Respiratory Journal, 17, 982-994. 
doi:10.1183/09031936.01.17509820 
Anzueto, A., Leimers, I., & Kesten, S. (2009). Impact of frequency of COPD exacerbations on 
pulmonary function, health status and clinical outcomes. International Journal of COPD, 
4, 245-251.  doi:10.2147/COPD.S4862 
Baghai-Ravary, R., Quint, J. K., Goldring, J. J., Hurst, J. R., Donadson, G. C., & Wedzicha, J. A. 
(2009). Determinants and impact of fatigue in patients with chronic obstructive 
pulmonary disease. Respiratory Medicine, 103, 216-223.  
           doi: 10.1016/j.rmed.2008.09.022 
Bailey, P. H. (2001).  Death stories: Acute exacerbations of Chronic Obstructive Pulmonary 
Disease.  Qualitative Health Research, 11, 322-338.  doi:10.1177/104973201129119136 
Balcells, E., Anto, J. M., Gea, J., Gomez, F. P., Rodriguez, E., & Marin, A. et al. (2009). 
Characteristics of patients admitted for the first time for COPD exacerbation. Respiratory 
Medicine, 103, 1293-1302.  doi:10.1016/j.rmed.2009.04.001 
Bandura, A. (1969).  Principles of Behavior Modification. New York: Holt, Rinehart & Winston. 
Bandura, A. (1982).  Self-efficacy mechanism in human agency.  American Psychologist, 37, 
122-147. 
Barnett, M. (2005). Chronic obstructive pulmonary disease: a phenomenological study of 
patients’ experiences. Journal of Clinical Nursing, 14, 805-812.   
                                                                              111 
            doi:10.1111/j.1365-2702.2005.01125.x 
Barr, R. G., Celli, B. R., Martinez, F. J., Reis, A. L., Rennard, S. L., & Reilly, J. J. et al. (2005). 
Physician and patient perceptions in COPD: The COPD resource network needs 
assessment survey. American Journal of Medicine, 118, 1415-1424. 
doi:10.1016/j.amjmed.2005.07.059 
Bennett, A. V., Amtmann, D., Diehr, P., Patrick D. L. (2012). Comparison of 7-day recall and 
daily diary reports of COPD symptoms and impacts.  Value in Health, 15, 466-474.   
            doi:10.1016/j.jval.2011.12.005 
Berwick, D. M., Murphy, J. M., Goldman, P. A., Ware, J. E., Barsky, A. J., Weinstein, M. C. 
(1991). Performance of a five-item mental health screening test. Medical Care, 29, 169–
76.  doi:10.1097/00005650-199102000-00008 
Bjelland, I., Dahl, A. A., Haug, T. T., Neckelmann, D. (2002).  The validity of the hospital 
anxiety and depression scale. An updated literature review.  Journal of Psychosomatic 
Research, 52, 69-77.  
Bourbeau, J., & Nault, D. (2007). Self-management strategies in chronic obstructive pulmonary 
disease. Clinics in Chest Medicine, 28, 617-628.  doi:10.1016/j.ccm.2007.06.002 
Bourbeau, J., & Van der Palen, J. (2009). Promoting effective self-management programmes to 
improve COPD. European Respiratory Journal, 23, 461-463.  
            doi:10.1183/09031936.00001309 
Bourbeau, J., Ford, G., Zackon, H., Pinsky, N., Lee, J., & Ruberto, G. (2007).  Impact on 
patient’s health following early identification of a COPD exacerbation. European 
Respiratory Journal, 30, 907-913.  doi:10.1183/09031936.00166606 
                                                                              112 
Brandon, A. F., Schuessler, J. B., Ellison, K. J. & Lazenby, R. B. (2009).  The effects of an 
advanced practice nurse led telephone intervention on outcomes of patients with heart 
failure. Applied Nursing Research, 22, e 1-8.  doi:10.1016/j.apnr.2009.02.003 
Brownlee, S., Leventhal, H., & Leventhal, E.A. (2000). Regulation, self-regulation, and 
construction of the self in the maintenance of physical health. In M. Boekaerts, P.R. 
Pintrich, & M. Zeidner (Eds.), Handbook of self-regulation (pp. 369-416). San Diego, 
CA: Academic Press. 
Byer, B., & Myer, L. B. (2000). Psychological correlates of adherence to medication in asthma. 
Psychology in Health and Medicine, 3, 389-393.  doi:10.1080/713690213 
Calverley, P., Pauwels, R., Lofdahl, C., Svensson, K., Higenbottam, T., & Carlsson, L. et al. 
(2005). Relationship between respiratory symptoms and medical treatment in 
exacerbations of COPD. European Respiratory Journal, 26, 406-413.   
            doi:10.1183/09031936.05.00143404 
Cameron, L. D., & Leventhal, H. (2003). Self-regulation, health, and illness: An overview. In L. 
D. Cameron & H. Leventhal (Eds.), Self-regulation of health and illness behaviour  (pp. 
1-12). New York: Routledge. 
Cameron, L. D., Leventhal, E. A., & Leventhal, H. (1993).  Symptom representation and affect 
as determinants of care seeking in a community-dwelling, adult sample population.  
Health Psychology, 12, 171-179.  doi:10.1037/0278-6133.12.3.171 
Carlson, B., Riegel, B., & Moser, D. K. (2001). Self-care abilities of patients with heart failure. 
Heart & Lung, 30, 351-359.  doi:10.1067/mhl.2001.118611 
Carver, C. S., & Scheier, M. F. (1981). Attention and self-regulation: A control theory approach  
 
 to human behavior.  New York: Springer-Verlag. 
 
                                                                              113 
Celli, B. R. (2006). Chronic obstructive pulmonary disease: From unjustified nihilism to 
evidence-based optimism. Proceedings of the American Thoracic Society, 3, 58-65. 
doi:10.1513/pats.200510-111JH 
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., & Mendez, R. A. et al. 
(2004). The body-mass index, airflow obstruction, dyspnea, and exercise capacity index 
in chronic obstructive pulmonary disease. New England Journal of Medicine, 340, 1005-
1012.   
Celli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., & Buist, A. S. et al. (2004). 
Standards for the diagnosis and treatment of patients with COPD: a summary of the 
ATS/ERS position paper. European Respiratory Journal, 23, 932-946. 
doi:10.1183/09031936.04.00014304 
Centers for Disease Control and Prevention (2002). Chronic obstructive pulmonary disease 
surveillance- United States, 1971- 2000, Morbidity and Mortality Weekly Report, 
51(SS06), 1-16.  Retrieved from: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5106a1.htm#fig7. 
Chandra, D., Tsai, C., Camargo, C. A. (2009). Acute exacerbations of COPD: Delay in 
presenting and the risk of hospitalization.  COPD: Journal of Chronic 0bstructive 
Pulmonary Disease, 6, 95-103.  doi:10.1080/15412550902751746. 
Chen, K. H., Chen, M. L., Lee, S., Cho, H. Y., & Weng, L. C. (2008).  Self-management 
behaviours for patients with chronic obstructive pulmonary disease: a qualitative study. 
Journal of Advanced Nursing, 64, 595-604.  doi:10.1111/j.1365-2648.2008.04821.x 
                                                                              114 
Cherrington, C. C., Lawson, T. N., & Clark, K. B. (2006).  Illness representations of patients 
with systolic heart failure. Progress in Cardiovascular Nursing, 21, 190-195. 
doi:10.1111/j.0889-7204.2006.05600.x 
Cicutto, L., Brooks, D., & Henderson, K. (2004).  Self-care issues from the perspective of 
individuals with chronic obstructive pulmonary disease. Patient Education and 
Counseling, 55, 168-176.  doi:10.1016/j.pec.2003.08.012 
Corsello, P., Tinkelman, D. (2008).  Optimizing disease management of chronic obstructive 
pulmonary disease.  Disease Management and Health Outcomes, 16, 289-296. 
doi:10.2165/0115677-200816050-00004 
Costi, S., Brooks, D., & Goldstein, R. S. (2006). Perspectives that influence action plans for 
chronic obstructive pulmonary disease. Canadian Respiratory Journal, 13, 352-368.   
Cote, C. G., Dordelly, L. J., & Celli, B. R. (2007). Impact of COPD exacerbations on patient-  
centered outcomes. Chest, 131, 696-704.  doi:10.1378/chest.06-1610 
Creswell, J.W. (2003).  Research design.  Qualitative, quantitative and mixed methods      
            approaches.  Thousand Oaks, CA: Sage. 
Derogatis L R; Lipman R S; Rickels K; Uhlenhuth E H; Covi L (1974).  The Hopkins Symptom  
            Checklist (HSCL).  A measure of primary symptom dimensions.  Modern problems of  
            pharmacopsychiatry, 7, 79-110. 
De Voogd, J. N., Wempe, J. B., Koeter, G. K., Postema, K., Van Sonderen, E., & Ranchor, A. V. 
et al. (2009). Depressive symptoms as predictors of mortality in patients with COPD. 
Chest, 135, 619-625.  doi:10.1378/chest.08-0078 
                                                                              115 
Diefenbach, M.A., & Leventhal, H. (1996). The common-sense model of illness representation: 
Theoretical and practical considerations. The Journal of Social Distress and the 
Homeless, 5, 11-38.  doi:10.1007/BF02090456 
Dodd, J. W., Getov, S. V., Jones, P. W. (2010).  Cognitive function in COPD.  European 
Respiratory Journal, 35, 913-922.  doi:10.1183/09031936.00125109 
Dodd, M., Janson, S., Facione, N., Faucett, J., Froelicher, E. S., & Humphreys, J. et al. (2001). 
Advancing the science of symptom management. Journal of Advanced Nursing, 33(), 
668-676.  doi:10.1046/j.1365-2648.2001.01697.x 
Donaldson, G. C., & Wedzicha, J. A. (2006). COPD exacerbations.1: Epidemiology. Thorax, 61, 
164-168.  doi:10.1136/thx.2005.041806 
Donaldson, G. C., Seeemungal, T. A., Bhowmik, A., & Wedzicha, J. A. (2002). Relationship 
between exacerbation frequency and lung function decline in chronic obstructive 
pulmonary disease. Thorax, 57, 847-852.  doi:10.1136/thorax.57.10.847 
Donaldson, G. C., Seemungal, T. A., Patel, I. S., Lloyd-Owen, S. J., Wilkinson, T. M., & 
Wedzicha, J. A. (2003). Longitudinal changes in the nature, severity and frequency of 
COPD exacerbations. European Respiratory Journal, 22, 931-936. 
doi:10.1183/09031936.03.00038303 
Donaldson, G. C., Wilkinson, T. M., Hurst, J. R., Perera, W. R., & Wedzicha, J. A. (2005). 
Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. 
American Journal of Respiratory and Critical Care Medicine, 171, 446-452. 
doi:10.1164/rccm.200408-1054OC 
Dowling, M. (2006). Approaches to reflexivity in qualitative research.  Nurse Researcher, 13, 7-
21. 
                                                                              116 
Dowson, C. A., Town, G. I., Frampton, C., & Mulder, R. T. (2004). Psychopathology and illness 
beliefs influence COPD self-management. Journal of Psychosomatic Research, 56, 333-
340.  doi:10.1016/S0022-3999(03)00040-0 
Earnshaw, V. A., Quinn, D. M. (2011).  The impact of stigma in healthcare on people living with 
chronic illness.  Journal of Health Psychology, 17, 157-168.  
            doi:10.1177/1359105311414952   
Effing, T., Monninkhof, E. M., van der Valk, P. D., van Herwaarden, C. L., Patridge, M. R., 
Walters, E. H., Zielhuis, G. A. (2007).  Cochrane Systematic Reviews, 4, CD002990. 
Embrey, N. (2006).  A concept analysis of self-management in long-term conditions.  British 
Journal of Neuroscience Nursing, 2, 507-513.   
Evangelista, L. S., Dracup, K., & Doering, L. V. (2000). Treatment-seeking delays in heart 
failure patients. Journal of Heart and Lung Transplantation, 19, 932-938. 
doi:10.1016/S1053-2498(00)00186-8 
Fishbein, M., & Ajzen, I. (1975). Belief, attitude, intention, and behavior. Reading, MA: 
Addison-Wesley. 
Fisk, J. D., Ritvo, P. G., Ross L., Haase, D. A., Marrie , T. J., Schlech, W. F. (1994).  Measuring 
the functional impact of fatigue: initial validation of the fatigue impact scale.  Clinical 
Infectious Diseases, 18 (Supp 1), S79-83.  doi:10.1093/clinids/18.Supplement_1.S79 
Folstein, M.F., Folstein, S.E., McHugh, P.R. (1975). ""Mini-mental state". A practical method 
for grading the cognitive state of patients for the clinician". Journal of psychiatric 
research 12 (3): 189–98.  doi:10.1016/0022-3956(75)90026-6. PMID 1202204. 
                                                                              117 
Fox, S., Chesla, C. (2008).  Living with chronic illness: A phenomenological study of the heath 
effects of the patient-provider relationship.  Journal of the American Academy of Nurse 
Practitioners, 20, 109-117.  doi:10.1111/j.1745-7599.2007.00295.x 
Fraser, D. D., Kee, C. C., & Minick, P. (2006). Living with chronic obstructive pulmonary 
disease: insiders’ perspectives. Journal of Advanced Nursing, 55, 550-558. 
Friedman, M. M., & Quinn, J. R. (2008). Heart failure patients’ time, symptoms, and actions 
before a hospital admission. Journal of Cardiovascular Nursing, 23, 506-512. 
Funk, G., Kirchheiner, K., Burghuber, O., & Hartl, S. (2009). BODE index versus GOLD 
classification or explaining anxious and depressive symptoms in patients with COPD- a 
cross-sectional study. Respiratory Research, 10, 1-8.  doi:10.1186/1465-9921-10-1 
Gift, A. G., & Shepard, C. E. (1999). Fatigue and other symptoms in patients with chronic 
obstructive pulmonary disease: Do women and men differ?  Journal of Obstetric, 
Gynecologic, and Neonatal Nursing, 28, 201-208.  doi:10.1111/j.1552-
6909.1999.tb01985.x 
Global Initiative for Chronic Obstructive Lung Disease. (2004). Global strategy for the 
diagnosis, management, and prevention of chronic obstructive pulmonary disease. 
Besthesda, MD: GOLD. 
Goodridge, D. M. (2006). COPD as a life-limiting illness: implications for advanced practice 
nurses. Topics in Advanced Practice Nursing eJournal, 6(4). 
Gruffydd-Jones, K., Langley-Jihnson, C., Dyer, C., Badlan, K., & Ward, S. (2007). What are the 
needs of patients following discharge from hospital after an acute exacerbation of chronic 
obstructive pulmonary disease (COPD)?  Primary Care Respiratory Journal, 16, 363-
368. 
                                                                              118 
Halding, A., Heggdal, K., Wahl, A. (2011).  Experiences of self-blame and stigmatization for 
self-infliction among individuals living with COPD.  Scandinavian Journal of Caring 
Sciences, 25, 100-107.  doi:10.1111/j.1471-6712.2010.00796.x 
Hale, E. D., Treharne, G. J., Kitas, G. D. (2007). Experiences of self-blame and stigmatization 
for self-infliction among individuals living with COPD.  Rheumatology, 46, 904-906. 
Haughney, J., Partridge, M. R., Larsson, T., Kessler, R., Stahl, E., & Brice, R. et al. (2005). 
Exacerbations of COPD: quantifying the patient’s perspective using discrete choice 
modelling. European Respiratory Journal, 26, 623-629. 
doi:10.1183/09031936.05.00142704 
Hedemalm, A., Schaufelberger, M., & Ekman, I. (2008). Symptom recognition and health care 
seeking among immigrants and native Swedish patients with heart failure. BMC Nursing, 
7(9), 1-7.  doi:10.1186/1472-6955-7-9 
Horne, R., & Weinman, J. (2002). Self-regulation and self-management in asthma: Exploring the 
role of illness perceptions and treatment beliefs in explaining non-adherence to preventer 
medication. Psychology and Health, 17, 17-32.  doi:10.1080/08870440290001502 
Horowitz, C. R., Rein, S. B., & Leventhal, H. (2004). A story of maladies, misconceptions and 
mishaps: effective management of heart failure. Social Science & Medicine, 58, 631-643. 
doi:10.1016/S0277-9536(03)00232-6 
Howard, C., Hallas, C. N., Wray, J., & Carby, M. (2009). The relationship between illness 
perceptions and panic in chronic obstructive pulmonary disease. Behaviour Research and 
Therapy, 47, 71-76.  doi:10.1016/j.brat.2008.10.004 
Hsieh, H & Shannon, S.E. (2005).  Three approaches to qualitative content analysis. Qualitative 
Health Research, 15, 1277-1288.  doi:10.1177/1049732305276687 
                                                                              119 
Hurst, J. R., Donaldson, G. C., Quint, J. K., Goldring, J. J., Baghai-Ravary, R., & Wedzicha, J. 
A. (2009).  Temporal clustering of exacerbations in chronic obstructive pulmonary 
disease. American Journal of Respiratory and Critical Care Medicine, 179, 369-374. 
doi:10.1164/rccm.200807-1067OC 
Hutchinson, A. F., Ghimire, A. K., Thompson, M. A., Black, J. F., Brand, C. A., & Lowe, A. J. 
(2007).  A community-based, time-matched, case-control study of respiratory viruses and 
exacerbations of COPD.  Respiratory Medicine, 101, 2472-2481. 
doi:10.1016/j.rmed.2007.07.015 
IBM Software (2010). PASW Statistics 19. Available at http://www.spss.com/software 
Insel, K. C., Meek, P. M., & Leventhal, H. (2005).  Differences in illness representation among 
pulmonary patients and their providers. Journal of Health Psychology, 10, 147-162. 
doi:10.1177/1359105305048561 
Izquierdo, J. L., Barcina, C., Jimenez, J., Munoz, M., & Leal, M. (2009).  Study of the burden on 
patients with chronic obstructive pulmonary disease.  International Journal of Clinical 
Practice, 63, 87-97.  doi:10.1111/j.1742-1241.2008.01936.x 
Jablonski, A., Gift, A., & Cook, K. E. (2007).  Symptom assessment of patients with chronic 
obstructive pulmonary disease.  Western Journal of Nursing Research, 29, 845-863. 
doi:10.1177/0193945906296547 
Janson, S., & Becker, G. (1998). Reasons for delay in seeking treatment for acute asthma: the 
patient’s perspective. Journal of Asthma, 35, 427-435.  doi:10.3109/02770909809048951 
Jennings, J. H., DiGiovine, B., Obeid, D., & Frank, C. (2009).  The association between 
depressive symptoms and acute exacerbation of COPD.  Lung, 187, 128-135. 
doi:10.1007/s00408-009-9135-9 
                                                                              120 
Jessop, D. C., & Rutter, D. R. (2003).  Adherence to asthma medication: The role of illness 
representations.  Psychology and Health, 18, 595-612. 
doi:10.1080/0887044031000097009 
Johnson, J. E., & Leventhal, H. (1974). The effects of accurate expectations and behavioral 
instructions on reactions during a noxious medical examination. Journal of Personality 
and Social Psychology, 29, 710-718.  doi:10.1037/h0036555 
Jones, P. W., Quirk, F. H., Baveystock, C. M. (1991).  The St George’s Respiratory 
Questionnaire.  Respiratory Medicine, 85(Suppl B) 25-31.   
            doi:10.1016/S0954-6111(06)80166-6 
Jurgens, C. Y. (2006).  Somatic awareness, uncertainty, and delay in care-seeking in acute heart 
failure.  Research in Nursing & Health, 29, 74-86.  doi:10.1002/nur.20118 
Jurgens, C. Y., Hoke, L., Byrnes, J., & Riegel, B. (2009). Why do elders delay responding to 
heart failure symptoms? Nursing Research, 58, 274-282. 
doi:10.1097/NNR.0b013e3181ac1581 
Kapstein, A. A., Scharloo, M., Fischer, M. J., Snoei, L., Hughes, B. M., Weinman, J., Kaplan, R. 
M., Rabe, K. F. (2009).  50 years of psychological research on patients with COPD – 
Road to ruin or highway to heaven?  Respiratory Medicine, 103, 3-11.   
            doi:10.1016/j.rmed.2008.08.019 
Keller, M. L., Ward, S., & Baumann, L. J. (1989).  Processes of self-care: Monitoring sensations 
and symptoms.  Advances in Nursing Science, 12, 54-66. 
Kempler, E.A., Stringfield, S, Tedlie, C. (2003). Mixed methods sampling strategies in social 
science research.  In Tashakkori, A., & Teddlie, C. (Eds.), Handbook of mixed methods 
273-297.  Sage: Thousand Oaks. 
                                                                              121 
Kessler, R., Stahl, E., Vogelmeier, C., Haughney, J., Trudeau, E., & Lofdahl, C. et al. (2006). 
Patient understanding, detection, and experience of COPD exacerbations: An 
observational, interview-based study. Chest, 130, 133-142.  doi: 10.1378/chest.130.1.133 
Kinsman, R. A., Yaroush, R. A., Fernandez, E., Dirks, J. F., Schocket, M., & Fukuhara, J. 
(1983). Symptoms and experiences in chronic bronchitis and emphysema. Chest, 83, 755-
761.  doi:10.1378/chest.83.5.755 
Knafl, K.A. & Webster D.C. (1988).  Managing and analyzing qualitative data: a description of 
tasks, techniques, and materials.  Western Journal of Nursing Research 10, 195–210. 
doi:10.1177/019394598801000207 
Koch T. & Harrington A. (1998).  Reconceptualizing rigour: the case for reflexivity.  Journal of  
 
           Advanced Nursing 28, 882–890.  doi:10.1046/j.1365-2648.1998.00725.x 
 
Langsetmo, L., Platt, R., Ernst, P., & Bourbeau, J. (2008).  Underreporting exacerbation of 
chronic obstructive pulmonary disease in a longitudinal cohort.  American Journal of 
Respiratory and Critical Care Medicine, 177, 396-401.   
            doi: 10.1164/rccm.200708-1290oc 
Lau, R. R., & Hartman, K. A. (1983).  Commonsense representations of common illnesses. 
Health Psychology, 2, 167-185. 
Leventhal, H. (1970).  Findings and theory in the study of fear communications.  Advances in 
Experimental Social Psychology, 5, 119-186.  doi:10.1016/S0065-2601(08)60091-X 
Leventhal, H. (1971).  Fear appeals and persuasion: The differentiation of a motivational 
construct.  American Journal of Public Health, 61, 1208-1224. 
doi:10.2105/AJPH.61.6.1208 
                                                                              122 
Leventhal, H., Benyamini, Y., Brownlee, S., Diefenbach, M., Leventhal, E. A., Patrick-Miller, 
L., & Robitaille, C. (1997). Illness representations: Theoretical foundations. In K. J. 
Petrie & J. A. Weinman (Eds.), Perceptions of health and illness: Current research and 
applications (pp. 19-45). London: Harwood Academic. 
Leventhal, H., Brissette, I., & Leventhal, E. A. (2003). The common-sense model of self-
regulation of health and illness. In L. D. Cameron & H. Leventhal (Eds.), The self-
regulation of health and illness behaviour (pp. 42-65). New York: Routledge. 
Leventhal, H., & Cameron, L. (1987).  Behavioral theories and the problem of compliance. 
Patient Education & Counseling, 10, 117-138.  doi:10.1016/0738-3991(87)90093-0 
Leventhal, H., Meyer, D., & Nerenz, D. (1980). The common sense representation of illness 
danger. In S. Rachman (Series Ed.), Contributions to medical psychology: Vol. 2., (pp. 7-
30). New York: Pergamon Press. 
Leventhal, H., & Nerenz, D. (1985). The assessment of illness cognition. In P. Korely (Ed.), 
Measurement strategies in health psychology (pp. 517-554). New York: Wiley. 
Leventhal, H., Nerenz, D. R., & Steele, D. (1984). Illness representations and coping with health 
threats. In A. Baum, S. Taylor,  & I. Singer (Eds.), Handbook of psychology and health 
(pp. 219-252). Hillsdale, NJ: Lawrence Erlbaum. 
Lincoln, Y.S., Guba, E.G. (1985). Naturalistic inquiry. Beverly Hills: Sage 
Mallia, P., & Johnston, S. L. (2005). Mechanisms and experimental models of chronic 
obstructive pulmonary disease exacerbations. Proceedings of the American Thoracic 
Society, 2, 361-366.  doi:10.1513/pats.200504-025SR 
Malterud, K. (2001). Qualitative research: Standards, challenges, and guidelines. The Lancet, 
358(9280), 483-488.  doi:10.1016/S0140-6736(01)05627-6 
                                                                              123 
Manning, S. (2011).  Bridging the gap between hospital and home: a new model of care for 
reducing readmission rates in chronic heart failure.  Journal of Cardiovascular Nursing, 
26, 368-376.  
Mannino, D. M., Gagnon, R. C., Petty, T. L., & Lydick, E. (2000). Obstructive lung disease and 
low lung function in adults in the United States: data from the National Health and 
Nutrition Examination Survey, 1988-1994. Archives of Internal Medicine, 160, 1683-
1689.  doi:10.1001/archinte.160.11.1683 
Mannino, D. M., Homa, D. M., Akinbami, L. J., Ford, E. S., & Redd, S. C. (2000).  Chronic 
obstructive pulmonary disease surveilance- United States, 1971-2000.  Morbidity and 
Mortality Weekly Report (MMWR) Surveillance Summary, 51, 1-16.  Available at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5106a1.htm 
Marin, J. M., Carrizo, S. J., Casanova, C., Martinez-Camblor, P., Soriano, J. B., & Agusti, A. G. 
et al. (2009).  Prediction of risk of COPD exacerbations by the BODE index.  Respiratory 
Medicine, 103, 373-378.  doi:10.1016/j.rmed.2008.10.004 
McCarley, C., Hanneman, S. K., Padhye, N., & Smolensky, M. H. (2007).  A pilot home study of 
temporal variation of symptoms in chronic obstructive lung disease.  Biological Research 
for Nursing, 7, 8-20.  doi:10.1177/1099800407303501 
Meek, P. M., Lareau, S. C., & Anderson, D. (2001).  Memory for symptoms in COPD patients: 
how accurate are their reports?  European Respiratory Journal, 18, 474-481. 
doi:10.1183/09031936.01.00083501 
Miles, M.B., Huberman, A. M. (1994).  Qualitative data analysis: an expanded sourcebook.  
Sage: Thousand Oaks. 
                                                                              124 
Milne, J., Oberle, K. (2005).  Enhancing rigor in qualitative description.  Journal of Wound, 
Ostomy & Continence Nursing, 32, 413-420.  doi:10.1097/00152192-200511000-00014 
Miravitles, M., Anzueto, A., Legnani, D., Forstmeier, L., & Fargel, M. (2007).  Patient’s 
perception of exacerbations of COPD- the PERCEIVE study.  Respiratory Medicine, 101, 
453-460.  doi:10.1016/j.rmed.2006.07.010 
Monninkhof, E. M., van der Valk, P. D., van Herwaarden, C. L., Partidge, M. R., Walters, E., 
Zielhuis, G. A. (2003).  Self-management education for chronic obstructive pulmonary 
disease.  Cochrane Database Systematic Reviews, 1, CD002990. 
Moss-Morris, R., Weinman, J., Petrie, K. J., Horne, R., Cameron, L. D., & Buick, D. (2002).  
The revised illness perception questionnaire (IPQ-R).  Psychology and Health, 17, 1-16. 
doi:10.1080/08870440290001494 
Murphy, S. L., Xu, J. Q., Kochanek, K. D. (2012).  Deaths: Preliminary data for 2010.   
 
            National Vital Statistics Reports, 60 (4).    
 
            http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60 04.pdf 
 
Murray, C. J., & Lopez, A. D. (1997).  Alternative projections of mortality and disability by 
cause 1990-2020.  Global burden of disease study (part 4).  The Lancet, 349, 1498-1505. 
doi:10.1016/S0140-6736(96)07492-2 
Nerenz, D. R., & Leventhal, H. (1983). Self-regulation theory in chronic illness. In T. G. Burish 
& L. A. Bradley (Eds.), Coping with chronic disease: Research and applications (pp. 13-
36). New York: Academic Press. 
Nielsen G. A., Bartely, A., Coleman, E., Resar, R., Rutherford, P., Souw, D., Taylor, J. (2008). 
Transforming care at the bedside how-to guide: Creating an ideal transition home for 
                                                                              125 
patients with heart failure. Cambridge, MA: Institute for Healthcare Improvement.  
Available at www.IHI.org. 
Nishimura, K., Sato, S., Tsukino, M., Hajiro, T., Ikeda, A., & Koyama, H. et al. (2009).  Effect 
of exacerbations on health status in subjects with chronic obstrucive pulmonary disease. 
Health and Quality of Life Outcomes, 7, 69-74.  doi:10.1186/1477-7525-7-69 
O’Neill, E. S. (2002).  Illness representations and coping in women with chronic obstructive 
pulmonary disease: A pilot study.  Heart & Lung, 31, 295-302. 
doi:10.1067/mhl.2002.123712 
O’Neill, E. S., & Morrow, L. L. (2001).  The symptom experience of women with chronic 
illness.  Journal of Advanced Nursing, 33, 257-268.  
            doi:10.1046/j.1365-2648.2001.01653.x 
O’Reilly, J. F., Williams, A. E., Holt, K., & Rice, L. (2006).  Defining COPD exacerbations: 
impact on estimation of incidence and burden in primary care.  Primary Care Respiratory 
Journal, 15, 346-353. 
Parker, C. M., Voduc, N., Aaron, S. D., Webb, K. A., & O’Donnell, D. E. (2005).  
Physioloogical changes during symptom recovery from moderate exacerbations of 
COPD.  European Respiratory Journal, 26, 420-428. 
doi:10.1183/09031936.05.00136304 
Parshall, M. B. (2002). Psychometric characteristics of dyspnea descriptor ratings in emergency 
department patients with exacerbated chronic obstructive pulmonary disease.  Research 
in Nursing & Health, 25, 331-344.  doi:10.1002/nur.10051 
                                                                              126 
Parshall, M. B., Mapel, D. W., Rice, L, Williams, .A, O'Reilly, J. (2008).  Predictive validity of 
short-form health survey [36 items] scales for chronic obstructive pulmonary disease 
exacerbation.  Heart & Lung: The Journal of Acute and Critical Care, 37, 356-365. 
Patel, H., Shafazand, M., Schaufelberger, M., & Ekman, I. (2007). Reasons for seeking acute 
care in chronic heart failure. European Journal of Heart failure, 9, 702-708. 
doi:10.1016/j.ejheart.2006.11.002 
Pauwels, R. A. (2004).  Similarities and differences in asthma and chronic pulmonary disease 
exacerbations.  Proceedings of the American Thoracic Society, 1, 73-76. 
doi:10.1513/pats.2306024 
Pauwels, R., Calverley, P., Buist, A. S., Rennard, S., Fukuchi, Y., & Stahl, E. et al. (2001). 
COPD exacerbations: the importance of a standard definition.  Respiratory Medicine, 98, 
99-107. doi:10.1016/j.rmed.2003.09.001 
Pleis, J. R., & Lucas, J. W. (2009). Summary health statistics for U.S. adults: National Health 
Interview Survey, 2007. Vital Heath Stat, 10(240), 1-169.  Available at: 
www.cdc.gov/nchs/data/series/sr_10/sr10_240.pdf 
Punturieri, A., Croxton, T. L., Weinmann, G., & Kiley, J. P. (2007).  The changing face of 
COPD.  American Family Physician, 75, 315-317. 
Putman-Casdorph, H., & McCrone, S. (2009).  Chronic obstructive pulmonary disease, anxiety, 
and depression: State of the science.  Heart & Lung, 38, 34-47. 
doi:10.1016/j.hrtlng.2008.02.005 
Quint, J. K., Baghai-Ravary, R., Donaldson, G. C., & Wedzicha, J. A. (2008).  Relationship 
between depression and exacerbations in COPD.  European Respiratory Journal, 32, 53-
60.  doi:10.1183/09031936.00120107 
                                                                              127 
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., & Calverley, P. et al. (2007). 
GOLD executive summary: Global strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary disease.  American Journal of Respiratory 
and Critical Care Medicine, 176, 532-555.  doi:10.1164/rccm.200703-456SO 
Radloff, L. S. (1977).  The CES-D scale: A self-report depression scale for research in the 
general population.  Applied Psychological Measurement, 1, 385- 401. 
doi:10.1177/014662167700100306 
Regvat, J., Zmitek, A., Vegnuti, M., Kosnik, M., Suskovic, S. (2011).  Anxiety and depression 
during hospital treatment of exacerbation of chronic obstructive pulmonary disease.  The 
Journal of International Medical Research, 2011, 1028-1038.   
Reishtein, J. L. (2005). Relationship between symptoms and functional performance in COPD. 
Research in Nursing & Health, 28, 39-47.  doi:10.1002/nur.20054 
Rennard, S., Decramer, M., Calverley, P. M., Pride, N. B., Soriano, J. B., & Vermeire, P. A. et 
al. (2002).  Impact of COPD in North America and Europe in 2000: subjects’ perspective 
of confronting COPD international survey.  European Respiratory Journal, 20, 799-805. 
doi:10.1183/09031936.02.03242002 
Rodriguez-Roisin, R. (2000).  Towards a consensus definition for COPD exacerbations.  Chest, 
117, 398S-401S.  doi:10.1378/chest.117.5_suppl_2.398S 
Rosenstock, I. M. (1966), "Why people use health services".  Milbank Memorial Fund 
Quarterly, 44 (3), 94–127.  doi:10.2307/3348967 
Rumpf, H. J., Meyer, C., Hapke, U., John, U. (2001).  Screening for mental health: Validity of 
the MHI-5 using DSM-IV Axis I psychiatric disorders as gold standard.  Psychiatry 
Research, 105, 243–53.  doi:10.1016/S0165-1781(01)00329-8 
                                                                              128 
Russell, C. K., Geraci, T., Hooper, A., Shull, L., & Gregory, D. M. (1998).  Patients“ 
explanatory models for heart failure and COPD exacerbations.  Clinical Nursing 
Research, 7, 164-188.  doi:10.1177/105477389800700206 
Sandelowski, M. (1994).  The use of quotes in qualitative research.  Research in Nursing & 
Health, 17, 479-482.  doi:10.1002/nur.4770170611 
Sandelowski, M. (1995a).  Sample size in qualitative research.  Research in Nursing & Health, 
18, 179-183.  doi:10.1002/nur.4770180211 
Sandelowski, M. (1995b).  Qualitative analysis: what it is and how to begin.  Research in 
Nursing & Health, 18, 371-375.  doi:10.1002/nur.4770180411 
Sandelowski, M. (2000).  Focus on research methods: What ever happened to qualitative 
description?  Research in Nursing & Health, 23, 334-340.  doi:10.1002/1098-
240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G 
Sandelowski, M. (2010.  What's in a name? Qualitative description revisited. Research in 
Nursing & Health, 33, 77–84.  doi:10.1002/nur.20362  
Schofield, I., Knussen, C., & Tolson, D. (2006).  A mixed methods study to compare use and 
experience of hospital care and a nurse-led acute respiratory assessment service offering 
home care to people with an acute exacerbation of chronic obstructive pulmonary 
disease.  International Journal of Nursing Studies, 43, 465-476. 
doi:10.1016/j.ijnurstu.2005.07.002 
Seemungal, T. A., Donaldson, G. C., Bhowmik, A., Jeffries, D. J., & Wedzicha, J. A. (2000). 
Time course and recovery of exacerbations in patients with chronic obstructive 
pulmonary disease.  American Journal of Respiratory and Critical Care Medicine, 161, 
1608-1613.   
                                                                              129 
Seemungal, T. A., Donalson, G. C., Paul, E. A., Bestall, J. C., Jeffries, D. J., & Wedzicha, J. A. 
(1998).  Effect of exacerbation on quality of life in patients with chronic obstructive 
pulmonary disease.  American Journal of Respiratory and Critical Care Medicine, 157, 
1418-1422.   
Sethi, S., Evans, N., Grant, B., & Murphy, T. (2002).  New strains of bacteria and exacerbations 
of chronic obstructive pulmonary disease.  New England Journal of Medicine, 347, 465-
471.  doi:10.1056/NEJMoa012561 
Scharloo, M., Kaptein, A. A., Schlosser, M., Pouwels, H., Bel, E., Rabe, K., & Wouters, E. F. 
(2007).  Illness perceptions and quality of life in patient's with chronic obstructive 
pulmonary disease.  Journal of Asthma, 44, 575-581. 
Scharloo, M., Kaptein, A. A., Weinman, J., Hazes, J. M., Willems, L. N., Bergman, W., & 
Rooijmans, H. G. (1998).  Illness perceptions, coping and functioning in patients with 
rheumatoid arthritis, chronic obstructive pulmonary disease and psoriasis.  Journal of 
Psychosomatic Research, 44, 573-585.  doi:10.1016/S0022-3999(97)00254-7 
Smeulders, E. S., van Haastregt, J. C., Ambergen, T., Uszko-Lencer, N. H., Janssen-Boyne, J. J., 
Gorgeis, A. P., …Kempen, G. I. (2010).  Nurse-led self-management group programme 
for patients with congestive heart failure: RCT.  Journal of Advanced Nursing, 7, 1487-
1489.  doi:10.1111/j.1365-2648.2010.05318.x 
Soler-Cataluna, J. J., Martinez-Garcia, M. A., Sanchez, P. R., Salcedo, E., & Navarro, M. (2005). 
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary 
disease.  Thorax, 60, 925-931.  doi:10.1136/thx.2005.040527 
                                                                              130 
Spencer, S., Calverley, P. M., Burge, P. S., & Jones, P. W. (2004).  Impact of preventing 
exacerbations on deterioration of health status in COPD.  European Respiratory Journal, 
23, 698-70.  doi:10.1183/09031936.04.00121404 
Sullivan-Bolyai, S., Bova, C., Harper, D. (2005).  Developing and refining interventions in 
persons with health disparities: The use of qualitative description.  Nursing Outlook, 
53(3), 127-133.  doi:10.1016/j.outlook.2005.03.005 
Theander, K., & Unosson, M. (2004).  Fatigue in patients with chronic obstructive pulmonary 
disease.  Journal of Advanced Nursing, 45, 172-177.  doi:10.1046/j.1365-
2648.2003.02878.x 
U.S. Department of Health and Human Services (USDHHS), National Institutes of Health, 
National Heart, Lung, and Blood Institute (2010).  NHLBI factbook, fiscal year 2009.  
Retrieved from: http://www.nhlbi.nih.gov/about/FactBook2009_final.pdf. 
Ware, J.E. & Sherbourne, C.D. (1992).  The MOS 36-item short-form health survey (SF-36). 
Conceptual framework and item selection.  Medical care, 30, 473-483. 
doi:10.1097/00005650-199206000-00002  
Webster, K., Cella, D., Yost, K. (2003).  The Functional Assessment of Chronic Illness Therapy 
(FACIT) measurement system: Properties, applications, and interpretation.  Health and 
Quality of Life Outcomes, 1, 79.  doi:10.1186/1477-7525-1-79 
Wedzicha, J. A. (2000).  The heterogeneity of chronic obstructive pulmonary disease.  Thorax, 
55, 631-632.  doi:10.1136/thorax.55.8.631 
Wedzicha, J. A. (2004).  Role of viruses in exacerbations of chronic obstructive pulmonary 
disease.  Proceedings of the American Thoracic Society, 1, 115-120. 
doi:10.1513/pats.2306030 
                                                                              131 
Weinmann, J., Petrie, K. J., Moss-Morris, R., & Horne, R. (1996).  The illness perception 
questionnaire: a new measure for assessing the cognitive representation of illness. 
Psychology and Health, 11, 431-445.  doi:10.1080/08870449608400270 
White, M. M., Howie-Esquivel, J., Caldwell, M. A. (2010).  Improving heart failure symptom 
recognition: a diary analysis.  Journal of Cardiovascular Nursing, 25, 7-12.  
Whittemore, R., Chase, S.K, Mandle, C.L. (2001).  Validity in qualitative research.  Qualitative 
Health Research, 11, 522-537.  doi:10.1177/104973201129119299 
World Health Organization (WHO) (2011).  Chronic obstructive pulmonary disease. Fact Sheet, 
315.  Retrieved from: http://www.who.int/mediacentre/factsheets/fs315/en/index.html. 
Wier, L. M., Elixhauser, A, Pfuntner, A., Au, D. H. (2011).  Statistical brief #106: Overview of    
            hospitalizations among patients with COPD, 2008.  Healthcare Cost and Utilization  
            Project (HCUP). Retrieved from: www.hcup-us.ahrq.gov/reports/statbriefs/sb106.jsp.  
Wilkinson, T. M., Donaldson, G. C., Hurst, J. R., Seemungal, T. A., & Wedzicha, J. A. (2004). 
Early therapy improves outcomes of exacerbation of chronic obstructive pulmonary 
disease. American Journal of Respiratory and Critical Care Medicine, 169, 1298-1303.  
Doi: 10.1164/rccm.200310-1443OC 
Wilson, J. S., O’Neill, B., Reilly, J., MacMahon, J., & Bradley, J. M. (2007).  Education in 
pulmonary rehabilitation: The patient’s perspective.  Archives in Physical Medicine and 
Rehabilitation, 88, 1704-1709.  doi:10.1016/j.apmr.2007.07.040 
Wolf, Z.R. (2003).  Exploring the audit trail for qualitative investigations.  Nurse Educator, 28, 
175-178.  doi:10.1097/00006223-200307000-00008  
                                                                              132 
Yu-Isenberg, K. S., Vanderplas, A., Chang, E. Y., & Shah, H. (2005). Utilization and medical 
care expenditures in patients with chronic obstructive pulmonary disease. Disease 
Management and Health Outcomes, 13, 405-412.  doi:173-8790/05/0006-0405 
Zigmond A. S., Snaith R. P. (1983).  The hospital anxiety and depression scale.  Acta  
           Psychiatrica  Scandinavica, 67, 361-370.  doi:10.1097/00006223-200307000-00008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                              133 
                                                                  Appendix A 
 
  
                                                        Demographic Data Sheet 
Subject #                                     Date:  
Age at interview ___________ 
Gender                          1=  Male  (  )      2= Female  (  ) 
Marital Status            1= Single           2= Married        3= Widowed    4= Co-habitating 
Race         
1= White- non-Hispanic (  )   2 = African American (  )   3= Asian  (  )    4= Other  (   )  _____ 
Ethnicity: 
1= Portuguese   2= Hispanic    3=Other _________________________ 
Highest grade completed in school  __________ 
Years since diagnosed with COPD* ______________________ 
Date of last COPD exacerbation *_____________________________ 
Number of exacerbation hospitalizations since diagnosed *_______________________ 
Current smoker             1 = yes (  )            2 = no (  )           3= never smoked (  ) 
Date quit ______________________________ 
Number of years smoked___________________ Number packs day ____________________ 
CalculatedPack/years_______________________________ 
Smokers in home         1= yes (  )          2= No (  ) 
COPD Medication List * 
 
Clinical Data                         Pulmonary Function Tests * 
FEV1  
FEV1/FVC %  
• Obtained from medical record 
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                                                        Appendix B 
Interview Guide     
Conceptual Area Aim Question Probe 
Symptom 
Recognition 
 
Cognitive 
Representation 
Explore individual’s 
perception of prodromal 
symptoms in the days 
preceding their acute 
exacerbation. 
Tell me about how youhave felt in the last 2weeks?What symptom(s) didyou experience? 
 
 
When exactly did youfirst notice (x) symptom?(Use a calendar as a pointof reference)
 
Did you experience: 
SOB, cough, sputum 
production or color 
changes, sore throat, 
chest tightness, fever, 
fatigue, sleeplessness, 
change in mood or nasal 
discharge?  
 
  Did you feel a cold 
coming on?  What were 
you doing in the days 
preceding these 
symptoms? 
 
What did you do on 
Monday?  
How did you feel? 
Symptom recognition 
 
Cognitive 
Representation 
Describe individuals 
experience of patterns 
associated with their 
acute exacerbations  
What symptoms did youhave with your lastexacerbation?What about theexacerbation before that?
What did you do at thattime ?
Were they similar to the 
symptoms you had this 
week? What was similar, 
what was different.  Do 
you notice a pattern 
here?
 
Have you had x,y,z occur 
together before? 
 
Did you have to see your 
HCP? 
 
Were you ever admitted 
for “exacerbation of 
COPD” or pneumonia? 
 
Illness 
Representation 
 
Cognitive and 
emotional 
Representation 
 
Cognitive domains 
Identity 
Time-line 
Consequences 
Cause 
Controllability 
Explore the impact of 
illness domains on 
illness representation 
and relationship to delay 
in treatment seeking 
during  acute 
exacerbation of COPD. 
What did you think yoursymptoms meant?(identity)What do you thinkcaused yourexacerbation? (cause)How serious did youthink youth illness was?What did you think mighthappen if your symptomsprogressed?
Did you think you had a 
cold, flu, pneumonia? 
exacerbation? Do you 
know what that word 
means? 
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Conceptual Area Aim Question Probe 
  What are you mostconcerned about?(consequences)
How long have you hadthis “flare up”“How long do you think itwould last” (timeline)What did you do tomanage your symptoms?How much control overyour symptoms or illnessdid you believe you had?(Controllability)What made you decide tocall your HCP (or come tothe hospital)?Do you think you shouldhave got care sooner?Why did you wait?(Treatment delayfactors)
 
 
 
 
 
 
 
 
 
 
 
Did you change your 
medications, activity etc. 
to improve your 
symptoms? 
 
 
 
 
 
 
 
 
 
  
 
 
 
